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Abstract 
Ovarian cancer is one of the most lethal malignancies and often presents at an 
advanced stage, resulting in a poor prognostic outlook. Platinum chemotherapy 
leads to an initial clinical response, however most patients will ultimately 
relapse and there remains a sub-group who are intrinsically resistant to 
platinum. 
 
I focussed on high grade serous ovarian cancer (HGSOC), the most common 
subtype of ovarian cancer. The ID8 CRISPR-generated models represented a 
novel and simple tool to investigate the biology of HGSOC. By using this in vivo 
model, I aimed to further the understanding of platinum sensitivity in HGSOC 
by investigating the homologous recombination pathway and the tumour 
microenvironment.  
 
In vitro work showed that sensitivity to PARP inhibitors was clearly correlated 
with defective homologous recombination but the relationship with platinum 
sensitivity was more complicated. Using the ID8 derivatives, in vivo cisplatin 
experiments identified Pten and Nf1 loss to be associated with the worst 
prognosis with the knockout of Brca1 or Brca2 prolonging survival. A Brca1 
mutation in the PALB2 domain compared to the BRCT2 domain was found to be 
associated with a greater sensitivity to cisplatin.  
 
The tumour microenvironment was shown to differ between genotypes and 
altered with the addition of platinum chemotherapy. Specifically, the loss of 
Pten was associated with an immunosuppressive microenvironment with 
increased levels of myeloid-derived suppressor cells (MDSCs) and tumour-
associated macrophages (TAMs). The chemokines, Ccl2 and Ccl7 were shown to 
be significantly increased in the Trp53-/-;Pten-/- genotype. 
 
I targeted both the cytokine/chemokine response directly by using a transgenic 
mouse model (CCR1, 2, 3, 5 receptors knockout) and the PI3K/AKT pathway by 
using a PI3K inhibitor (p110β) (AZD8186) to attempt to reverse the effect of 
Pten loss. The transgenic mouse model (GGTACKO) showed encouraging early 
results with a reduction in MDSCs and TAMs in the knockout mice injected with 
3 
 
the Trp53-/-;Pten-/- genotype but a repeat experiment is required before valid 
conclusions can be made.  
 
The AZD8186 in vivo experiment showed a significant reduction in MDSC levels 
in the ascites following AZD8186 treatment in mice injected with the Trp53-/; 
Pten-/- genotype and a non-significant decrease in the tumour samples. There 
was also a reversal in the anaemia previously shown with the loss of Pten and a 
decrease in Ccl2 and Ccl7 expression.  
 
I have used a transplantable in vivo model for HGSOC to investigate potential 
mechanisms of platinum sensitivity and identified poor prognostic genotypes 
(Pten, Nf1). I have found Pten loss to be associated with an immunosuppressive 
microenvironment and highlighted potential therapeutic targets. By targeting 
the PI3K/AKT pathway I have shown that the effect of Pten loss can be reversed. 
The next step will be to determine whether this reversal results in a prolonged 
survival. 
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1 Introduction 
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1.1 Incidence and Mortality Rates in Ovarian Cancer 
Ovarian cancer is one of the most lethal malignancies and often presents at an 
advanced stage, resulting in a poor prognostic outlook for many patients. 
Worldwide, it is estimated that nearly 239,000 women were diagnosed with 
ovarian cancer in 2012 (Ferlay et al., 2015). Ovarian cancer is the 5th most 
common cancer in females in the UK with approximately 7000 new cases 
diagnosed each year. Overall the incidence of ovarian cancer has increased in 
the UK since the late 1970’s. However, since 2000 the incidence has decreased 
by 11% (Figure 1.1) (CRUK). This decrease may be explained by the change in 
the classification of borderline tumours where prior to 2000 many borderline 
malignant ovarian tumours were classified as malignant. An additional 
explanation may also be the increased use of the contraceptive pill which 
reduces the risk of ovarian cancer (Beral et al., 2008). 
 
Figure 1.1: Ovarian cancer incidence rates in the UK between 1993-2014.  
The figure demonstrates a decrease in incidence rates over the last 20 years (figure 
adapted from CRUK). 
 
Approximately 152,000 women died worldwide from ovarian cancer in 2012 with 
around 4,300 women dying from the disease in the UK (Ferlay et al., 2015). 
Age-standardised mortality rates (Figure 1.2) have decreased between 1971-
1973 and 2010-2012 with a 20% decrease over the last decade. However, this 
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reduction in mortality had been in women under 70, women aged 70 or over 
have seen a worsening of mortality over the last 30 years (CRUK). This increase 
in mortality may be due to a rise in incidence since the 1970s and specific to 
this age group an increase in nulliparity and the use of hormone replacement 
therapy (CRUK).  
 
 
Figure 1.2: Ovarian cancer mortality rates in the UK between 1971-2014.  
The figure demonstrates an overall decrease in mortality rates over the last 40 years 
(figure adapted from CRUK) 
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1.2 Risk Factors 
The risk of developing ovarian cancer increases with age and usually occurs in 
women who have had their menopause. In the UK in 2012-2014 the age-specific 
incidence rates rise dramatically from 35-39, peaking in those aged 80-84 and 
then dropping sharply (Figure 1.3). On average each year more than half of 
cases were diagnosed in females over 65 (CRUK). 
 
Figure 1.3: Average Number of New Cases per Year and Age-Specific Incidence 
Rates between 2012-2014. 
The figure demonstrates the rise in incidence from 35-39 years (figure adapted from 
CRUK). 
 
The 5-year survival rate is higher in younger women and decreases with 
increasing age. In England from 2007-2011 the 5-year survival ranged from 87% 
in those aged 15-39yrs to 17% in those aged 80-99yrs. Age-specific mortality in 
ovarian cancer increases sharply from 40-45yrs with the worst mortality in the 
over 85 age group. An average of 43% of deaths were in women over 75yrs and 
72% were in those over 65yrs between 2010-2012 in the UK (CRUK).  
 
Around 3% of all ovarian cancer cases occur in women with a family history of 
ovarian cancer (CRUK). The risk of ovarian cancer to any first-degree relative 
of patients with ovarian cancer is about 3-fold greater compared with the 
general population. There is also some evidence that the risk to relatives of 
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patients diagnosed younger than 50 years is as high as twice that to relatives of 
older patients with ovarian cancer. The most common sub-types of ovarian 
cancer, endometrioid and high-grade serous (HGSOC) have been shown to be 
associated with a significant increase in familial risk (Jervis et al., 2014). As 
BRCA1 and BRCA2 mutations are primarily associated with HGSOC it is not 
surprising the familial relative risk is higher for this subtype.  
 
Inherited conditions are estimated to account for 5-15% of epithelial ovarian 
cancer. Hereditary Breast-Ovarian cancer syndrome with BRCA1/2 mutations 
account for 65-85% and Lynch Syndrome with mismatch repair mutations 
account for another 10-15% (Lynch et al., 2013). There has been a wide range 
of figures quoted for ovarian cancer risk in women with BRCA1/2 mutations. It 
is estimated that the risk is up to 65% higher in women with a BRCA1 mutation 
and up to 35% higher in women with a BRCA2 mutation (Ingham et al., 2013).  
 
The risk of ovarian cancer is 24% higher in breast cancer survivors compared to 
the general population. The risk is higher in patients diagnosed with breast 
cancer at a younger age and also in oestrogen-receptor negative or oestrogen-
receptor unknown breast cancer (Schonfeld et al., 2013). The risk of ovarian 
cancer is higher in bowel cancer survivors compared to the general population 
(Ahmed et al., 2006). 
 
Evidence has shown that factors that alter the number of ovulations and/or sex 
hormone levels can affect the risk of ovarian cancer. Pregnancy, breastfeeding 
and oral contraceptives reduce the number of ovulations in a women’s lifetime 
and have all been shown to decrease the risk of ovarian cancer (Lukanova and 
Kaaks, 2005). 
 
HRT has been found recently to increase the risk of ovarian cancer by 43% in 
current users compared to women who have never used HRT (Beral et al., 2015). 
The use of HRT for <5 years had been previously thought to be a safe period 
however these women who had been on HRT <5 years at the time of diagnosis 
were also found to have a significant increased risk of ovarian cancer. The risk 
of ovarian cancer was significantly increased for both oestrogen-only and 
combined HRT with little difference between the types (Beral et al., 2015). 
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Although nulliparity is a known risk factor for ovarian cancer the association 
with infertility treatment has been less clear. A number of early cohort studies 
found an increased risk of borderline and invasive ovarian cancer following high 
doses and multiple cycles of clomiphene citrate (Rossing et al., 1994, Sanner et 
al., 2009). However in more recent and larger cohort studies there was no 
association found between malignancy risk and infertility medication (Jensen 
et al., 2009, Calderon-Margalit et al., 2009). 
 
It has been suggested that 3% of ovarian cancer cases in the UK are linked to 
smoking (Beral et al., 2012, Faber et al., 2013). From meta- and pooled analyses 
there has been found to be significant variation in smoking-related risks 
between the tumour subtypes. In mucinous cancers, the incidence was 
increased in current versus never smokers however the increase was mainly in 
borderline malignant tumours. In both clear-cell and endometrioid cancers, 
studies have seen a reduction in cancer risk in current smokers however 
evidence for this is conflicting. There has been no significant association found 
between smoking and serous ovarian cancers (Beral et al., 2012, Faber et al., 
2013).  
 
Obesity is an important risk factor for many cancers. Some studies have shown 
a link between body size and ovarian cancer risk. The risk of ovarian cancer in 
HRT never-users is 10% higher per 5 unit BMI increment however the risk may 
only be increased in women with a BMI greater than 28 (Collaborative Group on 
Epidemiological Studies of Ovarian Cancer, 2012). Diabetes is associated with 
an increased risk of several cancer types although the exact mechanism of this 
link is not fully understood (Starup-Linde et al., 2013). A meta-analysis by Lee 
at al showed that the risk of ovarian cancer was increased by 55% in diabetics 
compared with non-diabetics when controlled for confounding variables (Lee et 
al., 2013).  
 
The exact aetiology of endometriosis remains unclear. However, it is widely 
known to be associated with certain sub-types of ovarian cancer. A meta-
analysis by Kim et al found that endometriosis increased ovarian cancer risk by 
27-80% depending on study type (Kim et al., 2014). They also found that early 
stage disease, low-grade serous disease, endometrioid and clear cell sub-types 
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were all strongly associated with endometriosis-associated ovarian cancer. 
Whereas there was a relatively low incidence of high grade serous carcinoma in 
endometriosis-associated ovarian cancer and no association between 
endometriosis and mucinous carcinoma risk (Kim et al., 2014).  
  
29 
 
1.3 Pathology 
1.3.1 Anatomy of the Fallopian Tube and Ovary 
The ovaries consist of three components: the surface layer formed by cuboidal 
epithelium, the cortex containing stroma and ovarian follicles and the medulla 
containing stroma and neurovascular bundles. The anatomy of the female 
reproductive system is illustrated below (Figure 1.4). 
 
 
Figure 1.4: Anatomy of the female reproductive system. 
The ovaries are located either side of the uterus within the broad ligament below the 
Fallopian tubes (http://seer.cancer.gov/statfacts/html/ovary.html). 
 
The Fallopian tube consist of four parts the Isthmus, Ampulla, Infundibulum and 
Fimbriae. The inner mucosa is lined with ciliated columnar epithelial cells and 
non-ciliated secretory cells (Figure 1.5). 
 
 
Figure 1.5: Anatomy of the Fallopian tube 
(http://teachmeanatomy.info/pelvis/female-reproductive-tract/fallopian-tubes/) 
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1.3.2 Ovarian Cancer Histopathology 
There are many different histological and molecular sub-types of ovarian cancer 
however they are often treated as a single disease. Nearly 10 years ago ovarian 
cancer surface epithelial tumours began to be classified into type I and type II 
tumours according to their pathway of tumourigenesis (Shih Ie and Kurman, 
2004).  Type I tumours included low grade serous, endometrioid, mucinous and 
clear cell types. Whereas Type II tumours at the time had no identified 
precursor lesion and included high-grade serous and carcinosarcoma (Shih Ie 
and Kurman, 2004) (Table 1.1 and Figure 1.6). However, between these 
subtypes there are significant genomic differences.  
 
Recent genomic findings suggest that many ovarian cancers are derived from 
non-ovarian tissue and there are few molecular similarities between the 
histotypes. Immunological markers and genomic studies have shown that many 
tumours that were previously classified as high-grade endometrioid should be 
re-classified as high grade serous cancers (Madore et al., 2010). 
 
This thesis focuses on high grade serous ovarian cancer, the most common sub-
type of ovarian cancer. 
Table 1.1: Ovarian cancer sub-types and associated mutations. 
 
Ovarian cancer 
Epithelial Non-epithelial 
High-
grade 
serous 
Low-
grade 
serous 
Mucinous Clear cell Endometrioid Sex cord-
stromal 
Others 
e.g 
germ 
cell 
TP53 BRAF KRAS ARID1A ARID1A Granulosa 
cell - 
FOXL2 
 
BRCA1/
2 
KRAS HER2 PIK3CA PIK3CA Sertoli-
Leydig cell 
- DICER1 
 
NF1 NRAS 
 
PTEN PTEN 
  
RB1 ERBB2 
 
CTNNB1 PPP2R1α 
  
CDK12 
  
PPP2R1α MMR deficiency 
  
HR 
repair 
genes 
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High-grade serous ovarian cancer (HGSOC) accounts for up to 70% of all ovarian 
cases. They have the highest frequency of TP53 mutation of any solid tumour 
at 97%, which is the essential driver mutation in the pathogenesis of HGSOC 
(Ahmed et al., 2010). TP53 is the only gene that is  mutated in >10% of cases at 
the somatic level and it has been suggested that 100% of HGSOC are TP53 
mutant (Cole et al., 2016). 
 
The increase in prophylactic salpingo-oophorectomy for familial risk has 
allowed pathologists to examine a larger number of specimens in women at 
higher risk of ovarian cancer.   
 
The distal fallopian tube has relatively recently been identified as the likely 
source of HGSOC with early STIC (serous tubal intra-epithelial carcinoma) 
lesions with hallmark p53 signatures predominating in the fimbria and secretory 
cells (Cole et al., 2016). The first step in the transformation of benign tubal 
secretory cells is the ‘p53 signature’ with benign appearing cells showing 
evidence of strong nuclear p53 protein expression or absent p53 expression on 
IHC, in keeping with TP53 missense and null mutations respectively. This is 
followed by the emergence of STIC lesions that are a multi-layered epithelium 
that lacks polarity and contains malignant secretory cells with DNA damage and 
p53 protein stabilisation in addition to a high proliferative index (Lee et al., 
2007). The transformation of STIC lesions to HGSOC is thought to take 
approximately 7 years followed by the rapid development of metastases 
(Labidi-Galy et al., 2017b). Although a tubal origin of HGSOC is likely and widely 
accepted, STIC lesions are only seen in about half of HGSOC cases (Lee et al., 
2007) and there have been mouse models of HGSOC that seem to primarily 
involve precursor cells in the ovary (Kim et al., 2012). 
 
PAX8 is one protein that is consistently overexpressed in epithelial ovarian 
cancer compared to normal ovarian tissue. PAX8 is one of 9 transcription factors 
involved in embryogenesis and has been found to be expressed in non-ciliated 
secretory cells of normal healthy fallopian tubes but absent from ovarian 
surface epithelium (Di Palma et al., 2014).  
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Figure 1.6: Five main sub-types of ovarian cancer. 
A High-grade serous carcinoma; B Low-grade serous carcinoma; C Mucinous carcinoma; 
D Endometrioid carcinoma; E Clear cell carcinoma. Adapted from (Prat, 2012). 
 
Recent studies have looked at the metastatic spread of HGSOC. HGSOC, like 
other intra-abdominal tumours, often metastasises to the omentum which is 
predominantly composed of adipocytes. The omental metastases (‘omental 
cake’) typically represent the largest tumour bulk in woman with ovarian cancer 
outside the pelvis. Nieman et al found that human omental adipocytes promote 
homing, migration and invasion of ovarian cancer cells and also act as an energy 
source (Nieman et al., 2011). 
 
Epithelial ovarian cancer is believed to metastasize randomly by direct contact 
with intra-abdominal surfaces helped by the peritoneal circulation. However as 
discussed, ovarian cancer metastases have a predilection for the omentum. In 
addition to the omentum, pelvic and/or para-aortic lymph nodes can be 
involved and rarely brain and lung metastases. A recent study using a pre-
clinical mouse model found haematogenous peritoneal dissemination of ovarian 
cancer cells with a tropism for the omentum, suggesting an additional mode of 
metastasis (Pradeep et al., 2014). 
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1.3.3 Mutations associated with high grade serous ovarian cancer 
High grade serous ovarian cancer is characterised by genomic instability, in 
particular copy number abnormalities but with a low prevalence of recurrently 
mutated genes beyond TP53 (2-6%) (Cancer Genome Atlas Research, 2011). 
Recent genomic studies have identified four gene expression clusters in high-
grade serous cancer which have been termed: proliferative, immunoreactive, 
mesenchymal and differentiated according to the gene content in the clusters 
(Cancer Genome Atlas Research, 2011). This classification has not yet been 
applied clinically. 
 
The Cancer Genome Atlas (TCGA) data suggested that up to 50% of HGSOC may 
have homologous recombination defects at the time of diagnosis (Cancer 
Genome Atlas Research, 2011). In addition to germline and somatic BRCA1/2 
mutations, these included a set of Fanconi Anaemia genes, EMSY, RAD51, PTEN 
and the DNA damage sensing genes ATM and ATR (Cancer Genome Atlas 
Research, 2011). However, these mutations were inferred and were not a 
functional assessment (Figure 1.7) and we specifically investigated the 
potential influence of PTEN loss on HR (see Chapter 3). 
 
The frequency of BRCA1 and BRCA2 germ-line mutations had been unclear until 
recently with patient testing previously based solely on family history. Rust et 
al sequenced all newly presented non-mucinous ovarian cancer patients 
irrespective of family history and found 13.1% to have germline BRCA1/2 
mutations. They also found that 48% of patients selected would not have been 
offered sequencing based on the family history (Rust et al., 2018).  
 
TCGA has analysed nearly 500 high grade serous ovarian cancer samples. They 
have reported 9 significantly mutated genes: TP53, BRCA1, BRCA2, RB1, NF1, 
FAT3, CSMD3, GABRA6 and CDK12 (Cancer Genome Atlas Research, 2011). As 
stated above, high grade serous cancer is characterised by near-universal TP53 
mutations as identified by Ahmed et al (Ahmed et al., 2010). BRCA1/2 were 
mutated in 21% of tumours when combining both somatic and germline 
mutations. The remaining 7 mutated genes were only identified in 2-6% of high 
grade serous ovarian cancer cases (Cancer Genome Atlas Research, 2011). 
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The number of recurrent somatic copy number alterations (SCNAs) was analysed. 
The most common focal amplifications were CCNE1, MYC and MECOM, each of 
which was highly amplified in more than 20% of tumours (Cancer Genome Atlas 
Research, 2011). TCGA also identified 50 focal deletions, the tumour suppressor 
genes – PTEN, RB1 and NF1 were in regions of homozygous deletions in at least 
2% of the tumours (Cancer Genome Atlas Research, 2011). 
 
However, TCGA utilised whole exome sequencing (for SNV) rather than whole 
genome sequencing (WGS), and therefore did not evaluate over 95% of the 
genome. In addition, CNA was assessed using SNP arrays, which again will miss 
large portions of the genome. This is important because HGSOC is marked by 
extreme copy number abnormalities leading to structural variants (SV) and re-
arrangement of large parts of the genome that alter gene integrity without 
specific mutations or large scale insertions/deletions, which will be missed by 
exome sequencing and SNP arrays (Patch et al., 2015). Critical genes whose 
function is altered by such SV include PTEN, NF1 and RB1. Thus, an updated 
representation of the genomic landscape of HGSOC is given in Figure 1.7. 
However, it is important to appreciate that the alterations in this figure are 
rarely mutually exclusive – for example, over half (9/16) of cases with NF1 loss 
in the ICGC WGS analysis (Patch et al) also had mutations in BRCA1/2. This 
makes classification of HGSOC genomes particularly challenging. 
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Figure 1.7: Mutational Landscape of High Grade Serous Ovarian Cancer. 
Adapted from (Patch et al., 2015) and (Cancer Genome Atlas Research, 2011). 
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1.4 Classification and Prognostic Factors 
1.4.1 Anatomical Factors 
The TNM (Tumour-Node-Metastases) classification and the FIGO (International 
Federation of Gynecology and Obstetrics) staging classification are both well-
established classification systems accepted for the staging of ovarian cancer 
(Sobin, 2009, Prat, 2015).  
 
The FIGO classification was updated in 2014 and the new TNM staging is 
awaiting publication. The FIGO classification emphasises surgical evidence, 
considers the likely tubal origin of HGSOC, and emphasises the importance of 
documenting the histologic subtype. It also correlates with the TNM system and 
is of prognostic significance (Table 1.2). 
 
Patients with Stage I disease have a greater than 90% 5-year survival compared 
to a less than 5% 5-year survival for patients with Stage IV disease. The higher 
stage indicates more extensive disease and optimal debulking is less likely to 
be achieved when compared to a tumour that is only confined to the pelvis. For 
optimal debulking to be achieved in stage III/IV disease more radical surgery is 
often needed and this is associated with a higher incidence of perioperative 
morbidities (Ezzati et al., 2014). 
 
The presence of a malignant pleural effusion in the absence of other stage IV 
criteria has a significantly worse prognosis when compared to stage III disease 
(Eitan et al., 2005). The presence of ascites is also an important component of 
the FIGO classification. Ascites in early-stage disease is a poor prognostic factor 
whereas smaller tumour volume and the absence of ascites in advanced disease 
are associated with a favourable outcome (Eitan et al., 2005). 
 
The presence of lymph node metastases is a significant prognostic factor in 
ovarian cancer (Ozols et al., 1980). Retroperitoneal lymph node involvement 
occurs in up to 50-80% of women with advanced ovarian cancer (Omura et al., 
1991). Women with tumours limited to the pelvis and positive lymph nodes have 
been found to have an improved 5-year survival (84%) compared to women with 
tumours that have spread beyond the pelvis (26%) (Ozols et al., 1980). There is 
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an on-going debate regarding the benefits of systematic lymphadenectomy 
versus lymph node sampling in advanced disease. The recent LION study 
concluded that systematic lymphadenectomy in patients with clinically 
negative lymph nodes and complete resection did not improve the overall and 
progression-free survival (Harter et al., 2017).  
 
Optimal surgical debulking is the single most important prognostic factor in 
advanced ovarian cancer with studies showing a significant survival advantage 
with ≤ 1cm of residual disease (Shimizu et al., 1998). However, to achieve 
optimal cytoreduction there is often an associated surgical morbidity. 
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Table 1.2: The FIGO Ovarian Cancer Staging (2014). 
Five-year relative percentage survival by stage between 2002 and 2006 (CRUK). 
Demonstrates the FIGO staging classification with the breakdown of each clinical 
parameter and corresponding TNM stage (Table adapted from similar in (Prat, 2015)). 
 
Stage 
5-year 
Survival 
Stage I: Tumour limited to the ovaries (one or both) 
IA (T1a-N0-
M0) 
Tumour limited to one ovary; capsule intact, no 
tumour on ovarian surface; negative washings. 
90% 
IB (T1b-N0-
M0) 
Tumour limited to both ovaries; capsules intact, no 
tumour on ovarian surface; negative washings. 
IC Tumour limited to one or both ovaries 
IC1 (T1C1-
N0-M0) 
Surgical spill 
IC2 (T1C2-
N0-M0) 
Capsule rupture before surgery or tumour on ovarian 
surface. 
IC3 (T1C3-
N0-M0) 
Malignant cells in the ascites or peritoneal washings. 
Stage II: Tumour involves one or both ovaries with pelvic extension (below the 
pelvic brim) or primary peritoneal cancer 
IIA (T2a-
N0-M0) 
Extension and/or implants on the uterus and/or 
tube(s) 
42.8% 
IIB (T2b-
N0-M0) 
Extension to and/or implants in other pelvic tissues 
Stage III: Tumour involves one or both ovaries with cytologically or histologically 
confirmed spread to the peritoneum outside the pelvis and/or metastasis to the 
retroperitoneal lymph nodes 
IIIA 
(positive retroperitoneal lymph nodes and/or 
microscopic metastasis beyond the pelvis) 
18.6% 
IIIA1 (T1/2-
N1-M0) 
Positive retroperitoneal lymph nodes only 
IIIA1 (i) Metastasis ≤ 10mm 
IIIA1 (ii) Metastasis > 10mm 
IIIA2 (T3a2-
N0/N1-M0) 
Microscopic, extrapelvic (above the brim) peritoneal 
involvement +- positive retroperitoneal lymph nodes 
IIIB (T3b-
N0/N1-M0) 
Macroscopic, extrapelvic, peritoneal metastasis ≤ 2cm 
+/- positive retroperitoneal lymph nodes. Includes 
extension to capsule of liver/spleen. 
IIIC (T3c-
N0/N1-M0) 
Macroscopic, extrapelvic, peritoneal metastasis > 2cm 
+/- positive retroperitoneal lymph nodes. Includes 
extension to capsule of liver/spleen 
Stage IV (any T-any N-M1): Distant metastasis excluding peritoneal metastasis 
IVA Pleural effusion with positive cytology 
3.5% 
IVB 
Hepatic and/or splenic parenchymal metastasis, 
metastasis to extra-abdominal organs (including 
inguinal lymph nodes and lymph nodes outside of the 
abdominal cavity) 
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1.4.2 Histological Factors  
Tumour grade is thought to influence tumour behaviour however there have 
been conflicting studies over the association with clinical outcome (Ozols et al., 
1980, Omura et al., 1991). Part of the difficulty is that there is no universally 
accepted grading system for ovarian cancer. Many pathologists use a FIGO 
system that characterises cellular architecture (AOGS, 1971) but a more recent 
system incorporates cellular architecture, nuclear grade and mitotic activity 
(Shimizu et al., 1998). This system correlates more accurately with lymph node 
metastasis and therefore survival. The histological sub-type is a much better 
predictor of survival than tumour grade (Bamias et al., 2012). 
 
The tumour sub-type has been shown to be a more relevant histopathological 
prognostic factor in advanced ovarian cancer treated with the standard 
platinum-taxane combination (Bamias et al., 2012). Tumour grade was only 
significant between the low versus high grade serous tumours while the 
prognosis between grade 2 and 3 were similar. Tumour grade was found to be 
of no prognostic significance in mucinous, endometrioid and clear cell 
carcinomas (Bamias et al., 2012). The main challenge in determining the exact 
prognostic importance of tumour histology has been the previous 
misclassification of many ovarian cancer sub-types.  
 
The histological sub-type has been generally thought to be associated with 
prognosis and studies have shown both mucinous and clear-cell carcinomas to 
be an adverse prognostic factor, but only in advanced stage (Zaino et al., 2011, 
Mackay et al., 2010). 
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1.4.3 Molecular Factors 
A wide variety of molecular markers have been reported to influence prognosis 
in ovarian cancer including cell cycle regulators, mediators of proliferation, 
apoptosis and angiogenesis. However, most studies looking at prognostic 
markers have not differentiated between the subtypes and therefore it is 
difficult to make valid conclusions. 
 
Tumour suppressor p53 has been one of the most investigated markers in 
ovarian cancer. A meta-analysis including 62 studies by (de Graeff et al., 2009) 
found wild-type p53 to be associated with a poor survival and when restricted 
to serous tumours there was a significant association with poor prognosis (HR 
1.47, 95% CI 1.33-1.61). However there have been conflicting results in relation 
to p53 status and response to platinum-chemotherapy (Gadducci et al., 2009, 
Canevari et al., 2006). The lack of reproducible results makes it difficult to 
make any valid conclusions about the role of p53 as a reliable prognostic 
biomarker. 
 
As discussed previously p53 has been found to be universally mutated in HGSOC 
therefore its potential as a prognostic marker is limited in this subtype. In 
addition, analysis of TCGA data suggest that type of TP53 mutation 
(missense/gain-of-function vs null) also has no influence on outcome (PFS - 
p=0.0981, OS - p=0.0787; log-rank test) (Kang et al., 2013). 
 
Wilms’ Tumour gene (WT1) expression has shown differing patterns of 
expression among the ovarian cancer subtypes with a higher expression found 
in the serous subtype (Le Page et al., 2010). However, there have been 
conflicting reports over the role of WT1 as a prognostic marker.  Some studies 
report no prognostic advantage associated with WT1 and others have shown a 
significantly worse prognosis when all histological subtypes are analysed (RR 
1.7, 95% CI 1.2-2.3) (Kobel et al., 2008, Hogdall et al., 2007). WT1 has been 
found to be a favourable marker in the cohort of patients with HGSOC and this 
may be because WT1 is a marker of serous differentiation and therefore poorly 
differentiated serous carcinomas are less likely to express WT1 and have a 
worse prognosis (RR 0.5, 95% CI 0.3-0.8) (Kobel et al., 2008). WT1 is a good and 
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widely used diagnostic marker in serous carcinoma and helps in differentiating 
high-grade disease from a mixed carcinoma population (Le Page et al., 2010). 
 
Ki67 is a proliferation marker commonly studied in cancer research as it is 
overexpressed in malignant tissue. It is a nuclear protein which is expressed 
throughout the cell cycle but absent in quiescent cells (G0) (Le Page et al., 
2010). The overexpression appears to be in the serous histotype (Kobel et al., 
2008) but this has not been found in all studies (Korkolopoulou et al., 2002). 
Again, there have been conflicting results on the prognostic value of Ki67, in 
the majority of reports high expression of Ki67 has been associated with a poor 
prognosis (Korkolopoulou et al., 2002). Kobel et al found that when 
retrospectively analysing all ovarian cancer subtypes for tissue-based 
biomarkers, Ki67 was associated with a negative prognosis (RR 1.7, 95% 1.2-2.4) 
however, HGSOC usually had a high Ki67 index. When the same subtypes were 
analysed individually, Ki67 was found to be of no prognostic significance (Kobel 
et al., 2008). 
 
Many studies have shown that cell cycle regulators are involved in tumour 
progression in ovarian cancer. Cyclins are a family of proteins that co-ordinate 
the progression of cells through the cell cycle by activating cyclin-dependent 
kinase (Cdk) enzymes. Cyclin-Cdk complexes are regulated by kinase inhibitors 
(CKIs) (Le Page et al., 2010). The Cyclins appear and disappear at specific time 
points during the cell cycle. Oncogenesis can be caused by abnormal expression 
of cyclins (positive regulators) or loss of CKIs (negative regulators) (Le Page et 
al., 2010). 
 
Cyclin E has been studied extensively in ovarian cancer and has been found to 
be associated with a poor prognosis in the serous disease subtype after 
retrospective IH analysis of 53 ovarian cancer samples (p=0.054 by Fisher test) 
(Rosenberg et al., 2001). A study by Etemadmoghadam measured genome wide 
copy number variation in 118 ovarian tumours and found CCNE1 expression to 
also be predictive of patient outcome and associated with resistance to 
platinum chemotherapy (p=<0.001 by Fisher test) (Etemadmoghadam et al., 
2009).  
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Apoptosis is a process of programmed cell death. The extrinsic and intrinsic 
pathways mediate the process, and both lead to the activation of caspases. The 
extrinsic pathway is initiated by TRAIL, TNF and Fas-L whereas the intrinsic 
pathway is initiated by signalling events such as p53 and Bcl-2 activation. 
 
TRAIL (TNF-related Apoptosis Inducing Ligand) is an extracellular protein that 
triggers apoptosis. The expression of different TRAIL receptors has been shown 
to enhance apoptotic ability of TRAIL (Duiker et al., 2006). The presence of 
stromal TRAIL in advanced disease has been shown to be associated with a 
favourable survival (p=0.049, log-rank test) (Horak et al., 2005) but this was 
not observed in patients treated with platinum chemotherapy (Duiker et al., 
2010). Further studies have not seen any association between TRAIL and survival 
(p=0.09, log-rank test) (Ouellet et al., 2007). There have been conflicting 
results with Bcl-2. A high expression of Bcl-2 has been shown to be associated 
with an improved survival (p=0.0021, multivariate analysis) (Baekelandt et al., 
1999) however this has not been found in the majority of studies (Geisler et al., 
2000). 
 
Poly (ADP-ribose) polymerase 1 (PARP1) is a key component in base excision 
repair, a significant pathway in the repair of DNA single-strand breaks.  It also 
helps regulate both HR and NHEJ pathways (De Lorenzo et al., 2013). PARP 
inhibitors have an important role as a therapeutic agent in ovarian cancer. 
Although patients with BRCA1/2 germline mutations are associated with better 
outcomes which is most likely due to a greater sensitivity to platinum 
chemotherapy, Farmer et al found BRCA1/2 mutant cell lines to be extremely 
sensitive to PARP inhibitors (Farmer et al., 2005). A recent randomised phase II 
trial by Ledermann et al found patients with platinum-sensitive relapsed serous 
ovarian cancer with BRCA-mutated disease to have a better progression free 
survival following the addition of a PARP inhibitor (11.2 months versus 4.3 
months, HR 0.18 CI 0.10-0.31) (Ledermann et al., 2014). The BRCA status, 
although not universally used in clinical practice yet, may help as a predictor 
of disease response to therapeutic agents. 
 
Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that 
stimulates angiogenesis and increases microvascular permeability by binding to 
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receptors expressed on vascular endothelial cells (Neufeld et al., 1994). It is 
overexpressed in ovarian cancer when compared to benign tumours (Shen et al., 
2000) and it has been shown to have a crucial role in neovascular formation in 
tumours (Ferrara, 1995). A high expression of VEGF on immunohistochemistry 
of 339 primary ovarian cancer samples has shown to improve survival in a study 
by Duncan et al (p=0.04, log-rank test) (Duncan et al., 2008) however a meta-
analysis by Hefler et al found a high VEGF to be associated with a poor overall 
survival (p=<0.001, multivariate analysis) (Hefler et al., 2006). 
 
The EGFR (epidermal growth factor receptor) is an extensively studied tyrosine 
kinase receptor and has been linked to a negative prognosis in many different 
cancers (Le Page et al., 2010). A meta-analysis found that EGFR and Her-2 had 
a limited impact on prognosis; however the analysis included a diverse number 
of tumour subtypes (de Graeff et al., 2009). This was further supported by the 
EORTC study that showed maintenance erlotinib (EGFR tyrosine kinase inhibitor) 
following first line chemotherapy in ovarian cancer did not improve progression-
free or overall survival (PFS 12.7 (erlotinib) vs 12.4 months (observation) (HR 
1.05, 95% CI 0.90-1.23) and OS 50.8 vs 59.1 months (HR 0.99, 95% CI 0.81-1.20) 
(Vergote et al., 2014).  
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1.4.4 Immunological Factors 
The immune system has been shown to play an important role in ovarian cancer 
survival. Up to 50% of the cells within any solid tumour or metastasis are non-
malignant (Balkwill et al., 2012). The complex tumour microenvironment 
includes many cells that have lost their protective function and operate in an 
immunosuppressive role. Cell types that retain their protective function are 
often inhibited by neighbouring cell types (Figure 1.8). 
 
T and B cell lymphocytes 
Zhang et al was the first to associate the presence of CD3+ tumour-infiltrating 
lymphocytes (TILs) with improved clinical outcome in ovarian cancer (Zhang et 
al., 2003). A further study found CD8+ TILs to be the only subtype associated 
with a favourable prognosis and that no stromal TILs of any subtype were 
associated with improved survival (Sato et al., 2005). The same study also found 
a high CD8+/CD4+ cell ratio improved survival although CD4+ and CD8+ alone had 
no association with prognosis (Sato et al., 2005). This finding implied that a 
further subpopulation of CD4+ T cells might counteract the anti-tumour effects 
of CD8+ cells (Sato et al., 2005). 
 
A CD4+ CD25+ FOXP3+ suppressor T cell (Treg) population has been found to be 
increased in late-stage ovarian cancer and associated with a worse prognosis 
(Curiel et al., 2004, Woo et al., 2001). Sato et al discovered that a high 
intraepithelial CD8+/Treg ratio was associated with an improved survival and 
this indicates that the number of Tregs within the CD4+ population influences 
the beneficial effects of CD8+ T cells (Sato et al., 2005). 
 
Myeloid-derived suppressor cells 
Immune cells within the tumour microenvironment can limit and stimulate 
tumour growth. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous 
population of immature myeloid cells that are recruited by tumour cells (Godoy 
et al., 2013). The two major MDSC subpopulations are granulocytic (human: 
CD11b+ CD14- CD15+ CD66b+; murine: CD11b+ Ly6G+ Ly6Clow/-) and monocytic 
(human: CD11b+ CD14+ HLA-DRlow/- CD15-; murine: CD11b+ Ly6G- Ly6Chigh) (Godoy 
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et al., 2013). MDSCs have immunosuppressive properties and enhance tumour 
growth, invasion and metastasis (Obermajer et al., 2011). 
 
In mice, changes in the phenotype of tumour-infiltrating dendritic cells have 
been found to influence disease progression in ovarian cancer. The depleting 
dendritic cells early in the disease accelerate tumour growth but the low 
dendritic cell number slow the aggressive progression in advanced disease 
(Scarlett et al., 2012). 
 
Immune checkpoint inhibitors 
Programmed death 1 (PD-1) is an inhibitory immune checkpoint receptor 
expressed by activated T cells (Hansen et al., 2016). PD-1 interacts with its 
ligands, PD-L1 and PD-L2 that are present on both tumour and stromal cells. 
Freeman et al found that binding of PD-1 by PD-L1 leads to inhibition of T cell 
lymphocyte proliferation and cytokine secretion (Freeman et al., 2000). 
 
Tumour-associated macrophages 
Macrophages are the most abundant immune cell in the tumour 
microenvironment. The two extreme states of macrophages are M1 and M2 with 
the latter correlated to poor prognosis in several human cancers (Dijkgraaf et 
al., 2013, Heusinkveld and van der Burg, 2011). Monocytes are recruited to the 
tumour microenvironment by a number of chemokines including CCL2, CCL5 and 
CXCL1 (Mantovani et al., 2004a), where they differentiate into tumour-
associated macrophages (TAM). The survival of TAMs is sustained by cytokines 
within the tumour microenvironment such as CSFs and VEGF-A (Obermueller et 
al., 2004). TAMs produce either pro-tumour or anti-tumour properties 
depending on the types of cytokines to which they are exposed. Colony 
stimulating factor-1 (CSF-1) is a key cytokine in the recruitment and activation 
of macrophages by binding to a high-affinity receptor tyrosine kinase (CSF-1R) 
(DeNardo et al., 2011). TAMs acquire M2 properties, such as promoting tumour 
proliferation and progression in response to further cytokines such as TGF-β, IL-
10 and M-CSF (Obermueller et al., 2004). The terms M1 and M2 are too 
simplified as macrophages can adapt to a range of activation states between 
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the M1 and M2 phenotype depending on the signals within the 
microenvironment (Heusinkveld and van der Burg, 2011). 
 
 
Figure 1.8: Illustration of the tumour microenvironment in ovarian cancer. 
The figure shows the variety of cell types present (modified from (Balkwill et al., 2012))   
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1.5 Tumour Microenvironment (TME) 
In addition to cells from the immune system several other components are 
involved in the tumour microenvironment. These include the tumour 
vasculature, lymphatics, fibroblasts, adipocytes and the extracellular matrix. 
(Figure 1.8). 
 
Tumour vasculature 
Many angiogenic signalling factors and specific cytokines are present within the 
tumour microenvironment, which may stimulate angiogenesis. The resulting 
blood vessels are leaky due to their abnormal structure and function. This, in 
turn, increases hypoxia and can influence drug distribution (Jain, 2005). As 
reviewed by Balkwill et al, VEGFA has been shown to be the predominant 
angiogenic factor in the tumour microenvironment (Balkwill et al., 2012).  
 
Pericytes provide structural support to blood vessels. Studies in different cancer 
types have suggested that a key role of pericytes is to act as a negative 
regulator of metastases and that a low pericyte coverage correlates with a poor 
prognosis and increased metastases (Balkwill et al., 2012, O'Keeffe et al., 2008, 
Yonenaga et al., 2005). 
 
In ovarian cancer the spread of disease is predominantly thought to be primarily 
via intraperitoneal ‘seeding’, although a study by Pradeep et al found 
preferential haematogenous metastasis to the omentum, albeit in a murine 
xenograft model, highlighting another important potential mode of metastasis 
(Pradeep et al., 2014). 
 
Omentum 
Ovarian cancer cells preferentially metastasise and proliferate in the omentum 
and as a result the ‘omental cake’ often represents the largest tumour bulk 
within the abdominal cavity. Nieman et al found that the secretion of 
adipokines aids with the recruitment of tumour cells and that adipocytes act as 
an energy source encouraging rapid tumour growth (Nieman et al., 2011). 
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Cancer-associated fibroblasts 
Myofibroblasts are abundant within the tumour microenvironment and are 
referred to as cancer-associated fibroblasts (CAF). CAFs secrete growth factors 
such as EGF and IGF-1 which contribute to tumour progression (Spaeth et al., 
2009, Tomasek et al., 2002). They also secrete key ECM components and 
remodelling enzymes. Depending on the tumour type, CAFs originate in a 
fibrovascular core and branch throughout the tumour mass or surround the 
tumour with dense stroma resulting in restricted chemotherapy distribution 
(Erez et al., 2010). 
 
Lymphatics 
Lymph nodes draining a tumour may protect the tumour from host immunity. 
The tumour-draining lymph nodes contain a high level of cytokines and antigens 
deriving from the tumour (Swartz and Lund, 2012). The lymph flow from 
tumours has been found to be increased compared to normal tissue in 
melanoma and increased lymph drainage has been positively correlated to 
metastasis in breast cancer (Harrell et al., 2007, Pathak et al., 2006). 
Lymphangiogenesis is driven by the production of VEGFC and VEGFD from the 
tumour and lymphatic endothelial cells within the tumour microenvironment 
have an important role in the dissemination of tumour cells (Alitalo, 2011). 
 
Extracellular matrix (ECM) 
The ECM is the non-cellular component present within all tissues and has a key 
role within the tumour microenvironment. In addition to providing scaffolding 
for many cells it is also crucial in the movement of cells into and out of the TME 
(Balkwill et al., 2012). The ECM is a highly dynamic structure that is constantly 
being remodelled (Frantz et al., 2010). The ECM interacts with cell surface 
receptors leading to signal transduction and gene transcript regulation (Frantz 
et al., 2010). A possible hypothesis for platinum-sensitive recurrence is that 
tumour cells can become chemotherapy resistant due to their contact with 
specific components of the ECM. These cells then persist after chemotherapy 
and go on to repopulate the tumour resulting in recurrence (Chien et al., 2013). 
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1.6 Management of Ovarian Cancer 
1.6.1 Diagnosis 
Ovarian cancer often presents with non-specific symptoms such as abdominal 
pain or distension, which can lead to a delay in diagnosis. The symptoms are 
frequently attributed to irritable bowel syndrome (IBS) and NICE guidelines 
recommend that women over 50 years with IBS symptoms should have a serum 
cancer antigen 125 (CA-125) performed  
(http://www.nice.org.uk/guidance/CG122). 
 
Serum CA-125 is a glycoprotein that is most widely measured to detect ovarian 
cancer however; it can also be elevated in endometriosis, pelvic inflammatory 
disease, liver disease and other malignant tumours (Bast et al., 1983, Jacobs 
and Bast, 1989). 
 
The CA-125 level and abdominal and transvaginal ultrasound are the key 
investigations when suspecting ovarian cancer. In the UK the risk of malignancy 
index (RMI) is used to help predict the risk of malignancy and to triage patients 
to the appropriate specialist. The RMI calculates a score according to ultrasound 
features, menopausal status and pre-operative CA-125 level (Geomini et al., 
2009). The IOTA classification is an alternative system based on specific 
ultrasound findings and has similar sensitivity and specificity to RMI (Alcazar, 
2016). A CT scan is routinely used to assess the site and spread of disease. 
 
If chemotherapy is offered to women with suspected advanced disease, a tissue 
diagnosis should be confirmed by histology or cytology if histology is not 
appropriate (http://www.nice.org.uk/guidance/CG122). 
 
1.6.2 Surgery 
Surgery aims to remove as much tumour as possible and to establish the FIGO 
stage. It should include a total hysterectomy, bilateral salpingo-oophorectomy, 
tumour debulking and omentectomy (Jayson et al., 2014). Optimal debulking 
has been widely accepted as one of the most important prognostic indicators. 
A meta-analysis by Allen et al demonstrated a survival benefit for women with 
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advanced disease who had no macroscopic disease or tumour deposit <2cm 
(Allen et al., 1995). More recently, the survival advantage of complete 
debulking (no visible residual disease) was confirmed prospectively in a large 
adjuvant five-arm chemotherapy study (GOG182/ICON5) (Bookman et al., 2009). 
Thus, the aim of debulking surgery is to remove all visible macroscopic disease. 
   
Increasingly radical surgery is being performed to free the patient of 
macroscopic disease, including diaphragmatic stripping, multiple bowel 
resections and resection of intrathoracic disease. However, the patient’s 
condition and the extent of disease such as the involvement of the porta hepatis 
and small bowel mesentery limit the ability to achieve maximal debulking 
(Aletti et al., 2006). 
 
Retroperitoneal lymphadenectomy has not been shown to confer a survival 
advantage in ovarian cancer but may be important for staging (Panici et al., 
2005).  
 
Primary surgery followed by adjuvant chemotherapy is considered the standard 
care in advanced ovarian cancer. The use of neoadjuvant chemotherapy when 
optimal surgical debulking is believed to be unachievable is now widely 
accepted, in the UK at least. This follows the publication of two trials in 
advanced disease that found no difference in survival between primary surgery 
and neoadjuvant chemotherapy (Vergote et al., 2010, Kehoe et al., 2015). 
 
1.6.3 Chemotherapy 
Adjuvant chemotherapy in early stage disease has been controversial with no 
clear consensus. Two RCTs, ICON1 and ACTION investigated the role of 
chemotherapy in early stage disease. With both studies combined, they 
demonstrated improved overall survival by 8% and progression-free survival by 
11% at 5 years for those receiving adjuvant chemotherapy (Trimbos et al., 2003). 
Following extended follow-up from the ICON1 study, it was concluded that 
chemotherapy should be offered to patients with early disease and particularly 
patients with high-risk disease (stage 1B/1C grade 2/3, any stage 1 grade 3 or 
clear cell histology) (Collinson et al., 2014). 
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For the last 20 years, carboplatin and paclitaxel have been the standard of care 
for chemotherapy in ovarian cancer. The addition of paclitaxel to cisplatin was 
discovered to extend both overall survival and progression-free survival 
(McGuire et al., 1996) and currently six 3-weekly cycles of less toxic carboplatin 
combined with paclitaxel are given to women with advanced disease. 
Treatment response is monitored radiologically and by the CA-125 level (Rustin, 
2003, Rustin et al., 2011). 
 
Intraperitoneal chemotherapy has been found to significantly prolong survival 
in one study (Armstrong et al., 2006). However, toxic effects meant the regime 
was often intolerable and only 42% received all 6 cycles of intraperitoneal 
chemotherapy. Research is on-going into more tolerable regimes. 
 
1.6.4 Recurrent disease 
Most patients with recurrent disease receive second-line chemotherapy 
however a subset of women where surgical resection is achievable may have 
second surgery. The choice of chemotherapy regimen is dictated by the interval 
from the last platinum-based treatment to the point of recurrence (Eisenhauer 
et al., 1997). 
 
Platinum-resistant disease is defined as disease progression within 6 months 
from the last platinum-based regime. Studies have found that <15% of women 
respond to second-line platinum if the ‘platinum-free interval’ is <6 months; 
this rises to >30% when the interval is greater than 6 months (Eisenhauer et al., 
1997, Markman et al., 1991). 
 
Randomised control trials have shown that platinum-sensitive recurrent disease 
is best treated with a combination of platinum-based chemotherapy with the 
addition of paclitaxel, gemcitabine or pegylated liposomal doxorubicin (Parmar 
et al., 2003, Pfisterer et al., 2006, Pujade-Lauraine et al., 2010).   
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1.6.5 New therapeutic options 
There has been extensive research into Poly (ADP-ribose) polymerase (PARP) 
inhibitors for tumours with a defective homologous recombination pathway 
(Farmer et al., 2005, Bryant et al., 2005). PARP inhibitors have been found both 
by Phase I and by randomised trials to be of clinical benefit in women with BRCA 
mutations (Fong et al., 2009, Kaye et al., 2012). Further studies have found a 
prolonged progression-free survival with the addition of a PARP inhibitor as a 
maintenance therapy in recurrent disease following response to platinum-based 
chemotherapy (Ledermann et al., 2012, Mirza et al., 2016, Coleman et al., 
2017). 
 
Trials have also investigated angiogenesis as a target in ovarian cancer with 
most clinical studies involving bevacizumab (monoclonal anti-VEGF antibody). 
Two first-line trials have found that, in advanced disease, with residual tumour 
after surgery, the addition of bevacizumab to carboplatin and paclitaxel can 
improve progression-free survival (Perren et al., 2011, Burger et al., 2011). 
However, overall survival benefits are modest and restricted only to those with 
stage IV disease and/or bulky residual disease following primary dubulking 
surgery (Oza et al., 2015). Similarly, studies in platinum-sensitive and platinum-
resistant relapse have also demonstrated that the addition of bevacizumab 
extends progression-free but not overall survival (Aghajanian et al., 2012, 
Pujade-Lauraine et al., 2014). 
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1.7 Platinum-based Chemotherapy 
1.7.1 Mechanism of action 
Cisplatin and Carboplatin are composed of a doubly-charged platinum atom 
surrounded by four ligands (Dasari and Tchounwou, 2014). Two amine ligands 
form strong interactions with the platinum atom, and the chloride ligands or 
carboxylate compounds form leaving groups allowing the platinum atom to form 
bonds with DNA bases (Goodsell, 2006). 
 
Cisplatin becomes activated once it enters the cell and its chloride ligands are 
displaced by water molecules. It forms intrastrand and interstrand cross-links 
with purine bases to form DNA adducts. The cisplatin-DNA adducts block cell 
division and result in cell death (Dasari and Tchounwou, 2014). Carboplatin has 
a similar mechanism of action to Cisplatin (Figure 1.9). 
 
Hongo et al demonstrated that carboplatin induced the same platinum-DNA 
adducts as those induced by cisplatin (Hongo et al., 1994). Carboplatin is less 
potent than cisplatin and the clinical standard dosage of carboplatin is usually 
4:1 compared to cisplatin (Dasari and Tchounwou, 2014). The main benefit to 
carboplatin is reduction in nephrotoxic, neurotoxic and emetogenic effects; 
however myelosuppression limits the dosage (Dasari and Tchounwou, 2014). 
 
 
Figure 1.9: Chemical and molecular structures of Cisplatin and Carboplatin. 
Both contain a doubly charged platinum atom with four ligands. Adapted from 
(Goodsell, 2006) and (Go and Adjei, 1999). 
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1.7.2 Mechanisms of resistance 
A major factor in the low five-year survival in HGSOC is platinum resistance 
(tumour progression within six months of completion of platinum 
chemotherapy). Classically, in advanced ovarian cancer, patients respond 
initially to chemotherapy (approximately 65%). However, become increasingly 
resistant with more than two thirds relapsing within two years, of which half 
will present with platinum resistant disease (i.e. relapse within 6 months) 
(Vasey et al., 2004). 
 
Multiple mechanisms are thought to contribute to drug resistance. The 
‘classical’ mechanisms include (Vasey, 2003): 
 Decreased drug uptake 
 Increased drug efflux 
 Increased repair of DNA damage induced by chemotherapy 
 Reduced ability to undergo apoptosis 
Newer molecular factors have been linked to platinum resistance that involve 
cell signalling pathways and the immune microenvironment. 
 
1.7.3 Resistance and DNA repair pathways 
The nucleotide excision repair (NER) pathway is responsible for repairing 
cisplatin bound to DNA. The excision repair cross-complementation group 1 
(ERCC1) protein plays a key role in nucleotide excision repair (Martin et al., 
2008). Increased ERCC1 expression has been associated with the development 
of cisplatin resistance in-vitro (Ferry et al., 2000). A study by Kang et al found 
ERCC1 mRNA levels in ovarian tumour samples to be inversely correlated to 
platinum response and survival (Kang et al., 2006). 
 
Mismatch repair pathway (MMR) is a strand-specific repair pathway that is 
initiated with the recognition of DNA damage. When the pathway is deficient, 
damaged DNA accumulates, resulting in microsatellite instability (Martin et al., 
2008). MMR deficiency allows cells to continue to proliferate despite DNA 
damage thus leading to resistance. Epigenetic silencing of MMR through Mut L 
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homologue 1 (hMLH1) promoter hypermethylation has been found in ovarian 
cancer. From mutational and expression data MMR deficiency is thought to be 
more common in non-serous ovarian cancer than serous subtypes (Xiao et al., 
2014). 
 
Homologous recombination (HR) plays a prominent role in the repair of DNA 
double-strand breaks. A number of studies have found that secondary mutations 
in both BRCA1 and BRCA2-mutated tumours can restore the wild-type reading 
frame of the BRCA1/2 protein and mediate acquired resistance to platinum-
based chemotherapy (Swisher et al., 2008, Sakai et al., 2008, Lord and 
Ashworth, 2013). 
 
1.7.4 Resistance and gene mutations 
Amplification of Cyclin E1 (CCNE1), located on chromosome 19q12, is seen in 
approximately 20% of HGSOCs. CDK2 is the regulatory kinase of Cyclin E1 and 
binding of CDK2 to Cyclin E1 allows progression of the cell cycle from G1 to S 
phase and is essential for DNA replication (Etemadmoghadam et al., 2009). 
CCNE1 amplification has been found to be associated with resistance in 
advanced serous ovarian cancer. The CCNE1 copy number is specifically 
associated with chemoresistance and has been validated as a marker of patient 
outcome in ovarian cancer (Etemadmoghadam et al., 2009). 
 
BRCA1/2 mutations and CCNE1 amplification are known to promote genomic 
instability and tumour progression (Etemadmoghadam et al., 2013). They have 
been found to be mutually exclusive with a functional BRCA1 selectively 
required in cancers that have CCNE1 amplification. This requirement for BRCA1 
may offer a potential therapeutic approach for treatment resistant CCNE1-
amplfied tumours (Etemadmoghadam et al., 2013). 
 
p53 protein is involved in controlling the progression of cells through the cell 
cycle and helps cellular responses to DNA damage by mediating DNA repair, cell 
cycle regulation and activation of apoptosis (Vasey, 2003). There is increasing 
evidence that mutant p53 tumours lose wild-type p53 suppressor activity and 
gain functions to help with tumour progression (Muller and Vousden, 2014). In 
56 
 
ovarian cancer a significant correlation has been found between p53 
accumulation, type of p53 mutation and poor response to platinum 
chemotherapy however, this data was found prior to accurate identification of 
disease subtype and before next-generation sequencing was available (Righetti 
et al., 1996). The high expression of both WT and mutant p53 in the cytoplasm 
of many tumours suggests that there is possible gain-of-function of p53 in 
driving oncogenesis (Chee et al., 2013). TP53 as mentioned previously is 
universally mutated in high-grade ovarian cancer and as understanding of 
mutant p53 improves, it may offer a therapeutic target. 
 
PTEN loss is a common event in HGSOC. TCGA previously showed homozygous 
deletion of PTEN in 6% of HGSOC cases (Cancer Genome Atlas Research, 2011), 
but following whole genome sequencing (Patch et al., 2015) and IHC studies 
(Martins et al., 2014), it was demonstrated that approximately 20% of HGSOC 
lose PTEN through complex SV and that up to 40% of tumour cells had loss of 
PTEN protein expression on IHC. PTEN is a phosphatase that inhibits cell 
proliferation induced by the PI3K/AKT pathway and acts as a tumour suppressor 
gene. Activation of the PI3K/AKT pathway is a critical step in cell survival 
through suppression of apoptosis, promotion of cell proliferation, migration, 
cell metabolism and protein translation (Martins et al., 2014). Studies have 
found that activation of the PI3K/AKT pathway may lead to chemotherapy 
resistance (Ohta et al., 2006, Lee et al., 2005). 
 
1.7.5 Platinum Sensitivity  
Women with BRCA1/2 mutations tend to be hypersensitive to platinum 
chemotherapy and have a better prognosis compared to non-carriers (Foulkes, 
2006). However, these patients still frequently develop platinum resistance. A 
recent paper from Candido-dos-Reis et al showed that BRCA1/2 mutations were 
associated with an improved short-term survival. However over time in BRCA1 
carriers this advantage decreased and is reversed by 10 years (Candido-dos-Reis 
et al., 2015). This reversal in survival advantage for BRCA1 carriers is difficult 
to explain at present. However, the short-term survival advantage of BRCA1/2 
carriers is a result of an increased sensitivity to platinum-based chemotherapy 
and impressive sensitivity to PARP inhibitors. 
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TCGA also found improved survival between patients with BRCA1 and BRCA2 
mutations. In patients with a BRCA2 mutation the 5-year survival rate was 61% 
versus 25% in the wild-type. Among the BRCA2 mutated group 100% were 
platinum sensitive and this was compared to 80% of BRCA1 mutated patients 
and 85% of wild-type cases (Cancer Genome Atlas Research, 2011). The BRCA2 
mutated patients also had a longer platinum-free survival when compared to 
both BRCA1 mutated and wild-type patients.  
 
Bolton et al observed that survival in BRCA1 carriers depended on the mutation 
location. The N-terminal mutations on the BRCA1 protein were associated with 
a worse survival compared to C-terminal mutations (Bolton et al., 2012). There 
is also evidence that a mutation in the RING domain (N-terminal) of BRCA1 
results in a poor response to Cisplatin and PARP inhibitors (Drost et al., 2011). 
A recent study by Labidi-Galy et al found that mutations in the RAD51 binding 
domain in BRCA2 carriers was associated with a prolonged progression-free 
survival, platinum-free interval and overall survival (Labidi-Galy et al., 2017a). 
Further research into the location of the BRCA1 and BRCA2 mutations is 
required and particularly how this relates to survival and sensitivity to 
chemotherapy (Figure 1.10). 
 
Increased platinum sensitivity is believed to occur in patients with mutations in 
other homologous recombination genes. This has been supported by Pennington 
et al that looked at 13 homologous recombination genes and found that patients 
with defects in these genes had an improved overall survival and increased 
sensitivity to platinum chemotherapy (Pennington et al., 2014). This was 
further supported by a recent study that found HR mutations including non-
BRCA genes significantly prolonged both progression-free survival and overall 
survival in ovarian cancer (Norquist et al., 2017). As discussed previously the 
TCGA has found that up to 50% of HGSOC may have homologous recombination 
defects (Cancer Genome Atlas Research, 2011). 
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Figure 1.10: Schematic diagram of BRCA1/BRCA2 binding partners. 
Adapted from (Roy et al., 2011). 
BRCA1 contains an N-terminal RING domain that is associated with BARD1, nuclear 
localisation signals (NLS), a coiled coil domain that is associated with BRCA2 via PALB2, 
and two C-terminal BRCT domains that bind ATM-phosphorylated abraxas, CtBP-
interacting protein (CtIP) and BRIP1. 
BRCA2 contains an N-terminal RING domain that binds PALB2, eight BRC motif repeats 
that bind RAD51, a DNA binding domain that bind both ssDNA and dsDNA and a C-
terminal that contains an NLS that also binds RAD51. 
Specific germline mutations found in Ashkenazi Jews (BRCA2 6174delT, BRCA1 
185delAG and 5382insC) are illustrated in the above figure. 
 
 
At present women with HR mutations including BRCA1/2 are the only group of 
patients that we can predict are more likely to be sensitive to platinum 
chemotherapy. However, a study by Alsop et al found that of women with 
BRCA1/2 mutations 85% were sensitive versus 68% and 15% of women with 
BRCA1/2 mutations were resistant to platinum chemotherapy (Alsop et al., 
2012). This study however defined sensitivity by the Ca125 and CT findings 
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whereas in clinical practice sensitivity and resistance are defined by the time 
to relapse. The reason for differences in cisplatin response in this group of 
patients in unclear and further research into the site and type of BRCA1/2 
mutation may offer an explanation. 
 
1.7.6 Influence on tumour microenvironment 
There is good evidence that HGSOC is an immunogenic tumour and recent in-
vivo models have shown the immune system to play an important role in 
response to certain chemotherapy (Vacchelli et al., 2014, Michaud et al., 2011). 
The ability to take tumour biopsies at the time of diagnosis and following NACT 
gives us an opportunity to look at the influence chemotherapy has on the 
tumour microenvironment and whether the introduction of immunotherapy may 
be beneficial. 
 
Böhm et al found that in omental biopsies after neoadjuvant chemotherapy 
there was evidence of T cell activation with significantly fewer FoxP3+ T 
regulatory (Treg) cells and increased levels of immune-checkpoint molecules 
PD-1+, CTLA4+ and PD-L1+. This suggests that platinum chemotherapy can 
initially enhance the host’s immune response, but this effect is tempered by an 
increase in immune checkpoint molecules (Bohm et al., 2016). 
 
A recent study by Lo et al found that neoadjuvant chemotherapy increased the 
densities of CD3+, CD8+, TIA-1+ and CD20+ tumour infiltrating lymphocytes in 
tumour samples (Lo et al., 2017). However, other than PD-1 that was increased, 
other immunosuppressive cell types were unchanged. They identified three 
major PD-1+ TIL subsets: PD-1+ CD8-, PD-1+ CD8+ and PD-1+ FoxP3+. However, 
when analysed individually none of the subsets increased significantly so the 
overall increase may be due to small increases in all three subsets (Lo et al., 
2017).  
 
Pre-treatment tumours with increased densities of CD3+, CD8+, CD20+ and TIA-
1+ have previously been shown to have a strong association with survival (Sato 
et al., 2005, Zhang et al., 2003). A feasible hypothesis is that post-neoadjuvant 
chemotherapy samples would have a greater prognostic significance given that 
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the altered microenvironment should influence the chance of disease 
recurrence. Lo et al found CD20+ B cells to be significantly associated with 
survival however there was no significant association with CD3+, CD8+ and TIA-
1+ (Lo et al., 2017). 
   
Lo et al also identified TIL response patterns using hierarchical clustering of the 
pre- and post-neoadjuvant chemotherapy samples. In the pre-NACT samples 
three subgroups of patients were identified. The first subgroup was positive for 
most of the immune markers (CD3+, CD4+, CD8+, TIA-1+, CD20+, FoxP3+ and PD-
1+) representing an immunoreactive tumour. The second showed 
low/intermediate levels of immune markers and the third was negative for most 
immune markers (Lo et al., 2017). Three response patterns were identified in 
the post-NACT samples. The pre-NACT samples that were positive for the 
immune markers generally showed a higher expression after NACT, samples 
with intermediate levels of immune markers also showed a higher expression 
and samples that were initially negative/low remained the same after NACT (Lo 
et al., 2017). 
 
De Nardo et al found that in breast cancer an increased macrophage density 
correlated with a poor survival and that the ratio of macrophages/CD68+ to CD8+ 
was inversely correlated. They inhibited the tumour associated macrophages 
in-vivo and with the addition of chemotherapy showed an increase in the CD8 
response and a positive influence on overall outcome (DeNardo et al., 2011). 
 
There is evidence that treatment of cervical and ovarian cancer cell lines with 
platinum chemotherapy skews the monocytes to M2-like macrophages 
(Dijkgraaf et al., 2013). 
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1.8 Cancer Signalling Pathways 
TCGA has identified both PTEN and NF1 as common mutations in HGSOC. PTEN 
acts as a tumour suppressor gene and inhibits cell proliferation normally 
induced by the PI3K/AKT pathway. NF1 is located at chromosome 17q11.2 and 
acts as a tumour suppressor gene that affects RAS-MAPK signalling. TCGA found 
NF1 gene alterations in 12% of HGSOC patients (8% homozygous deletion and 4% 
mutations) (Yap et al., 2014). 
 
1.8.1 PI3K/AKT Pathway 
PI3K/AKT signalling pathway controls cellular processes such as proliferation, 
migration, apoptosis and metabolism. The Akt signalling cascade is activated 
by receptor tyrosine kinases and G-protein-coupled receptors that lead to 
production of PIP3 by PI3K. This results in phosphorylation of Akt that stimulates 
multiple pathways including mTOR signalling (Figure 1.11). 
 
PTEN catalyses the dephosphorylation of PIP3 to PIP2 (membrane phospholipids) 
resulting in inhibition of the Akt activity. 
 
 
Figure 1.11: PI3K/AKT pathway illustrating the role of PTEN. 
PI3K phosphorylates PIP2 to PIP3. Increases in PIP3 recruits AKT to the membrane 
where it is activated by other kinases. Akt phosphorylation mediates several important 
targets including mTOR which is responsible for up-regulation of protein synthesis. 
PTEN opposes PI3K by hydrolysing PIP3 to PIP2 (dephosphorylation) and resulting in 
inhibition of the PI3K/AKT pathway. 
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1.8.2 RAS/RAF/MEK/ERK Pathway 
The RAS/RAF/MEK/ERK pathway is an important signalling pathway in cancer. 
Signalling through this pathway regulates several cellular functions including 
cell cycle regulation and migration that are crucial for tumorigenesis. 
 
NF1 encodes for the neurofibromin protein and acts as a negative regulator of 
RAS. Neurofibromin inactivates Ras by accelerating the hydrolysis of active RAS-
GTP to inactive RAS-GDP (Yap et al., 2014). As a consequence of RAS 
inactivation, downstream effectors of RAS are also suppressed, including PI3K, 
Akt, mTOR, RAF, MEK and ERK. In somatic NF1-associated tumours, biallelic loss 
of NF1 is common and the main driver of oncogenesis whereas in non-NF1 
associated tumours e.g. ovarian cancer, loss is not thought to act as an 
oncogene. In ovarian cancer, it is unknown whether biallelic loss of NF1 or 
hemizygous loss is driving tumour progression (Ratner and Miller, 2015). The 
RAS/RAF/MEK/ERK and PI3K/AKT pathways interact with each other to regulate 
growth and tumour survival (Figure 1.12). 
 
Figure 1.12: RAS/RAF/MEK/ERK pathway illustrating the role of NF1.  
RAS is in its activated state when bound to GTP. Activated RAS activates the protein 
kinase activity of RAF kinase which subsequently activates MEK/ERK kinases. NF1 
negatively regulates the RAS signalling pathway. Loss of NF1 results in increased levels 
of GTP-bound RAS levels and activation of signalling pathways downstream of RAS. 
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1.9 Homologous Recombination 
DNA double-strand breaks (DSBs) are generally considered the most toxic of all 
DNA lesions. The repair of DSBs involves two complementary pathways – 
Homologous recombination (HR) and Non-homologous end joining (NHEJ). NHEJ 
is error-prone and promotes inaccurate re-ligation of DSBs, whereas HR is more 
precise and restores the genomic sequence by utilising sister chromatids as a 
template for repair (Ciccia and Elledge, 2010). 
 
 
Figure 1.13: Illustration of double strand break (DSB) repair by HR. 
DSB is initiated by 5’ to 3’ resection of the DNA ends. The resulting 3’ strand invades 
an intact homologous duplex. A D-loop is formed and extended by DNA synthesis until 
it can pair with an exposed complementary sequence. The 3’ strand of the second end 
serves as a primer for fill-in synthesis. 
 
The HR pathway is activated when components of the MRN complex 
(MRE11/RAD50/Nbs1) bind to DNA double-strand breaks. The complex promotes 
activation of ATM and the preparation of DNA for HR (Ciccia and Elledge, 2010). 
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RAD50 contains ATPase domains that interact with MRE11. MRE11 stabilises DNA 
ends and has endonuclease and exonuclease activities involved in the initial 
DNA end resection. Nbs1 interacts with MRE11 and promotes the recruitment 
of ATM to DSBs (Williams et al., 2010). 
 
DNA end resection is regulated by ATM through CtIP, which interacts with BRCA1 
and MRN in the BRCA1-C complex (Huen et al., 2010). DSB resection and 
formation of 3’ single stranded DNA (ssDNA) ends lead to RPA accumulation 
which help stabilise the ssDNA regions. BRCA1 associates with BRCA2 through 
PALB2/FANCN which is a major binding protein of BRCA2. BRCA1 has been found 
to be an upstream regulator of BRCA2 in DNA repair and the PALB2 is the main 
linker between BRCA1 and BRCA2 (Zhang et al., 2009). 
 
RAD51 filaments assemble on RPA-coated ssDNA mediated by BRCA2. RAD51 
induce strand invasion into the homologous DNA sequence and DNA 
polymerisation occurs using the sister chromatid as a template (Ciccia and 
Elledge, 2010). Further regulation of HR is provided by RAD51 phosphorylation 
mediated by CHK1, which is required for RAD51 recruitment to damage sites. 
BRCA2 is also phosphorylated by ATM/ATR (Figure 1.13 and Figure 1.14). 
 
BRCA1/BRCA2 mutations are the most common cause of defective homologous 
recombination in HGSOC. BRCA1 and BRCA2 mutations have been found to be 
associated with several clinical characteristics. Further analysis of the TCGA 
data found patients with BRCA1 mutations were younger at diagnosis and the 
5-year survival was significantly higher compared to wild-type patients. 
 
Specific mutations in BRCA1 and BRCA2 occur more frequently in Ashkenazi 
Jews than in the general population. In Ashkenazi Jews, three mutations have 
been identified in breast/ovarian cancer families: 185delAG and 5382inC in 
BRCA1 and 6174delT in BRCA2 (Levy-Lahad et al., 1997). In a large population-
based study of young Ashkenazi Jews the frequency of these mutations was 2.5% 
(BRCA1 185delAG 1%, BRCA1 5382inC 0.1% and BRCA2 6174delT 1.4%) (Roa et 
al., 1996). 
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Figure 1.14: Homologous recombination pathway. 
The MRN complex is recruited to DSBs by PARP and mediates the initial DSB resection 
together with CtIP and BRCA1. DSB resection leads to RPA accumulation and stabilises 
the ssDNA. Displacement of RPA and assembly of RAD51 filaments mediated by BRCA2 
leads to strand invasion into homologous sequence. PALB2 links BRCA1/BRCA2 and 
BRCA1 acts as an upstream regulator of BRCA2. 
 
 
The HR process is closely linked to the cell cycle. BRCA1 and RAD51 are only 
expressed in S and G2 phases of the cell cycle, therefore making HR impossible 
in G1. Also cells in G0 and G1 have not replicated their DNA and therefore lack 
sister chromatids that provide homologous sequences for HR (De Lorenzo et al., 
2013). 
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1.10 Tumour Heterogeneity  
The use of next-generation sequencing technology has helped us to understand 
that no two cancers are alike and that even different regions within the same 
tumour vary in their composition. Current evidence suggests that cancers 
evolve in a branched or punctuated pattern that results in temporal and spatial 
heterogeneity (Hiley and Swanton, 2014). This heterogeneity affects key 
pathways and presents a significant challenge to personalised medicine where 
a single biopsy is often used to guide management and develop biomarkers. 
 
There are thought to be many factors that contribute to tumour evolution. 
These include intrinsic factors such as genomic instability and extrinsic factors 
such as the tumour microenvironment and cytotoxic chemotherapy (Hiley and 
Swanton, 2014). Widespread genomic instability is prominent in HGSOC. This 
instability generates a diverse cell population that can be subject to selection 
within the microenvironment and following chemotherapy. 
 
Several studies have looked at genomic diversity within and between primary 
tumours and metastasis in ovarian cancer. Bashashati et al found widespread 
intratumoural variation in mutation, copy number and gene expression profiles 
and with key mutations only present in a subset of samples (Bashashati et al., 
2013). TP53 was the only somatic mutation consistently present in all samples 
(Bashashati et al., 2013). 
 
A recent study looked at intra-tumour heterogeneity pre- and post-
chemotherapy in HGSOC. They determined that subclonal tumour populations 
were present prior to chemotherapy and these can undergo expansion during 
chemotherapy resulting in relapse. Patients with high clonal expansion were 
associated with a worse survival. However due to the size of the patient cohort 
it is difficult to make any strong conclusions (Schwarz et al., 2015). 
 
Interestingly, in most patients who relapse after chemotherapy they are 
platinum-sensitive. Therefore, the original concept of intratumoural 
heterogeneity and clonal selection of resistant cells by chemotherapy does not 
fit well in ovarian cancer. A possible hypothesis for platinum sensitive 
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recurrence is the presence of dormant chemo-sensitive stem cells that, 
following completion of chemotherapy, start to regrow and repopulate the 
tumour (Chien et al., 2013). 
 
As discussed, the diverse tumour population includes a variety of different 
genotypes. The interaction between these different genotypes within a tumour 
and how this environment is altered following chemotherapy is not known. 
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1.11 ID8 Cell Line and Derivatives  
The ID8 cell line is the most widely used transplantable murine model of ovarian 
cancer (Roby et al., 2000). This originated from cells from 5 C57BI/6 mice 
ovaries that had been trypsin-digested. After about 20 passages, the cells lost 
contact inhibition and their classic cobblestone appearance. Ten different 
clones were derived, one of which, ID8, has been widely used in ovarian cancer 
research. 
 
Following intraperitoneal injection of the ID8 cell line in-vivo, diffuse 
peritoneal tumour deposits with blood-stained ascites develop after 
approximately 110 days (Roby et al., 2000) (Figure 1.15). 
 
Next generation sequencing by the host lab has shown that the parental ID8 cell 
line lack any of the characteristic mutations that you would expect in HGSOC 
(Walton et al., 2016). Using the CRISPR/Cas9 gene editing technique, single 
(Trp53-/-), double (Trp53-/-;Brca2-/-), double (Trp53-/-;Brca1-/-), double 
(Trp53-/-;Pten-/-), double (Trp53-/-;Nf1-/-), triple (Trp53-/-;Brca1-/-; Pten-
/-) and triple (Trp53-/-;Brca2-/-;Pten-/-) knockout derivatives of ID8 have been 
generated by Dr Josephine Walton (post-doc, McNeish Lab) (Walton et al., 2017). 
 
 
Figure 1.15: ID8 intraperitoneal injected mice. 
The figure shows classical features of ovarian cancer with bloody ascites and 
widespread peritoneal tumour deposits. 
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The ID8 derivatives were used extensively in my research and the different cell 
lines are outlined below (Figure 1.16). 
 
 
Figure 1.16: ID8 cell line and derivatives. 
This illustrates the different ID8 derivatives generated by CRISPR/Cas9 gene editing 
technology. Trp53-/- knockout clones were generated from the original ID8 parental 
cell line and all subsequent knockouts originated from the F3 Trp53-/- clone. The 
circles show the different clones from each genotype that I used throughout this thesis. 
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1.12 Research Aims and Hypothesis 
This thesis investigated the role of homologous recombination and the tumour 
microenvironment in HGSOC and how this environment is altered by platinum 
chemotherapy. By using a transplantable HGSOC mouse model the different 
immune cell populations and cytokines were assessed. 
 
This tested the hypothesis that platinum chemotherapy alters the tumour 
microenvironment in different HGSOC genotypes supporting an 
immunosuppressive state. To test the hypothesis, the main objectives were to: 
 
1. Establish the relationship between homologous recombination and platinum 
and PARP inhibitor sensitivity 
 Assess homologous recombination status on HGSOC cell lines and ID8 
derivatives 
 Platinum and PARP inhibitor dose-response on cell lines 
 
2. Assess in vivo cisplatin response in ID8 sublines 
 Determine differences in survival between the ID8 genotypes 
 Assess differences in the tumour microenvironment within the 
tumour and ascites between the ID8 genotypes 
 
3. Assess in vivo tumour heterogeneity 
 Generate fluorescent ID8 sublines 
 Determine differences in tumour development between the ID8 
genotypes and influence of platinum chemotherapy 
 
By addressing these aims it is hoped that this project will further the 
understanding of platinum sensitivity in HGSOC and, by looking at the tumour 
microenvironment, offer attractive therapeutic targets for future research. 
71 
 
2 Materials and Methods 
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2.1 Cell Culture 
High grade serous ovarian cancer (HGSOC) cell lines were cultured in T75 flasks 
in Dulbecco’s Modified Eagle Medium (DMEM) (Thermofisher, 21969-035) 
supplemented with 10% foetal bovine serum (FBS) (Thermofisher, 10500-064), 
100μg/ml Penicillin/100μg/ml Streptomycin (P/S) (Thermofisher, 15140-122), 
and 2mM L-Glutamine (LG) (Thermofisher, 25030-024) at 95% humidity, 5% CO2 
and 37°C. 
 
ID8 cells  (Roby et al., 2000) were cultured in T75 flasks in DMEM, supplemented 
with 4% FBS, 100μg/ml Penicillin/ 100μg/ml Streptomycin (P/S), 5μg/ml insulin, 
5μg/ml transferrin and 5ng/ml sodium selenite (ITS) (Thermofisher, 41400-045) 
and 2mM L-Glutamine (LG) at 95% humidity, 5% CO2 and 37°C. 
 
ID8 cells were passaged 1:20 twice weekly; cells were washed once with PBS 
and detached using 1x 0.5% Trypsin-EDTA (Thermofisher, 15400-054) in PBS. 
The cells were cryopreserved for long-term storage: cells were centrifuged at 
1200rpm and the cell pellet resuspended in FBS containing 10% DMSO. The cells 
were stored overnight in a Mr Frosty at -80°C prior to transfer to liquid nitrogen 
the next day. 
 
OvidT 479 (DICER-/-;Pten-/-) cells were cultured in T75 flasks in Dulbecco’s 
Modified Eagle Medium F12 (DMEM F12) (Thermofisher, 11320-074) 
supplemented with 10% FBS, 100μg/ml Penicillin and ITS at 95% humidity, 5% 
CO2 and 37°C. 
 
HGSOC cell lines were obtained from the National Cancer Institute (NCI, 
Frederick, MA, USA), OvidT 479 cells from Dr Seth Coffelt (CRUK Beatson 
Institute, Glasgow) and ID8 parental cells from Dr Katherine Roby (University of 
Kansas). 
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All cell lines were verified by Short Tandem Repeat profiling (STR) using the 
Promega GenePrint 10 system (Promega, UK) at the CRUK Beatson Institute. 
Cell lines were routinely tested for mycoplasma at the Wolfson Wohl Cancer 
Research Centre, University of Glasgow, using MycoAlertTM, Mycoplasma 
Detection Kit (Lonza, LT01-318). The cell lines used throughout this thesis are 
outlined in Table 2.1. 
 
Table 2.1: Outline of cell lines and corresponding mutations. 
 
Human (HGSOC) 
PEO1 BRCA2 mutation 
PEO2 BRCA2 wild-type 
UWB1.289 BRCA1 mutation 
UWB1.289BRCA1 BRCA1 wild-type 
OVCAR3 / 
OVCAR4 / 
COV318 / 
Mouse (ID8) 
Clones  
F3, A2, M20, C7 Trp53-/- 
3.15, 2.14 Trp53-/-;Brca2-/- 
1.36, 1.26, 6.20 Trp53-/-;Brca1-/- 
1.11, 1.12, 1.14, 1.15 Trp53-/-;Pten-/- 
1.9, 1.10 Trp53-/-;Pten-/+ 
1.20, 1.23 Trp53-/-;Nf1-/- 
3.15.10, 2.14 22 Trp53-/-;Brca2-/-;Pten-/- 
1.36.23, 6.20.10, 1.26.19 Trp53-/-;Brca1-/-;Pten-/- 
Mouse (OvidT 479) 
DKO 4 Dicer-/-;Pten-/- 
TKO 13 Dicer-/-;Pten-/-;Trp53-/- 
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2.2 Survival Assays 
2.2.1 MTT assay 
Thiazolyl Blue Tetrazolium Bromide powder, (Sigma Aldrich, M2128) was 
dissolved in PBS to give a 0.5% w/v solution. Medium was aspirated from cells 
in 24 well plates and replaced with 700μl of 1:10 MTT solution and incubated 
for 2 hours at 37°C. Medium was aspirated and formazan crystals dissolved in 
300μl DMSO. Plates were read at 560nm on a Tecan, Infinite 200Pro plate reader 
and absorbance from a blank well was subtracted from all absorbances.  
 
2.2.2 Sulphorhodamine B assay 
Cells in a 24 well plate were washed in PBS and fixed with 250μl 10% 
Trichloroacetic acid (TCA) (Sigma Aldrich, T9159) for 30 minutes at 4°C. The 
cells were then washed three times in dH2O, left to air dry and stained for 30 
minutes with 250μl of Sulphorhodamine B (Sigma Aldrich, 230162) (0.4% w/v in 
1% acetic acid). Following this, the Sulphorhodamine B was washed off with 1% 
acetic acid until running clear and left to air dry. Cells were dissolved in 500μl 
1mM Tris pH9. Plates were read at 565nm on a Tecan Infinite 200Pro plate 
reader and absorbance from a blank well was subtracted from all absorbances.  
 
2.2.3 Dose-response curves 
Cisplatin (Accord Healthcare, Harrow, UK) was obtained from the 
chemotherapy pharmacy, Beatson West of Scotland Centre. Rucaparib was 
provided by Clovis Oncology (Boulder CO, USA). ID8 cells and derivatives were 
washed, trypsinised and plated at 3000 cells/well for Cisplatin and 10,000 
cells/well for rucaparib in a 24 well plate. Four hours later, medium was 
removed and replaced with fresh medium (control) or medium containing 
cisplatin (0.01-1000μM) or rucaparib (0.003-30μM). Three wells were used for 
each drug concentration, with 5 wells used for a control and one well left as 
blank. 72 hours after initial plating, survival was determined by MTT assay 
(cisplatin) and sulphorhodamine B assay (rucaparib). Survival was expressed as 
a percentage of the control and IC50s were determined using Prism v6.0 
(GraphPad, CA, USA).  
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HGSOC and OvidT 479 cell lines were plated at 10,000 cells/well (cisplatin and 
rucaparib) and the drug was added after 24 hours. The survival was determined 
72 hours later by MTT or sulphorhodamine B assay.  
 
2.2.4 Proliferation assay 
ID8 and fluorescent ID8 cell lines were washed, trypsinised and plated at 3000 
cells/well in a 24 well plate. At each time point (24h, 48h, 72h, 96h, 120h), an 
MTT assay was performed on a single row of three wells. Absorbances from 
blank wells were subtracted from absorbances at each time point. From these 
values the linear regression was calculated (Prism v6.0). 
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2.3 Homologous recombination assays 
2.3.1 RAD51/γH2AX assay 
The original assay was developed and published by the lab of Nicola Curtin and 
Richard Edmondson to assess HR competence (Mukhopadhyay et al., 2010). A 
cell line is deemed to be HR competent if cells can double the number of Rad51 
foci in response to DNA double strand breakage (defined as ≥2-fold increase in 
γH2AX foci) induced by 24 hours of treatment with 10μM rucaparib. This assay 
was used to assess the HR status of HGSOC cell lines, OvidT 479 cell lines, 
parental ID8s and their derivatives.  
 
Coverslips were sterilised in 70% ethanol and plated in 24 well plates. 500µl of 
0.1% poly-L-lysine was added to each coverslip and incubated at 37° for 5 
minutes. The poly-L-Lysine was aspirated and washed once with dH2O and left 
for 2 hours before plating cells. HGSOC and DICER cell lines were plated at 5 x 
104 per well and ID8 cells at 3 x 104 per well. The following day cells were 
treated either with 10μM rucaparib/medium or irradiation (10Gy)/medium. 
 
Cells were stained 6 hours after exposure to irradiation or 24 hours following 
rucaparib treatment. 
 
Cells were permeabilised for 1 minute in 0.2% Triton, and immediately fixed for 
10 minutes in 3% PFA with 2% sucrose. Cells were washed in PBS (x3) using a cut 
pipette tip, before staining with primary antibodies in 2% BSA at 37°C for 30 
minutes. Cells were washed with PBS (x3) and stained with secondary antibodies 
in 3% BSA at 37°C for 30 minutes (Table 2.2). Cells were washed a further three 
times with PBS before mounting using DAPI and kept at 4°C overnight. The slides 
were blinded to cell line, but with knowledge of treatment. All images were 
captured using a Zeiss 710 confocal microscope. Rad51 and γH2AX were counted, 
with at least 30 cells counted per cell line across multiple areas. Rad51 and 
γH2AX foci following rucaparib or irradiation treatment are expressed relative 
to medium control +/- SEM. 
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Table 2.2: Primary and secondary antibodies used for the RAD51/γH2AX assay. 
 
Primary antibodies Rad51 γH2AX 
Supplier Santa Cruz Millipore 
Catalogue No. Sc8349 14-576 
Dilution 1:100 1:800 
Secondary antibodies ALEXA 568 (anti-rabbit) ALEXA 488 (anti-mouse) 
Supplier Invitrogen Invitrogen 
Catalogue No. A-11011 A-11001 
Dilution 1:200 1:200 
 
2.3.2 DR-GFP assay 
The GFP/ISce-I endonuclease assay is considered the gold standard for 
determining homologous recombination status. 5 x 105 HGSOC cells were plated 
per well in a 6 well plate. The following day 5μg of pDR-GFP plasmid was 
transfected into cells using a 3:1 FuGene 6 to plasmid ratio (Promega, E2691) 
and surviving colonies selected using puromycin (1 in 1000). Once surviving 
colonies were expanded, cells were replated and transfected with pISce-I or 
pCAAGS (control plasmid) (FuGene 3:1). 48 hours following transfection, cells 
were trypsinised and GFP positivity assessed by flow cytometry (Figure 2.1). 
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Figure 2.1: DR-GFP assay. 
This assay uses the I-SceI rare-cutting endonuclease from Saccharomyces cerevisiae. I-
SceI recognises an 18-bp DNA sequence not found in the human genome. It employs an 
inactive GFP plasmid (DR-GFP) containing a restriction site for I-SceI in the 5’GFP 
construct (SceGFP). Downstream of the SceGFP is an internal GFP fragment (iGFP), 
which is under an inactive promoter. The DR-GFP plasmid is transfected in the human 
cells and clones established by selection with puromycin. Cells expressing pDR-GFP are 
then transfected with pI-SceI which induce a single site-specific DSB in the 5’GFP 
construct (Golding et al., 2004).  
 
Once a single site-specific DSB is introduced, the 3’copy of GFP DNA (iGFP) can be used 
as a template for repair by homologous recombination, resulting in a functional GFP 
gene. The GFP positive cells are easily quantifiable by flow cytometry and HR status 
determined. 
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2.4 Development of mCherry and GFP ID8 cell lines 
2.4.1 GFP lentiviral transfection 
2.5 x 106 HEK 293T cells were plated in a 10cm dish (DMEM, 5% FBS + no P/S) 
for a confluency of 50-70% the next day. Following day, 30μl FuGene 6 (Promega, 
E2691) added to 600μl of Opti-MEM (Thermofisher, 31985070) (serum-free 
medium), mixed with a pipette and incubated at room temperature for 5 
minutes. 4μg GFP lentiviral plasmid (HIV-7-GFP), 4μg package plasmid (psPAX 
contains gag, pol, rev and tat) and 4μg envelope plasmid (VSV-G) mixed by 
inverting eppendorf and incubated at room temperature for 20 minutes. The 
contents were added to the dish and to ensure efficient mixing, plates were 
swirled in a figure of eight motion before incubation at 37°C. 
 
The pHIV-7-GFP plasmid was obtained from Dr Vignir Helgason, Institute of 
Cancer Sciences, University of Glasgow, Glasgow, UK 
 
2.4.2 mCherry retroviral transfection 
2.5 x 106 Phoenix cells (encoding Gag-Pol-Env) were plated in a 10cm dish 
(DMEM, 5% FBS + no P/S) for a confluency of 50-70% the next day. Following day, 
12μl FuGene 6 added to 200μl of Optimem (serum-free medium), mixed with a 
pipette and incubated at room temperature for 5 minutes. 4μg mCherry 
retroviral plasmid (Addgene, pMSCV-IRES-mCherry FP) (1:3 ratio) is added, 
mixed by inverting eppendorf and incubated at room temperature for 20 
minutes. The contents were added to the dish and mixed as above before 
incubation at 37°C. 
 
2.4.3 Lentiviral and retroviral harvest 
The following day, medium was aspirated and replaced with serum-containing 
DMEM medium. 24 hours later the supernatant was removed using a 10ml 
syringe and then centrifuged at 3000rpm for 10 minutes to remove HEK293T or 
Phoenix cells. The remaining supernatant was filtered with a 2μM filter and 
frozen at -80°C. Medium was added to the cells, incubated for a further 24hr 
and the process repeated to obtain additional viral supernatant. 
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2.4.4 Infection of ID8 cells with mCherry retrovirus and GFP lentivirus 
1 x 105 cells were plated on a 6cm plate. After 24 hours 250μl of viral 
supernatant was added and medium was changed the next day. 72 hours after 
incubation the cells were expanded into a T75 flask. GFP cells were visible 
under the microscope.  
 
2.4.5 Sorting GFP and mCherry cell lines    
As GFP positive cells were visible under the microscope, these cells were sorted 
by dilution cloning. A starting concentration of 2 x 104 cells (200μl) were plated 
in the first well of a 96 well plate. A multi-channel pipette was used for the 
dilution cloning. After 3-4 days, single cell GFP colonies were visible and were 
gradually expanded to T75 flasks before freezing at -80°C. 
 
mCherry expression was not visible under our microscope. Positive mCherry 
single cells were sorted by flow cytometry using a negative control (3.15 clone) 
into a 96 well plate. These single cell colonies were again gradually expanded 
to T75 flasks before freezing at -80°C.  
 
 
  
81 
 
2.5 Immunohistochemistry 
Three tissue microarrays (TMA) from the cisplatin in-vivo experiment were 
generated by the Histology Service, CRUK Beatson Institute. The TMA blocks 
were created using a 1mm punch set (Estigen Tissue Science, Estonia, Cat No: 
MP10) on a Manual Tissue Arrayer MTA-1 (Beecher Instruments Inc, Sun Prairie, 
WI, USA) using formalin-fixed paraffin-embedded tumours. Four blocks were 
used per genotype and each cisplatin treatment group, and three cores were 
taken per paraffin-embedded block. The cores were spread across three TMAs 
with the histology department generating a randomised map. 
 
5μm sections from the TMAs and other paraffin-embedded tumours were 
optimised and stained at the Histology Service, CRUK Beatson Institute using a 
Dako Autostainer (Dako, UK) (Table 2.3). 
Table 2.3: Antibodies used for immunohistochemistry staining. 
Mouse antibodies Supplier Cat No. Dilution 
F4/80 Abcam C1:A3-1 1/200, Proteinase K retrieval 
CD3 Abcam ab16669 1/50, pH6 
CD8a eBioscience 14-0808-82 1/75, pH8 
p-Akt (Ser473) Cell Signalling 4060 1/45, pH6 
CD206 Abcam Ab64693 1/1000, ER2 retrieval 
iNOS Abcam Ab15323 1/50, ER2 retrieval 
BrdU BD Biosciences 347580 1/500, pH6 
GFP Cell Signalling 2555 1/50, pH8 
mCherry  Cell Signalling 4060 1/100, pH9 
 
Stained slides were digitised (Hamamatsu NanoZoomer NDP, Hamamatsu 
Photonics, Welwyn Garden City, UK). The slides were then uploaded onto 
HALOTM digital image analysis software v2.0.1061.3 (IndicaLabs) and classifiers 
created to differentiate tumour from non-tumour (Figure 2.2). Cellular staining 
algorithms for each marker (CD3, F4/80) were designed and the analysis was 
performed only on the tumour areas (Figure 2.3).  
 
The slides were scored using the histoscore method as described in (Kirkegaard 
et al., 2006). This algorithm grades staining intensity as negative (0), weak (1), 
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moderate (2) and strong (3), multiplied by the percentage of tumour cells in 
each category giving a histoscore ranging from a minimum of 0 to a maximum 
of 300.  
 
  
Figure 2.2: Classifier to differentiate tissue type.  
Tumour (red) and non-tumour (blue) areas. Analysis of staining intensity was 
performed only on the tumour areas. 
 
 
Figure 2.3: Example of the staining algorithm. 
Mouse p-Akt (Ser473) and F4/80, staining intensity was scored as negative (0), weak 
(yellow - 1), moderate (orange - 2) and strong (red - 3). 
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2.6 Gene expression analysis 
2.6.1 Tumour cellularity 
A proportion of the tumours were assessed for tumour cellularity prior to RNA 
extraction. The samples had been initially placed in PBS prior to being snap 
frozen. To improve the quality of the haematoxylin and eosin (H&E) staining 
half the tumour was placed in 60% sucrose for 2 hours and transferred to 30% 
sucrose overnight and snap frozen again. RNA was then extracted from tumours 
with a cellularity >50%.  
 
2.6.2 RNA extraction from tumours 
A master mix of 10μl/ml β mercaptoethanol (Sigma Aldrich, M3148) in RLT 
buffer (Qiagen RNeasy Mini kit) was prepared and kept on ice for at least 30 
minutes prior to RNA extraction. Snap-frozen tumours were placed in foil on 
dry ice, crushed and transferred to RLT/β mercaptoethanol mix. Tumours were 
homogenised using a Polytron® PT 1200 E homogeniser (Kinematica) and the 
resulting lysate frozen at -80 for no longer than 1 month before RNA extraction. 
 
Homogenised lysates were thawed to room temperature prior to RNA extraction. 
RNA was extracted using the RNeasy RNA Mini kit (Qiagen). The lysate was 
centrifuged at 13,000rpm for 3 minutes. The supernatant was transferred to an 
eppendorf tube. 1 volume of 70% ethanol was added to the lysate, pipetted 
gently up and down to mix and a maximum of 700μl transferred to an RNA 
binding column collection tube. The column was centrifuged for 15 seconds at 
8000rpm, the flow through discarded, any additional supernatant was added to 
another column, and the cycle repeated. A master mix of DNAase solution was 
made up (70μl RDD buffer and 10μl DNase stock) (RNase-free DNase set, Qiagen, 
79254). 80μl of mix was pipetted directly onto the column and incubated for 15 
minutes. Following this, 350μl buffer RW1 was added, centrifuged at 8000rpm 
for 15 seconds and the follow through discarded. 500μl of RPE buffer was added, 
centrifuged at 8000rpm for 15 seconds and flow through discarded. A further 
500μl of RPE buffer was added, centrifuged for 2 minutes at 8000rpm and flow 
through discarded. The column was then placed in a new 2ml tube and 
centrifuged for 1 minutes at 13,000rpm to dry the membrane. The column was 
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transferred to a 1.5ml RNase free Eppendorf. 50μl RNase free dH2O was 
pipetted onto the column and RNA was eluted by centrifugation at 9000rpm for 
1 minute. RNA was quantified using the NanoDrop 2000 spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA).  
 
Immediately after quantification of RNA, the RNA was diluted with nuclease-
free H2O into 2 eppendorfs to minimise the number of freeze-thaw cycles. The 
first Eppendorf with 3μl of 50-100ng/μl for RNA quality check and the second 
at 1µg/50μl for the RNA library preparation/sequencing. 
 
2.6.3 RNA quality  
Prior to library preparation, each RNA sample was run through an Agilent 2220 
TapeStation System (Agilent Technologies, Santa Clara, CA, USA) and a RNA 
integrity number (RIN) calculated. Samples were included for RNA sequencing 
if RIN >7. 
 
2.6.4 Library preparation for RNA sequencing 
‘With-Beads’ library preparation was done using TruSeq Illumina Stranded Total 
RNA Library Prep kit by the Sequencing Department, CRUK Beatson Institute.  
 
Step 1: Purification of poly(A)-RNA from total RNA 
 
50μl of oligo-dT magnetic beads were added to the 1μg/50μl total RNA and 
mixed well by pipetting. The samples were incubated in the thermocycler to 
bind poly(A)-RNA to the beads:  
 
65°C for 5mins  →  4°C for 1 mins  →  25°C for 5 mins 
 
The beads on the magnet were collected and supernatant removed. The beads 
were re-suspended with 200μl of Bead Wash Buffer and beads collected and 
supernatant removed. The beads were re-suspended again with 50μl of Elution 
buffer and samples incubated in the thermocycler to elute poly(A)-RNA from 
the beads: 
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80°C for 2 min → 25°C for 3 mins 
 
Beads were re-suspended with 50μl of Bead Binding buffer and incubated for 5 
mins at room temperature. The beads were then collected, and supernatant 
removed. The beads were re-suspended with 200μl of Bead Wash Buffer and 
beads again collected and supernatant removed. 
 
Beads contain poly(A)-RNAs immobilised on their surface. Fragmentation and 
priming step was proceeded to immediately. 
 
Step 2: Fragmentation and priming of poly(A)-RNA  
 
The beads were resuspended with 19.5μl of Fragment Prime Finish Mix and 
samples incubated in the thermocycler to elute, fragment and prime RNA: 
 
94°C for 8 mins → 4°C for 3 mins 
 
This should result in RNA fragmentation to 120-210nt with median 155nt. The 
supernatant will contain fragmented and primed RNA ready for reverse 
transcription. The next step was proceeded to immediately.  
 
Step 3: 1st Strand cDNA synthesis 
 
A mix of 1μl of SuperScript III and 7μl of First Strand Synthesis Act D per sample. 
17μl of fragmented and primed RNA was combined with 8μl of SuperScript III 
master mix. The samples were incubated in the thermocycler for reverse 
transcription: 
 
25°C for 10 mins → 42°C for 15 mins → 70°C for 15 mins → 4°C hold 
 
The samples were cooled to 4°C. The supernatant now contained RNA-DNA 
hybrid. The next step was proceeded to immediately. 
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Step 4: 2nd Strand cDNA synthesis 
 
5μl of Resuspension Buffer and 20μl Second Strand Marking Master Mix were 
added to each sample. The samples were incubated in the thermocycler: 
 
16°C for 60 mins → 25°C for 3 mins 
 
90μl of well mixed RT Ampure XP beads were added to each sample. The 
samples were incubated for 5 mins at room temperature, beads on the magnet 
collected, washed twice with 180μl 80% Ethanol and allowed to air dry for 5 
mins. DNA was eluted by adding 18.5μl of Resuspension Buffer and incubated 
for 5 mins at room temperature. The beads were pelleted to measure the DNA 
concentration by Qubit dsDNA HS (1μl into 200μl of Qubit dsDNA HS). 
The RNA samples were converted to dsDNA and stored at -20°C overnight. 
 
Step 5: Adenylation of 3’ Ends and Adapters Ligation  
 
12.5μl of A-Tailing Mix was added to 17.5μl of the sample and mixed well by 
pipetting. The samples were incubated in the hot-block: 
 
37°C for 30 mins → 70°C for 5 mins → room temperature 
 
2.5μl of indexed RNA Adapter was added to each sample. 2.5μl of DNA ligase 
Mix was combined with 2.5μl of Resuspension Buffer per sample and then 5μl 
of the resulting mixture was added to each sample and incubated in the hot-
block: 
 
30°C for 10 mins → room temperature  
 
5μl of Stop Ligase Mix was added to each sample and vortexed/centrifuged to 
give a final volume of 42.5μl. 47μl (1.1x) of 20% PEG8000/2.5M NaCl was added 
to each sample and centrifuged at max rpm for 5 mins, the beads collected, 
washed twice with 80% Ethanol and air dried for 5 mins. The DNA was eluted in 
50μl pf Resuspension Buffer (5mins at max rpm) and, without separating the 
beads and supernatant, 55μl (1.1x) of 20% PEG8000/2.5M NaCl was added to 
87 
 
each sample and centrifuged for 5 mins at max rpm. The beads were collected, 
washed twice with 80% Ethanol and air dried for 5 mins. The DNA was eluted in 
25μl of Resuspension Buffer (5mins at max rpm). 
 
The supernatant and beads were separated. The beads were washed twice with 
0.05% Tween/TE and resuspended in 55μl (1.1x) of 20% PEG8000/2.5M NaCl. 
The eluted DNA was then quantified (1μl into 200μl of Qubit dsDNA HS) to 
determine the number of PCR cycles required for amplification. 
 
Step 6: PCR amplification 
 
5μl of PCR Primer Cocktail, 25μl of PCR Master Mix and 20μl of sample were 
combined and mixed well. The samples were incubated in the thermocycler for 
amplification (14 cycles for 5ng DNA, 11 cycles for 50ng DNA): 
 
98°C for 30 secs → 98°C for 10 secs → 60°C for 30 secs →72°C for 30 secs → 
72°C for 5 mins → 4°C hold  
 
The 50μl samples were purified using 55μl (1.1x) of beads in 20% PEG8000/2.5M 
NaCl. The beads were collected on the magnet, washed twice with 80% Ethanol 
and air dried for 5 mins. The samples were eluted into 20μl of Resuspension 
Buffer and 18μl collected. 
 
1μl of elute was analysed by Tapestation D1000 screen tape and DNA 
concentration measured by combining 1μl of elute and 199μl of dsDNA HS on 
Qubit. 
 
2.6.5 Sequencing 
The amplified library was sequenced on the NextSeq 500 (Illumina) with a 
paired-end sequencing strategy. The read length was a 2 x 36 cycle PE with an 
expected library size of ~260bp (median insert size ~150bp). There were 10-15 
million reads per sample.  
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The analysis of the RNA sequencing data was performed by Rosie Upstill-
Goddard (bioinformatician) at the Bioinformatics department, Wolfson Wohl 
Cancer Research Centre, Glasgow University. The primary sequencing reads 
produced were subjected to quality control. FASTQ files were clipped and the 
low-quality reads were removed by Cutadapt. Sequenced libraries were mapped 
to UCSC mouse mm10 reference genome using the STAR aligner. The sequencing 
alignment was performed using the bcbio-nextgen project RNAseq pipeline. 
Genes without at least 1 count per million in at least 3 samples were removed 
from downstream analysis. 
 
Differential gene expression analysis was performed using R packages (edgeR, 
limmaR and DESeq2). Genes with p=<0.05 and absolute log fold change >1 were 
considered significantly differentially expressed. Heatmaps of differentially 
expressed genes with p=<0.05 and absolute fold change >2 were generated 
using an R package (ComplexHeatmap). 
 
Enrichment analysis was performed on the significantly expressed genes using 
R (dnet). Genes were compared to genes associated with gene ontology terms: 
biological process (GOBP), molecular function (GOMF), cellular component 
(GOCC) and disease ontology (DO).  
 
2.6.6 cDNA synthesis for RT-qPCR 
Prior to cDNA synthesis, each RNA sample was quantified using the NanoDrop. 
The High-capacity cDNA reverse transcription kit (ThermoFisher, 4375222) was 
used for reverse transcription of RNA. The kit components and RNA samples 
were thawed on ice. A 2X RT master mix was prepared (without RNase inhibitor) 
including 2µl 10X RT buffer, 0.8µl 25X dNTP Mix (100mM), 2µl 10X RT Random 
Primers and 1µl MultiScribeTM Reverse Transcriptase per sample (5.8µl). A 
master mix was prepared without reverse transcriptase for the NRT (no reverse 
transcriptase control). Both mastermixes were vortexed and centrifuged.  
 
The mastermix (5.8µl), nuclease-free H2O and appropriate volume of RNA (for 
2µg per sample) was pipetted into each q-PCR tube to a total volume of 20µl. 
For the NTC (no template control), nuclease-free H2O was added instead of RNA. 
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The samples were vortexed and centrifuged prior to loading onto the 
thermocycler (Applied Biosystems).  
 
The thermocycler was adjusted to the following settings: 
1. 25° for 10 minutes 
2. 37° for 120 minutes 
3. 85° for 5 minutes 
4. 4° (infinite hold) 
The cDNA was stored at -20 prior to RT-qPCR.   
 
2.6.7 Real Time quantitative PCR (RT-qPCR) 
The cDNA was made to a concentration of 100ng/µl. The cDNA, primers and 
probes were thawed on ice. The cDNA was diluted by adding 80µl of dH2O to 
10µl of cDNA (50ng/9µl). Each reaction consisted of 10µl 2X Luna® Universal 
probe qPCR Mastermix (Biolabs, 003101), 1µl 20X primer and 50ng of cDNA. Into 
each well of a PCR plate, 11µl of primer/probe mix and 9µl of cDNA dilution 
were added to make a total volume of 20µl.    
 
The PCR plate was sealed with adhesive, centrifuged and loaded onto a CFX96 
Real Time System (BioRad).  
 
The following settings were applied: 
1. 2 minutes 50° 
2. 10 minutes 95° 
3. 40X (15 seconds 95°, 1 minute 60°) 
 
Gene expression was calculated by subtracting the Ct value of the gene of 
interest from the Ct value of the housekeeper gene (Rpl34) (Table 2.4). 
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Table 2.4: Primer and probes. 
Gene 
Exon spanning 
region 
Supplier Cat No. 
Ribosomal 
Protein 
L34 (Rpl34) 
E1-E2 
Applied 
Biosystems 
Mm01321800_m1 
Phosphatase and 
tensin homolog 
(Pten) 
E4-E5 
Applied 
Biosystems 
Mm00477208_m1 
Chemokine 
ligand 2 (Ccl2) 
E1-E2 
Applied 
Biosystems 
Mm00441242_m1 
Chemokine 
ligand 7 (Ccl7) 
E1-E2 
Applied 
Biosystems 
Mm00443113_m1 
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2.7 In vivo experiments  
2.7.1 Cisplatin experiment 
ID8 cells and derivatives were washed, trypsinised, resuspended in complete 
medium and counted. Pellets were washed once in PBS and resuspended at 2.5 
x 107 cells/ml in 37°C PBS. Each experiment routinely contained twelve 
C57BL/6 female mice, which were injected intraperitoneally (IP) with 5 x 106 
cells in a volume of 200μl. The cages were randomised by the BSU staff to a 
treatment and control group. On days 28, 35 and 42, six mice were injected 
intraperitoneally with cisplatin (5mg/kg in PBS) and six mice injected with PBS. 
The PBS and cisplatin was given in a volume of 200μl and warmed to 37°C prior 
to injection. 
 
Mice were monitored daily and killed when they reached UK Home Office limits. 
The defined endpoint was distended abdomen not exceeding that of pregnancy, 
high gait and pale feet. Experiments were performed at the Biological Services 
Unit at the CRUK Beatson Institute, Glasgow under suitable UK Home Office 
project and personal licence authority. All decisions about animal welfare were 
made by BSU staff. 
 
2.7.2 GGTACKO pilot experiment 
The GGTACKO mice are a transgenic mouse model that originate from C57BL/6n 
mice and have CCR1, 2, 3 and 5 knocked out. These mice were a gift from 
Professor Graham’s lab, University of Glasgow. ID8 cells and derivatives were 
prepared and injected as above. The mice were culled once they reached the 
UK Home office limits.  
 
2.7.3 PI3K inhibitor experiment 
ID8 cells and derivatives were prepared and injected as above. The mice were 
given twice daily oral gavage of either 0.5% hydroxyl-propyl-methylcellulose + 
0.1% tween-80 + ddH20 (vehicle) or AZD8186 (PI3K p110β inhibitor) (50mg/kg) 
(1.25mg/dose = 25g mouse) from day 37-42 in the Trp53-/- F3 mice or from day 
25-30 in the Trp53-/-;Pten-/- 1.14 mice. On day 6 of treatment (day 30 or day 
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42) the mice were given a final treatment dose and a single IV injection of BrdU. 
One hour after the last dose of AZD8186/vehicle the mice were culled. 
 
2.7.4 Harvesting of samples 
Ascites 
For the cisplatin experiment the ascites was harvested, total volume recorded 
and centrifuged at 2000rpm for 10 minutes. Supernatant was harvested, 
aliquoted and stored at -80°C. Ascites cells were treated with 5ml Red Blood 
Cell Lysis buffer (Sigma Aldrich, 11814389001) for 5 minutes at room 
temperature. PBS was added, and the tube centrifuged again at 2000rpm. 
Pellets were cryopreserved, aliquoted into four cryovials, and stored at -80°C. 
 
In the GGTACKO and PI3K inhibitor experiments, the ascites was processed as 
above but used fresh for flow cytometry analysis (see section 2.9.3). If no 
ascites was present during the harvesting of the PI3K inhibitor mice, the 
peritoneal cavity was washed out with cold PBS. 
 
Tumour and Mesentery for formalin fixation 
Tumour and mesentery were immediately fixed in a maximum volume of 20mls 
10% Neutral Buffered Formalin (NBF) and left at room temperature for 24 hours. 
The following day, NBF was replaced with 70% ethanol. Tumour and mesentery 
were paraffin embedded and an H&E stain was carried out. Both were 
performed by the Histology Service, CRUK Beatson Institute.  
 
Only tumour was fixed in formalin as above in the GGTACKO and PI3K inhibitor 
experiment. 
 
Tumour samples 
A small sample of tumour was wrapped in foil and immediately placed on dry 
ice before transfer to -80°C and another tumour sample was initially put in PBS 
before it was snap frozen and transferred to the -80°C. 
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For the GGTACKO and PI3K inhibitor experiments, a small sample of tumour was 
snap frozen to be used for RT-qPCR and a small sample in PBS was used fresh 
for flow cytometry analysis (see section 2.9.4). 
 
Full Blood Count (FBC) 
A blood sample was taken from all mice that were culled in both the GGTACKO 
and PI3K inhibitor experiments and a FBC obtained using a Procyte Dx® 
Haematology Analyzer, IDEZZ Laboratories. 
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2.8 Operetta (Wt1 staining) 
1 x 104 mouse ascites cells were plated in a clear-bottomed black 96 well plate. 
These were plated alongside the ID8 F3 (Trp53-/-) cell line (positive control) 
and the NIH/3T3 cell line (mouse fibroblast cell line) (negative control). 24 
hours after plating, cells were initially washed once with PBS and fixed with 2% 
sucrose/3% PFA for 10 minutes. The cells were then washed with PBS (x3) and 
permeabilised with 0.5% triton for 10 minutes. Following further PBS washes 
(x3), the Wt1 primary antibody 1:100 in 2% BSA (Abcam, Cat No: ab89901) was 
added to the cells for 45 minutes at 37°C. The same amount of IgG isotype 
control (IgG rabbit) was added to the same cell lines on different wells. Again, 
the cells were washed with PBS (x3) and secondary antibody (Invitrogen, Cat 
No: A-11036, Alexa Fluor goat anti-rabbit 568) 1:500 in 2% BSA was added to all 
wells for 45 minutes at 37°C. The cells were washed with PBS (x3) and DAPI 
1:10,000 in PBS added for 15 minutes at room temperature. The cells were 
finally washed with PBS (x3) and then read on the Operetta high-content 
imaging system at 10x magnification (Perkin Elmer).  
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2.9 Flow cytometry 
2.9.1 Flow cytometry for DR-GFP assay 
Cells were trypsinised, washed and re-suspended to a final concentration of 1 
x 106 cells. The suspension was centrifuged at 1200rpm for 3 minutes and 
resuspended in 5ml of PBS. A final centrifuge was performed at 1200rpm for 6 
minutes and then resuspended in 1ml of cold PBS. The suspension was passed 
through a strainer and taken on ice for flow analysis. 
 
2.9.2 Cell sorting for mCherry expressing cells 
Cells were trypsinised, washed and re-suspended in normal medium. The 
suspension was centrifuged for 3 minutes at 1200rpm and pellet washed with 
2ml of cold sorting buffer followed by centrifuge at 1200rpm for 3 minutes. The 
cells were re-suspended in 2ml of cold sorting buffer to a concentration of 1 x 
107 cells. A final centrifuge was performed at 1200rpm for 3 minutes and re-
suspended in 1ml of sorting buffer before filtered through a 70-micron strainer. 
The suspension was taken on ice for sorting along with a 96 well plate containing 
ID8 medium. 
 
Sorting buffer: PBS, 1mM EDTA, 25mM HEPES pH 7, 1% FBS (heat-inactivated), 
0.2μm filter sterilised. 
 
2.9.3 Flow cytometry for ascites 
Flow cytometry analysis was performed using frozen ascites from the cisplatin 
experiment. Before antibody staining, cryopreserved ascites was thawed 
rapidly at 37°C and transferred to a 15ml tube containing pre-warmed ID8 
medium. The tubes were centrifuged at 1200rpm 4°C and resuspended in 5ml 
of FACS buffer. Six FMO controls (Fluorescence minus one) (CD11b, F4/80, MHCII, 
CD86, PDL-1 and CD3) were created by using a spread of samples across 
different genotypes and treatments. 4 x 106 cells were plated on a v-bottom 
plate and kept on ice. 
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Flow cytometry analysis was performed using fresh ascites and tumour from 
both the GGTACKO and PI3K inhibitor experiment. Ascites was processed as 
previously described (see section 2.7.4) and resuspended in 5ml of FACS buffer 
before plating as above.  
 
2.9.4 Flow cytometry for murine tumours 
The tumour was transferred to a 6cm dish in PBS and chopped into small pieces 
(<1mm) before transfer to a 15ml tube and centrifuged at 1500rpm for 5 
minutes. The PBS was aspirated and resuspended in 5ml of digestion mix (500µl 
trypsin, 50µl collagenase (Sigma, C7657), 50µl dispase (Sigma, Cat No: 42613-
33-2), 0.1% BSA in RPMI medium). The 15ml tube was put on a roller and 
incubated at 37°C for 30 minutes. Following incubation, the sample was 
transferred to a 50ml tube and 10ml 0.1% BSA/RPMI added. The tube was then 
shaken vigorously up and down (about 20 times). This was repeated a further 
three times until a total volume of 45ml was reached.  
 
The sample was then filtered using a 100µm filter into another 50ml tube, 
centrifuged for 5 minutes at 1500rpm and resuspended in FACS buffer. 
Depending on the number of mice a proportion of each mouse sample was used 
for the FMOs. The samples were plated on a v-bottom plate and kept on ice.  
 
2.9.5 Antibody staining 
50µl of Mouse Fc block (BD Biosciences, Cat No: 553142) was added at 1:200 to 
each well, cells resuspended and incubated at 4°C for 15 minutes. 50µl of the 
antibody mastermix or FMO mix was added to the samples and FMO controls 
and incubated at 4°C for 30 minutes. The mastermix contained a panel of 11 
fluorescently conjugated antibodies against murine CD45, CD11b, F4/80, MHCII, 
Ly6C, Ly6G, CD3, CD8a, CD86, CD19, PDL-1. The concentrations had previously 
been optimised within the McNeish lab (Table 2.5). The samples were then 
washed with PBS and centrifuged at 1500rpm 4°C for 5 minutes followed by a 
further wash with PBS and centrifuged. 50µl of Zombie red viability dye (1:200 
PBS) was added to the samples and incubated at 4°C for 20 minutes. Samples 
were then washed and centrifuged with FACS buffer before fixation with 100µl 
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of 1:1 solution of 4% PFA and FACS buffer. The samples were finally incubated 
at 4°C for 20 minutes. The samples were then washed with FACS buffer and 
centrifuged before resuspension in 350µl of FACS buffer and transferred to FACS 
tubes. The FACS tubes were kept at 4°C for no longer than 1 week before 
analysis. 
 
FACS buffer: PBS, 0.5% BSA, 2mM EDTA 
 
2.9.6 Compensation 
Compensation with beads was used prior to the experiments with one tube per 
fluorochrome. Each tube contained positive and negative control beads. Anti-
rat compensation beads for 10 fluorochromes (BD CompBeads, Cat No: 552845) 
and anti-mouse compensation beads for the F4/80 fluorochrome (BD 
CompBeads, Cat No: 552843). A separate tube was used to compensate for the 
viability dye again with positive and negative control beads (ArCTM Amine 
reactive compensation beads, Invitrogen, Cat No: A10628). In addition to beads, 
100µl of FACS buffer and 1µl of antibody was added to each tube. 
 
The samples were analysed by flow cytometry and used to set compensation 
for all subsequent experiments.  
 
2.9.7 Flow analysis 
Flow cytometry was performed on a BD Fortessa (BD Biosciences). For each 
sample, 30,000 CD45 events were collected and analysed with FlowJo software 
(Tree Star, Ashland, OR). A consistent gating strategy was applied to all 
experiments with the use of the 6 FMOs (Figure 2.4).  
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Table 2.5: 12 fluorochrome flow cytometry panel.  
The panel was used to analyse the ascites and murine tumour by flow cytometry and 
shows the 6 FMOs (CD11b, F4/80, MHCII, CD86, PDL-1 and CD3) used. 
 
Antibodies Supplier 
Catalogue 
No. 
Fluorochrome Filter Dilution 
CD45 
Life 
Technologies 
MCD4530 Pacific Orange UV580/20 1 in 20 
CD11b 
(FMO) 
BD 
Biosciences 
6245992 BUV 737 UV 785/62 1 in 300 
Ly6G Biolegend 127645 
Brilliant Violet 
785 
V 780/60 1 in 50 
Ly6C Biolegend 128010 AlexFluor 647 R 670/14 
1 in 
1500 
F4/80 
(FMO) 
Miltenyi 
Biotec 
130-102-
943 
PE YG 786/15 1 in 50 
MHCII 
(FMO) 
Miltenyi 
Biotec 
130-102-
910 
FITC B 530/30 1 in 50 
CD86 
(FMO) 
Biolegend 105014 PE/Cy7 YG 780/60 1 in 20 
CD8a Biolegend 100742 
Brilliant Violet 
650 
V 655/8 1 in 80 
PDL-1 
(FMO) 
Biolegend 124315 
Brilliant Violet 
421 
V 450/50 1 in 300 
CD3 
(FMO) 
Biolegend 100217 PerCP-Cy5.5 B 685/35 1 in 150 
CD19 Biolegend 218940 APC/Fire 750 R 780/60 1 in 300 
Fixable 
viability 
dye 
Biolegend 423110 Zombie red YG 610/20 1 in 200 
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Figure 2.4: Gating strategy used for the flow cytometry. 
The 6 FMOs (CD11b, F4/80, MHCII, CD86, PDL-1 and CD3) were used to assist with 
gating. The PDL-1 and CD86 gating is not shown in this example.   
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2.10 Statistical Analysis 
All data are expressed as the mean, and error bars represent standard deviation 
of the mean (SD), apart from the Rad51/γH2AX assay, in which standard error 
of the mean (SEM) is used. Statistical tests were performed using Prism v6.0 
(GraphPad, San Diego, CA). Pearson correlation (r) was used to determine the 
correlation between two variables. 
 
Differences between groups of mice and lines were analysed using unpaired t-
tests or One-Way ANOVA with Bonferroni’s test for multiple comparisons. 
Differences in survival were calculated using log-rank test. A p value ≤0.05 (*) 
was considered significant. The level of statistical significance is indicated using 
asterisks (*p<0.05, **p<0.01, ***p<0.001, ****<0.0001). 
 
Linear regression analysis was used to assess differences in cell proliferation. 
The Kruskal-Wallis test was used for RNA sequencing analysis to compare gene 
expression between genotypes. P values from differential gene expression were 
adjusted for multiple testing using the Benjamini-Hochberg procedure. 
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3 Homologous Recombination and platinum and 
PARP inhibitor sensitivity 
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3.1 Introduction 
Platinum sensitivity in HGSOC is thought to be related to a multitude of factors 
but underlying defects in homologous recombination (HR) may be a strong 
predictor of sensitivity. Several studies including TCGA have consistently shown 
frequent genetic and epigenetic alterations of key HR genes in HGSOC, with 
BRCA1 and BRCA2 the most commonly mutated (Konstantinopoulos et al., 2015). 
This is further highlighted by the fact that acquired platinum resistance can be 
related to mutations in BRCA1/2 that restore their function in HR. In the TCGA 
analysis, approximately 50% of HGSOC of cases were thought to exhibit 
defective homologous recombination. Although clinical trials consistently 
demonstrate high platinum sensitivity in BRCA1/2 mutated tumours, there are 
still subgroups of patients with BRCA1/2 mutations that are resistant to 
platinum chemotherapy and others that are sensitive that are BRCA1/2 wild-
type (Alsop et al., 2012).  
 
HR-deficient cells have been shown to be extremely sensitive to PARP inhibitors. 
This has been supported by recent clinical trials in patients with BRCA1/2 
mutations, where 40% did not develop progressive disease for at least 3 years 
following treatment with maintenance olaparib therapy after responding to 
platinum chemotherapy (Ledermann et al., 2012, Ledermann et al., 2014). 
However, the exact mechanism of sensitivity remains poorly understood.  
 
This chapter investigates the relationship between homologous recombination 
and both platinum and PARP inhibitor sensitivity. The HR status was established 
on HGSOC cell lines, ID8 knockout derivatives and a transgenic murine ovarian 
cancer cell line and then correlated with platinum and PARP inhibitor sensitivity. 
The aim was to determine whether defective homologous recombination was a 
strong predictor of sensitivity to both these drugs. 
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3.2 Assessment of Homologous Recombination status in cell lines 
A cell line’s ability to repair DSBs by homologous recombination was assessed 
using the Rad51/γH2AX immunofluorescence assay. This assay was developed 
in Newcastle by the lab of Nicola Curtin and Richard Edmondson (Mukhopadhyay 
et al., 2010). In the initial experiments with HGSOC and ID8 cell lines, cells 
were exposed to rucaparib (10µM) (PARP inhibitor) for 24 hours and, as 
described in the original assay, a two-fold increase in Rad51 foci defined HR 
competency in the presence of proven DNA DSB damage (two-fold increase in 
γH2AX foci following PARP inhibitor treatment).  
 
As the Homologous Recombination status was being correlated with PARP 
inhibitor sensitivity it was felt that an alternative treatment should be used to 
induce DSBs. In subsequent experiments, cell lines were exposed to irradiation 
(10Gy) and γH2AX/Rad51 foci assessed 24 hours later.  
 
The γH2AX foci seen following irradiation were more discrete and resulted in 
clearer confocal images. In terms of the HR status of cell lines the results 
between the rucaparib and irradiation showed complete concordance. 
 
RAD51/γH2AX assay: 
In all high grade serous ovarian cancer cell lines tested, treatment with 10μM 
of Rucaparib for 24hrs resulted in at least a 2-fold increase in γH2AX, showing 
DNA damage had occurred (Figure 3.2). In the ID8 derivatives treatment with 
10Gy of irradiation resulted in at least a 2-fold increase in γH2AX foci in all cell 
lines showing again DNA damage had occurred (Figure 3.1, Figure 3.3, Figure 
3.4, Figure 3.5, Figure 3.6). There was therefore adequate DNA damage to 
detect RAD51 foci and determine whether a cell line was HR-competent or 
deficient. The mean number of γH2AX and RAD51 foci per cell was calculated 
and compared to the control. 
 
DR-GFP assay: 
Following pDR-GFP transfection and puromycin selection, the surviving colonies 
were re-plated and transfected with pISce-I or pCAAGS (control plasmid). 48 
hours following transfection the cells were assessed for GFP positivity by flow 
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cytometry. An increase in GFP positivity in the pISce-I group compared to 
pCAAGs demonstrates adequate HR-mediated DNA DSB repair has occurred 
(Figure 3.11). 
 
Dose response for cisplatin and rucaparib: 
The IC50 levels were taken from the cisplatin and PARP inhibitor dose response 
curves of each cell line and the mean IC50 from a triplicate experiment plotted 
(Figure 3.2 to Figure 3.10). 
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Figure 3.1: Assessment of HR status comparing the ID8 F3 Trp53-/- and the ID8 
3.15 Trp53-/-;Brca2-/- cell lines. 
The red dots correspond to the Rad51 foci and green dots to the γH2AX. The foci were 
quantified by manually counting 30 nuclei per condition. There was a 2-fold increase 
in γH2AX foci compared to the control in both cell lines following irradiation (10Gy) 
indicating adequate DNA DSB induction. There was a 2-fold increase in Rad51 foci 
compared to the control in the F3 Trp53-/- cell line but not in the 3.15 Trp53-/-; Brca2-
/- cell line consistent with an HR-defective cell line.  
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3.2.1 High grade serous ovarian cancer cell lines 
The HR-competent HGSOC cell lines (PEO4, OVCAR3, OVCAR4, COV318 and 
UWB1.289BRCA1) all showed at least a 2-fold increase in RAD51 foci in response 
to rucaparib over the untreated controls. HR-deficient HGSOC cell lines (PEO1 
and UWB1.289) showed a less than 2-fold increase in RAD51 foci formation 
(Figure 3.2). 
 
The BRCA1/2 mutation status (and hence the theoretical HR competence status) 
of the HGSOC cell lines prior to the experiments was already known. PEO1 cell 
line has a BRCA2 mutation and UWB1.289 cell line has a BRCA1 mutation. The 
remaining cell lines (PEO4, OVCAR3, OVCAR4 and UWB1.289BRCA1) are 
BRCA1/2 wild-type and thus theoretically HR competent. 
 
There was considerable variability in the cisplatin and PARP inhibitor sensitivity 
between the cell lines. When comparing the matched cell pair PEO1 (HR 
deficient) and PEO4 (HR competent), PEO1 was more sensitive to both cisplatin 
and PARP inhibitor (cisplatin mean IC50 7.40 (PEO1), 14 (PEO4), p=0.02*; 
rucaparib mean IC50 2.7 (PEO1), 14.2 (PEO4) p=0.02*). However, comparing the 
UWB1.289 (HR deficient) and UWB1.289BRCA1 (HR competent) cell lines, 
UWB1.289 was more sensitive to PARP inhibition but showed similar sensitivity 
to cisplatin (cisplatin mean IC50 5.1 (UWB1.289), 2.4 (UWB1.289BRCA1), p=0.14; 
rucaparib mean IC50 10.3 (UWB1.289), 54.9 (UWB1.289BRCA1), p=0.03*) (Figure 
3.2). 
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Figure 3.2: Assessment of HR status and cisplatin and rucaparib sensitivity in HGSOC 
cell lines.  
A, HGSOC cell lines were treated with rucaparib (10µmol/L), fixed and stained for 
γH2AX and RAD51, and counterstained with DAPI. RAD51 foci were counted in 30 
untreated and treated cells. Bars, mean (± SEM) foci per cell relative to untreated 
cells. The dotted line represents a two-fold increase in foci relative to untreated cells.  
B, Each dot represents the mean IC50 value from a triplicate experiment. Unpaired t-
tests were performed on the matched cell lines with known HR status (PEO1 - BRCA2 
mutation, PEO4 - BRCA2 wild-type, UWB1.289 – BRCA1 mutation and UWB1.289BRCA1 
– BRCA1 wild-type). 
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3.2.2 ID8 derivatives 
The ID8 cell line is a transplantable murine model of ovarian cancer originating 
from C57BI/6 mice ovaries and created in 2000 by Dr Kathy Roby (Roby et al., 
2000). Using the CRISPR/Cas9 gene editing technique, the McNeish lab has 
recently generated several knockout derivatives of the ID8 cell line to closer 
resemble the genetic background of HGSOC (Walton et al., 2016, Walton et al., 
2017). 
 
3.2.2.1 Trp53-/- and Trp53-/-;Brca1 and 2-/- 
The Trp53-/- knockouts were generated using three different guide RNA 
constructs to target exon 5 of Trp53. F3 (guide G), A2 (guide K), C7 and M20 
(guide R) clones were all found to contain bi-allelic deletions in Trp53 exon 5. 
The F3 clone had a 43bp and A2 clone had a 280bp bi-allelic deletion. All clones 
showed absent basal p53 expression by immunoblot (Walton et al., 2016). The 
F3 Trp53-/- clone was used to create all the subsequent knockout derivatives.  
 
The Trp53-/-;Brca1-/- knockout was generated using the F3 clone by targeting 
the Brca1 PALB2-binding domain in exon 12 or the BRCT-2 domain in exon 19. 
Three different Brca1-/- clones had confirmed bi-allelic deletions (clones 1.26, 
1.36 – PALB2-binding domain and 6.20 – BRCT2 domain) (Walton et al., 2017). 
 
The Trp53-/-;Brca2-/- knockout again was generated from the Trp53-/- F3 
clone by targeting the Brca2 PALB2-binding domain in exon 3. Three clones 
(2.14, 3.15 and 1.4) derived from different guides had confirmed bi-allelic 
deletions (Walton et al., 2016).  
 
Our data in the ID8 parental clone and ID8 Trp53-/- clone (F3) all showed at 
least a 2-fold increase in RAD51 foci in response to irradiation over the 
untreated controls. The ID8 Trp53-/-;Brca2-/- clones (2.14 and 3.15) and Trp53-
/-;Brca1-/- clones (1.26, 1.36 and 6.20) showed a less than 2-fold increase in 
RAD51 foci formation (Figure 3.3). 
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The ID8 parental cell line has been shown to have no mutations in key HR genes 
and it has been previously found to be HR competent (Walton et al., 2016). This 
is consistent with my data that found the ID8 parental cell line to also be HR 
competent. p53 has not been found to play an important role in HR and 
therefore the ID8 Trp53-/- clones would also be expected to be HR competent. 
 
The ID8 Trp53-/-;Brca2-/- clones (2.14, 3.15) and Trp53-/-;Brca1-/- clones 
(1.36, 1.26) all have distinct mutations in the region, which encodes the PALB2 
binding domain. Whereas the Trp53-/-;Brca1-/- clone (6.20) has a mutation in 
the BRCT-2 domain. As both BRCA1 and BRCA2 are key genes in the HR pathway 
these clones should theoretically be HR deficient.  
 
The Trp53-/-;Brca1-/- genotype was significantly more sensitive to both 
cisplatin and rucaparib compared to the F3 Trp53-/- clone (Trp53-/-;Brca1-/- 
cisplatin p=≤0.0001****; Trp53-/-;Brca1-/- rucaparib p=≤0.0001****). A similar 
pattern of sensitivity was also seen in the Trp53-/-;Brca2-/- genotype compared 
to the F3 (Trp53-/-;Brca2-/- cisplatin p=≤0.0001****; Trp53-/-;Brca2-/- 
rucaparib p=≤0.0001****) (Figure 3.3 and Table 3.1). 
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Figure 3.3: Assessment of HR status and cisplatin and rucaparib sensitivity in ID8 
Trp53-/-, Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- knockouts.  
A, ID8 derivatives were irradiated (10Gy), fixed and stained for γH2AX and RAD51, and 
counterstained with DAPI. B, Each dot represents the mean IC50 value from a triplicate 
experiment.  
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3.2.2.2 Trp53-/-;Pten-/- and Pten+/- 
The Trp53-/-;Pten-/- knockout was generated using the F3 clone by targeting 
the Pten phosphatase domain in exon 5. Four clones (1.11, 1.12, 1.14, 1.15) 
had confirmed bi-allelic deletions and two clones (1.9, 1.10) had single allele 
deletions. PTEN was found to be absent on immunoblots in the Trp53-/-;Pten-
/- clones and reduced in the heterozygote clones. There was also an increase 
in AKT phosphorylation following serum starvation in both the Trp53-/-;Pten-/- 
and Pten+/- clones (Walton et al., 2017). 
 
The ID8 Trp53-/-;Pten-/- clones (1.11, 1.12, 1.14 and 1.15) and the ID8 Trp53-
/-;Pten-/+ clones (1.9 and 1.10) all showed at least a 2-fold increase in RAD51 
foci in response to irradiation over the untreated controls and were therefore 
HR competent.  
 
There have been conflicting reports of the possible role of PTEN in homologous 
recombination. Some reports have suggested that PTEN reduces RAD51 
recruitment to double strand DNA breaks (McEllin et al., 2010) and sensitises 
cells to PARP inhibition (Mendes-Pereira et al., 2009); however more recent 
reports conclude no involvement in the HR pathway (Hunt et al., 2012, Fraser 
et al., 2012). 
 
There was no significant difference in cisplatin and rucaparib sensitivity 
between the Trp53-/-;Pten-/- genotype and F3 Trp53-/-. There was a 
significant difference in cisplatin sensitivity between the Trp53-/-;Pten-/+ 
clones and F3 Trp53-/- (cisplatin p=<0.0001) but no difference in rucaparib 
sensitivity (Figure 3.4 and Table 3.1). 
 
3.2.2.3 Trp53-/-;Brca1-/-;Pten-/- and Trp53-/-;Brca2-/-;Pten-/- 
The Trp53-/-;Brca1-/-;Pten-/- knockouts were generated using the 1.26 and 
6.20 Trp53-/-;Brca1-/- clones and targeted the Pten phosphatase domain in 
exon 5. Two clones (1.26.19, 6.20.10) had confirmed bi-allelic deletions in exon 
5.  
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The Trp53-/-;Brca2-/-;Pten-/- knockouts were generated using the Trp53-/-; 
Brca2-/- clones 2.14 and 3.15 and again targeted the same Pten domain. Two 
clones (2.14.22, 3.15.10) had bi-allelic deletions confirmed. 
 
All the triple knockout clones (1.26.19, 6.20.10, 2.14.22, 3.15.10) had absent 
PTEN on immunoblot and an increase in AKT phosphorylation following serum 
starvation (Walton et al., 2017).  
 
Both the ID8 Trp53-/-;Brca1-/-;Pten-/- and Trp53-/-;Brca2-/-;Pten-/- clones 
showed a less than 2-fold increase in RAD51 foci formation in response to 
irradiation over the untreated controls and therefore remaining HR defective.  
 
The Trp53-/-;Brca1-/-;Pten-/- genotype was significantly more sensitive to 
both cisplatin and rucaparib compared to the F3 Trp53-/- clone (Trp53-
/-;Brca1-/-;Pten-/- cisplatin p=≤0.0001; Trp53-/-;Brca1-/-;Pten-/- rucaparib 
p=≤0.0001). This was also seen in the Trp53-/-;Brca2-/-;Pten-/- genotype 
compared to the F3 clone (Trp53-/-;Brca2-/-;Pten-/- cisplatin p=≤0.0001; 
Trp53-/-;Brca2-/-;Pten-/- p=≤0.0001) (Figure 3.5 and Table 3.1). 
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Figure 3.4: Assessment of HR status and cisplatin and rucaparib sensitivity in ID8 
Trp53-/-;Pten-/- and Trp53-/-;Pten+/- knockouts. 
A, ID8 derivatives were irradiated (10Gy), fixed and stained for γH2AX and RAD51, and 
counterstained with DAPI B, Each dot represents the mean IC50 value from a triplicate 
experiment. 
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Figure 3.5: Assessment of HR status and cisplatin and rucaparib sensitivity in ID8 
Trp53-/-;Brca1-/-;Pten-/- and Trp53-/-;Brca2-/-;Pten-/- knockouts  
A, ID8 derivatives were irradiated (10Gy), fixed and stained for γH2AX and RAD51, and 
counterstained with DAPI B, Each dot represents the mean IC50 value from a triplicate 
experiment. 
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3.2.2.4 Trp53-/-;Nf1-/- 
For the Trp53-/-;Nf1-/- knockouts, exon 2 was targeted in the F3 clone and the 
two generated clones (1.20, 1.23) had confirmed bi-allelic deletions. These 
clones showed evidence of activated RAS signalling with increased GTP-bound 
RAS and also increased ERK phosphorylation on immunoblot (Walton et al., 
2017).  
 
These two ID8 Trp53-/-;Nf1-/- clones (1.20, 1,23) all showed at least a 2-fold 
increase in RAD51 foci in response to irradiation over the untreated controls 
and were therefore HR competent. 
 
There was no significant difference in cisplatin sensitivity between the Trp53-
/-;Nf1-/- genotype and F3 Trp53-/- clone. However, the Trp53-/-;Nf1-/- 
genotype was significantly more sensitive to rucaparib compared to the F3 
clone (p=≤0.01*). The reason for this difference in sensitivity is unclear (Figure 
3.6 and Table 3.1).  
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Figure 3.6: Assessment of HR status and cisplatin and rucaparib sensitivity in ID8 
Trp53-/-;Nf1-/- knockouts. 
A, ID8 derivatives were irradiated (10Gy), fixed and stained for γH2AX and RAD51, and 
counterstained with DAPI B, Each dot represents the mean IC50 value from a triplicate 
experiment. 
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3.2.3 OVIDT 479 cell lines 
The Dicer-/-;Pten-/- cell line originated from a transgenic murine fallopian 
tube carcinoma model. Cre recombinase under the control of the anti-Mullerian 
hormone type 2 receptor promoter (Amhr2-Cre) was used to delete Dicer and 
Pten in the fallopian tube (Kim et al., 2012). 
 
Dicer is a key processor of microRNAs and low Dicer expression has been 
correlated with poor clinical outcomes in ovarian cancer (Merritt et al., 2008).  
 
The Dicer-/-;Pten-/-;Trp53-/- knockouts were generated by Dr Josephine 
Walton using the same guide RNA used to generate the ID8 F3 clone (targeting 
exon 5). Clone 13 was found to have a biallelic deletion in exon 5 and p53 
expression was absent on immunoblot (Walton et al., 2017).  
 
 
Figure 3.7: Assessment of HR status and cisplatin and rucaparib sensitivity in Dicer-
/-;Pten-/- (DKO 4) and Dicer-/-;Pten-/-;Trp53-/- (TKO 13) knockouts. 
A, Each dot represents the mean IC50 value from a triplicate experiment B, Dicer cell 
lines were irradiated (10Gy), fixed and stained for γH2AX and RAD51, and 
counterstained with DAPI. 
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The Dicer-/-;Pten-/- (DKO 4) and Dicer-/-;Pten-/-;Trp53-/- (TKO 13) all showed 
at least a 2-fold increase in RAD51 foci in response to irradiation over the 
untreated controls and were therefore HR competent. 
 
The TKO 13 clone was significantly less sensitive to cisplatin and rucaparib 
compared to the DKO 4 clone (cisplatin p=≤0.0001****, rucaparib p=≤0.01**) 
(Figure 3.7). 
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3.3 All genotypes and HR/cisplatin/PARPi sensitivity 
The cisplatin and rucaparib IC50 levels were plotted against the HR status for 
the ID8 cells (HR competent or defective) (Figure 3.8). 
 
 
Figure 3.8: Cisplatin and rucaparib sensitivity of the ID8 genotypes and the 
relationship between HR and platinum and PARP inhibitor sensitivity. 
A, Each dot represents the mean IC50 value from a triplicate experiment B, Each dot 
represents the mean IC50 from a triplicate experiment and plotted according to HR 
status determined by the γH2AX/RAD51 assay. ***, P < 0.001 C, Scatter plot showing a 
poor correlation between cisplatin and rucaparib sensitivity (r=0.28). 
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When the HR status of cell lines and cisplatin and rucaparib IC50 levels are 
analysed there is a significant difference between HR status and rucaparib 
sensitivity (p=<0.0001****) however there is no difference between HR status 
and cisplatin sensitivity (p=0.17). There is also a poor correlation between 
cisplatin and rucaparib sensitivity (r=0.28) (Figure 3.8). 
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3.4 Palb2 and BRCT2 binding domains 
The Trp53-/-;Brca1-/- clones (1.26, 1.36) and both the Trp53-/-;Brca2-/- 
clones (2.14, 3.15) have mutations in the Palb2 domain whereas one Trp53-
/-;Brca1-/- clone (6.20) has a mutation in the BRCT2 domain.  
 
 
 
Figure 3.9: Cisplatin and rucaparib sensitivity comparing the different BRCA1 and 
BRCA2 binding domains.  
Each dot represents the mean IC50 value from a triplicate experiment. 
 
 
When comparing both cisplatin and rucaparib sensitivity between the Trp53-
/-;Brca1-/- clones with mutations in the Palb2 domain (1.26, 1.36) and those 
with a mutation in the BRCT2 domain (6.20), the Palb2 clones are significantly 
more sensitive to both drugs (cisplatin p=≤0.0001; rucaparib p=≤0.0001). The 
same pattern is seen when comparing the Trp53-/-;Brca1-/- BRCT2 clone (6.20) 
with the Trp53-/-;Brca2-/- clones (2.14, 3.15) which also have mutations in 
Palb2 (cisplatin p=≤0.0001; rucaparib p=≤0.0001). However, when comparing 
Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- Palb2 clones there is no significant 
difference in cisplatin and rucaparib sensitivity (Figure 3.9 and Table 3.2). 
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3.5 Trp53-/-;Brca2-/-;Pten-/- and drug sensitivity 
The triple deleted Trp53-/-;Brca2;Pten-/- clones (2.14.22, 3.15.10) were 
significantly more resistant to cisplatin compared to the Trp53-/-;Brca2-/- 
genotype (p=≤0.01); however there is no significant difference in rucaparib 
sensitivity between the two genotypes (Figure 3.10). 
 
 
Figure 3.10: Cisplatin and rucaparib sensitivity comparing the Trp53-/-;Brca2-/- 
and Trp53-/-;Brca2-/-;Pten-/- genotypes.  
Each dot represents the mean IC50 value from a triplicate experiment. 
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Table 3.1:  In-vitro cisplatin and rucaparib sensitivity for the ID8 genotypes. 
The table shows the mean IC50 value from a triplicate experiment. The IC50 values 
were compared using one-way ANOVA with Bonferroni’s test for multiple comparisons 
with the Trp53-/- genotype. 
 
Genotype 
Rucaparib IC50 
(µM) mean +/- 
sd 
p= 
Cisplatin IC50 
(µM) mean +/- 
sd 
p= 
Trp53-/- 9.4 +/- 2.2   1.1 +/- 0.4   
Trp53-/-;Brca1-/- 0.2 +/- 0.2 <0.0001 0.4 +/- 0.2 <0.0001 
Trp53-/-;Brca1-/-
;Pten-/- 
0.2 +/- 0.2 <0.0001 0.4 +/- 0.3 <0.0001 
Trp53-/-;Brca2-/- 0.2 +/- 0.1 <0.0001 0.2 +/- 0.03 <0.0001 
Trp53-/-;Brca2-/-
;Pten-/- 
0.3 +/- 0.1 <0.0001 0.3 +/- 0.1 <0.0001 
Trp53-/-;Pten-/- 11.2 +/- 6.9 ns 0.9 +/- 0.2 ns 
Trp53-/-;Pten-/+ 7.6 +/- 3.3 ns 2.4 +/- 0.6 <0.0001 
Trp53-/-;Nf1-/- 4.3 +/- 1.3 <0.01 0.9 +/- 0.4 ns 
 
Table 3.2: In-vitro cisplatin and rucaparib sensitivity comparing the Palb2 and 
BRCT2 domains.  
The table shows the mean IC50 values from a triplicate experiment. The IC50 values 
were compared between the Palb2 and BRCT2 domains using an unpaired t-test. 
 
Genotype 
Rucaparib IC50 (µM) 
mean +/- sd 
Cisplatin IC50 (µM) 
mean +/- sd 
Trp53-/-;Brca1-/- : 0.2 +/- 0.2 0.4 +/- 0.2 
          Palb2 (1.26 + 1.36) 0.2 +/- 0.1 0.3 +/- 0.1 
          BRCT2 (6.20) 0.5 +/- 0.1 0.7 +/- 0.1 
Trp53-/-;Brca2-/- (Palb2) 0.2 +/- 0.1 0.2 +/- 0.03 
  Rucaparib p= Cisplatin p= 
Palb2 vs BRCT2 <0.0001 <0.0001 
Palb2 vs Trp53-/-;Brca2 
(Palb2) 
ns ns 
BRCT2 vs Trp53-/-;Brca2-/- 
(Palb2) 
<0.001 <0.0001 
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3.6 DR-GFP assay 
An attempt at optimising an alternative HR assay (DR-GFP) on HGSOC cell lines 
was performed. 
 
The OVCAR4 cell line does not harbour mutations in any known HR gene and 
was shown to be HR competent in the RAD51/γH2AX assay (Figure 3.2). The 
OVCAR4 cell line showed a mean GFP positivity of 0.51% following pISce-I 
transfection compared to 0.07% for control pCAAGS transfection (Figure 3.11). 
 
However, although the GFP positivity in the OVCAR4 cell line was consistently 
increased compared to the control, the rates of GFP positivity were extremely 
low and variable. Using the assay in other HGSOC cell lines that were known to 
be HR competent (PEO1 and UWB1.289BRCA1) did not show similar results to 
OVCAR4. Therefore, I did not continue with the DR-GFP assay as the 
RAD51/γH2AX assay gave reliable and consistent results.  
 
Figure 3.11: DR-GFP assay assessing HR-mediated DNA DSB repair in HGSOC cell 
lines.  
A, GFP positivity determined by flow cytometry in a single experiment on OVCAR4 
showing an increase in GFP positivity of pISce-I compared to the pCAAGS (control) B, 
Left bars correspond to the pCAAGS (control) and right bars to the pSce-1. Each bar 
represents the mean % GFP positivity of a triplicate experiment.  
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3.7 Discussion 
The Rad51/γH2AX assay, as previously mentioned, was validated in Newcastle 
and is widely used to determine the homologous recombination status of cell 
lines (Mukhopadhyay et al., 2010). The assay however can show variation in the 
number and size of RAD51 foci and is unable to detect abnormalities 
downstream of RAD51. In addition, it requires culture of viable cells for at least 
48 hours. These factors limit the long-term utility of the assay and there is a 
requirement for a functional HR assay that can be used in primary tissue. The 
DR-GFP assay is considered the gold standard for determining homologous 
recombination status. We attempted to optimise the DR-GFP assay initially on 
ovarian cancer cell lines with known HR status. However, we did not get reliable 
and consistent results that we had previously obtained with the Rad51/γH2AX 
assay. It was therefore decided not to pursue the DR-GFP assay further.  
 
HGSOC cell lines with known BRCA1/2 mutations were used to optimise the 
Rad51/γH2AX assay and correlate with cisplatin and rucaparib sensitivity. 
Although cell lines that were known to be HR deficient (PEO1 and UWB1.289) 
were more sensitive to rucaparib there was variation in cisplatin sensitivity 
(Figure 3.2). We performed the assay on primary ascites samples in an attempt 
to develop an assay with clinical utility (data not shown); however subsequent 
sequencing of cultured ascites cells found mutant TP53 in <20% of samples, 
indicating that tumour cells were not being cultured. 
 
Our data from the ID8 Trp53-/- clones show that the cell lines were HR 
competent (Figure 3.3). There is currently no evidence to suggest that p53 is 
associated with defective homologous recombination. It is established that 
mutant p53 not only results in loss of tumour suppressor function but also 
acquires additional oncogenic activity. This p53 gain-of-function contributes to 
genomic instability and there is evidence to suggest that DSB homologous 
recombination is stimulated in cells expressing mutant p53 resulting in ‘hyper-
recombination’ (Muller and Vousden, 2013, Restle et al., 2008). However, the 
ID8 Trp53-/- clones are all loss of function null mutants as shown from previous 
work (Walton et al., 2016) rather than missense mutations with gain-of-function 
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and therefore further work is required to generate clones with missense 
mutations to investigate this further.      
 
From previous experiments there was no significant difference in cisplatin and 
rucaparib sensitivity between the ID8 parental cell line and ID8 Trp53-/- clones 
(Walton et al., 2016). We found a significant variation in cisplatin and rucaparib 
sensitivity between the Trp53-/- clones (F3, A2, M20 and C7) with the F3 and 
A2 more sensitive to these drugs compared to the M20 and C7 clones (Figure 
3.3). There is increasing evidence that different p53 mutants vary with respect 
to loss of wild-type p53 activity and gain of function as mentioned previously. 
Although the Trp53-/- clones resulted from the same guide RNA target (exon 5) 
there was variation in the size and site of mutation. There is minimal data 
regarding the type and location of p53 mutation and drug sensitivity. It is 
possible that subtle differences in mutation may result in alterations in 
structure and stability of the p53 protein and lead to differences in drug 
sensitivity (Muller and Vousden, 2014). We have not investigated this further 
but would require a significant range of different Trp53-/- clones to identify 
obvious patterns of sensitivity.  
 
As expected, Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- clones were all found to 
be HR deficient using the Rad51/γH2AX assay (Figure 3.3). Both BRCA1 and 
BRCA2 genes play key roles in DNA double strand break repair via homologous 
recombination. However, they have distinct and complementary functions 
(Yang et al., 2011). BRCA2 regulates the RAD51 protein by mediating the RAD51 
filament assembly on ssDNA which is crucial for homologous recombination. 
BRCA1 functions in both checkpoint activation and in DNA repair. BRCA1 has 
been found to be an upstream regulator of BRCA2 in DNA repair and the PALB2 
is the main linker between BRCA1 and BRCA2 (Zhang et al., 2009). It is therefore 
expected that the loss of BRCA1 or BRCA2 function would result in a defective 
homologous recombination pathway.  
 
We found that the Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- clones were 
significantly more sensitive to both cisplatin and rucaparib compared to the F3 
Trp53-/- clone (Figure 3.3 and Table 3.1). It is now widely accepted that the 
loss of BRCA1 or BRCA2 results in greater sensitivity to cisplatin in most cases, 
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the hypothesis being that cells that have a defective homologous recombination 
pathway are unable to repair DNA double strand breaks effectively. Therefore, 
the tumour is unable to repair DNA cross-links formed by the introduction of 
chemotherapy such as cisplatin resulting in increased lethality. This is 
consistent with evidence from Alsop et al that found that patients with germline 
BRCA1 or BRCA2 mutations were less likely to have disease progression within 
6 months compared to non-BRCA1/2 carriers following cytotoxic chemotherapy 
(14.9% vs 31.7%; p=<0.001) (Alsop et al., 2012). 
 
Interestingly it has been suggested that the location of mutations within BRCA1 
and BRCA2 may influence response to chemotherapy and overall survival. 
Several studies, although involving small numbers, have found a worse survival 
in patients with a mutation on the 5’ end compared with the 3’ end of BRCA1 
(Bolton et al., 2012). A recent study from Labidi-Galy et al found that BRCA2 
carriers with mutations in the RAD51 binding domain had a significantly 
prolonged 5-year overall survival (HR 0.36; 95% CI 0.20-0.64; p=0.001) (Labidi-
Galy et al., 2017a). 
 
The Trp53-/-;Brca1-/- clones were generated using two different RNA guides, 
one targeted the PALB2-binding domain (exon 12) and the other the BRCT-2 
domain (exon 19). This resulted in the 6.20 clone (BRCT-2) and the 1.36 and 
1.26 clones (PALB2) all with bi-allelic deletions in BRCA1 but within different 
domains. These Trp53-/-;Brca1-/- clones offered an opportunity to investigate 
differences in cisplatin and rucaparib sensitivity in-vitro. Our data showed that 
the Palb2 clones (1.26, 1.36) were significantly more sensitive to both drugs 
compared to the BRCT-2 clone (6.20). This is further validated when comparing 
sensitivity with the Trp53-/-;Brca2-/- clones (2.14, 3.15) that also have 
deletions within the Palb2 domain. The Palb2 clones (1.26, 1.36, 2.14 and 3.15) 
have similar levels of sensitivity to both drugs but again the 6.20 (BRCT-2) clone 
is significantly less sensitive to cisplatin and rucaparib compared to the Trp53-
/-;Brca2-/- clones (2.14, 3.15) (Figure 3.9 and Table 3.2).  
 
PALB2 is a DNA-binding domain that binds ssDNA and interacts with RAD51 to 
stimulate strand invasion. It has been found to bind to BRCA2 and function 
synergistically to further promote strand invasion (Buisson et al., 2010). PALB2, 
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as previously mentioned, is the link between BRCA1 and BRCA2 and the 
interaction between BRCA1 and PALB2 is important for homologous 
recombination (Zhang et al., 2009). The BRCT domain (BRCA1 C-terminal) is 
involved in cell cycle signalling in the DNA damage response but is less 
important in homologous recombination (Leung and Glover, 2011). The 
differences in sensitivity between the Trp53-/-;Brca1-/- clones may be because 
of the varying importance of the domains in the homologous recombination 
pathway.  
 
Alsop et al have shown that, although patients with BRCA1/2 mutations respond 
well to platinum chemotherapy there remains a subgroup of patients that are 
resistant or refractory to chemotherapy despite having mutations in these genes 
(Alsop et al., 2012). The site of BRCA1/2 mutation may explain differences in 
response to chemotherapy as well as mutations in other important genes e.g 
PTEN as described below. 
 
Except for BRCA1/2, little is known about the prognosis of other prevalent 
mutations in high grade serous ovarian cancer.  As discussed previously, PTEN 
is a tumour suppressor gene that inhibits cell proliferation induced by the PI3K 
pathway. TCGA identified PTEN loss in 7% of tumours; however following re-
analysis by Martins et al, 36% of tumours showed heterozygous loss of PTEN 
(Martins et al., 2014).  The Trp53-/-;Pten-/- and Trp53-/-;Pten+/- clones were 
all found to be HR competent using the Rad51/γH2AX assay (Figure 3.4). Despite 
early conflicting reports regarding the role of PTEN in homologous 
recombination it is now accepted that PTEN does not have an important role in 
the HR pathway (Hunt et al., 2012, Fraser et al., 2012).  
 
In vitro, there was no difference in cisplatin and rucaparib sensitivity between 
the Trp53-/-;Pten-/- clones and F3 Trp53-/-. However, the Trp53-/-;Pten+/- 
clones were significantly more resistant to cisplatin compared to the Trp53-/- 
genotype (Figure 3.4 and Table 3.1). No difference was seen in rucaparib 
sensitivity. A possible explanation could be that heterozygous Pten loss has led 
to partial inactivation of Pten and altered gene expression resulting in an 
increase in cisplatin resistance.  
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The Trp53-/-;Brca1-/-;Pten-/- and Trp53-/-;Brca2-/-;Pten-/- clones all were 
found to be HR defective (Figure 3.5). They were also significantly more 
sensitive to cisplatin and rucaparib compared to the F3 Trp53-/- genotype. 
Interestingly the Trp53-/-;Brca2-/-;Pten-/- clones were significantly less 
sensitive to cisplatin compared to the Tpr53-/-;Brca2-/- genotype suggesting 
that Pten loss may contribute to platinum resistance without interfering with 
overall HR function (Figure 3.10). 
 
NF1 is a tumour suppressor gene that encodes for neurofibromin-1, a RAS 
GTPase-activating protein (Ratner and Miller, 2015). Neurofibromin is an 
important negative regulator of the Ras pathway. NF1 loss has been associated 
with chemotherapy resistance and a poor prognostic factor in glioblastoma 
multiforme and colorectal cancer (Yap et al., 2014). The Trp53-/-;Nf1-/- clones 
were all found to be HR competent (Figure 3.6). There is no evidence to suggest 
that NF1 is involved in homologous recombination and therefore these results 
were expected.   
 
There was no significant difference in cisplatin sensitivity between the F3 
Trp53-/- genotype and Trp53-/-;Nf1-/- clones in vitro. However, the Trp53-
/-;Nf1-/- clones showed a small but statistically significantly increase in 
sensitivity to rucaparib (Figure 3.6 and Table 3.1). DNA replication stress 
mechanisms such as serial replication stalling forks have been shown to result 
in genomic rearrangements with NF1 loss (Hsiao et al., 2015). These 
rearrangements may explain the difference in PARP inhibitor sensitivity. 
 
The DICER-/-;Pten-/- (DKO) and DICER-/-;Pten-/-;Trp53-/- (TKO) cell lines are 
additional transgenic in vivo models to further investigate the influence of p53 
loss in HGSOC. The DICER cell lines originated from fallopian tube carcinoma 
cells and Trp53 was targeted using the same guide RNA used for the F3 Trp53-
/- clone (Walton et al., 2017). The DKO and TKO were found to be HR 
competent (Figure 3.7). This is an additional HGSOC in vivo model that shows 
again that the loss of Pten does not alter the homologous recombination 
pathway.  
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Trp53 loss was associated with a significant reduction in sensitivity to both 
cisplatin and rucaparib (Figure 3.7). This contrasts with data using the ID8 
Trp53-/- clones where no difference was seen in sensitivity when compared to 
the ID8 parental cell line. As mentioned previously this may be because of the 
type and position of p53 mutation.  
 
Interestingly, the loss of p53 function has been shown to significantly reduce 
the median survival in vivo (Walton et al., 2017). Similar findings were found 
with the ID8 derivatives. The DICER cell lines have not been used in any further 
experiments in this thesis as the ID8 derivatives offer a range of different 
knockouts that allow comparison between the genotypes.  
 
When the HR status of cell lines is analysed with the cisplatin and rucaparib 
IC50 levels there is a significant difference between HR status and rucaparib 
sensitivity (p=0.0001). However there is no difference between HR status and 
cisplatin sensitivity (p=0.17). In addition, there is a poor correlation between 
cisplatin and rucaparib sensitivity (r=0.28) (Figure 3.8). Although many women 
with mutations in key HR genes e.g. BRCA1/2 are more sensitive to platinum 
chemotherapy, the relationship between defective homologous recombination 
and platinum sensitivity is much more complicated and is likely to involve many 
different factors, including key mutated genes, chromosomal instability and the 
tumour microenvironment. The interaction between these variables and how it 
relates to platinum chemotherapy is not well known but hopefully a greater 
understanding of these factors will aid in predicting which patients will respond 
to chemotherapy in the future. 
 
In summary, I have investigated the homologous recombination status of a range 
of ovarian cancer cell lines and how this relates to both cisplatin and rucaparib 
sensitivity. I have shown that the relationship between homologous 
recombination and cisplatin sensitivity is complicated and is likely to involve 
factors beyond HR status. By establishing the HR status, it may be possible to 
select patient subgroups that respond better to chemotherapy, but it does not 
identify poor prognostic groups. The next step was to assess platinum sensitivity 
in vivo to determine if this differs from in vitro data and to establish differences 
in survival between the ID8 derivatives. 
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4 In-vivo platinum sensitivity
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4.1 Introduction 
Mutations in key genes are thought to contribute to both platinum sensitivity 
and resistance. Although patients with BRCA1/2 mutations tend to be extremely 
sensitive to platinum-based chemotherapy, this is not universal, and most 
patients will develop resistance. As discussed previously, Drost et al observed 
that N-terminal mutations on the BRCA1 protein was a poor prognostic factor 
and that mutations in the RING domain (N-terminal) were associated with a 
poor response to cisplatin and PARP inhibitors (Drost et al., 2011). The BRCA1/2 
mutation may explain differences in chemotherapy response and the Trp53-
/-;Brca1-/- clones with mutations in the Palb2 and BRCT2 domains allowed us 
to begin to investigate this further.  
 
The loss of PTEN is a common event in HGSOC and, following re-analysis of the 
TCGA data, 36% of tumours were found to have heterozygous loss of PTEN 
(Martins et al., 2014). As mentioned earlier, studies have found that activation 
of the PI3K/AKT pathway may be associated with chemotherapy resistance 
(Kolasa et al., 2009, Yang et al., 2008).  
 
TCGA also found alterations in the NF1 gene in 12% of patients but not much is 
known about platinum sensitivity in patients with an alteration in this gene 
(Cancer Genome Atlas Research, 2011). The loss of NF1 results in activation of 
RAS/MAPK signalling with recent evidence showing the MAPK pathway to be a 
significantly mutated pathway in ovarian cancer (Kanchi et al., 2014). Further 
studies have suggested that MAPK activation is associated with a poor prognosis 
(Hew et al., 2016).  
 
By using C57Bl/6 mice, I aimed to see if there was any difference in cisplatin 
sensitivity compared to previous in-vitro data and attempt to identify poor 
prognostic groups independent of HR status. The ID8 derivatives allowed us to 
look at the platinum sensitivity between the genotypes. As this was an 
immunocompetent model, it also allowed us to see how the tumour 
microenvironment was altered between genotypes and with the addition of 
cisplatin. 
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4.2 Cisplatin in-vivo experiment 
The mice were treated with cisplatin (5mg/kg) or PBS (control) on days 28, 35 
and 42. From previous in-vivo tumorgenicity experiments we knew that the 
Trp53-/-;Brca2-/- models had the longest survival (median survival 53 days) and 
the Trp53-/-;Pten-/- models had the shortest survival (median survival 34 days). 
The timing of treatment allowed the mice to get all 3 dosages of cisplatin and 
attempted to replicate clinical regimens i.e. multiple cycles of platinum-based 
chemotherapy.  
    
 
Figure 4.1: Protocol investigating in vivo cisplatin sensitivity using ID8 derivatives. 
C57BL/6 (female) mice were injected i.p with 5x106 ID8 cells, treated at Day 28, 35 
and 42 with either cisplatin (5mg/kg) or PBS (control). The mice were then taken at 
the Home office endpoint.  
 
4.2.1 Survival  
The six different ID8 genotypes were injected intraperitoneally as described 
above (Figure 4.1). There were 24 mice per experiment (12 cisplatin treated, 
and 12 PBS treated), with at least two separate clones per genotype. The mice 
were monitored daily and killed when they reached UK Home Office limits.  
134 
 
 
Figure 4.2: In vivo experiments investigating platinum sensitivity between 
different ID8 genotypes.  
A, Kaplan-Meier survival curves comparing C57BL/6 (female) mice injected with 
different ID8 genotypes and treated with either cisplatin or PBS. Hazard ratios and p 
values are comparing the cisplatin treated groups with the Trp53-/- cisplatin group. B, 
Ascites volumes from all in vivo experiments comparing mice treated with either 
cisplatin or PBS. 
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The PBS treated groups had a median survival ranging from 34 to 53 days. The 
Trp53-/- genotype had a median survival of 45 days, Trp53-/-;Brca1-/- of 42 
days, Trp53-/-;Brca2-/- of 53 days, Trp53-/-;Pten-/- of 34 days, Trp53-/-;Nf1-
/- of 42 days and Trp53-/-;Brca2-/-;Pten-/- of 37 days (Figure 4.2). This data 
is consistent with previous in vivo data using the ID8 genotypes (Walton et al., 
2016, Walton et al., 2017). 
 
With the addition of cisplatin treatment, the survival was extended for all the 
genotypes. The cisplatin treated groups had a median survival ranging from 69 
to 113 days. The Trp53-/- genotype had a median survival of 80.5 days. The 
Trp53-/-;Brca1-/- had a median survival of 97 days and when compared to the 
Trp53-/- genotype a hazard ratio of 0.227 (p=<0.0001). The Trp53-/-;Brca2-/- 
genotype had a median survival of 113 days (HR = 0.218, p=<0.0001), Trp53-
/-;Pten-/- of 69 days (HR = 3.315, p=0.0002), Trp53-/-;Nf1-/- of 71 days (HR = 
2.693, p=0.002) and Trp53-/-;Brca2-/-;Pten-/- of 99 days (HR = 0.231, p=0.0001) 
(Figure 4.2, Figure 4.3 and Table 4.1).  
 
Two mice were excluded from the Trp53-/-;Brca2-/-;Pten-/- cisplatin 
experiment, one because the mouse only received one dose of cisplatin and in 
all previous experiments the mice had tolerated three doses of cisplatin. The 
other mouse was excluded because it survived greater than 2 weeks after the 
last culled mouse.  
 
There was no significant difference in ascites volumes between the PBS treated 
and cisplatin treated groups (Figure 4.2). 
 
 
Figure 4.3: Kaplan-Meier survival curve comparing all the ID8 genotypes. 
The dotted lines correspond to PBS treated groups and solid lines to cisplatin treated. 
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Table 4.1: In vivo survival in the cisplatin treated groups. 
The median survival of the cisplatin treated groups are outlined in the table below and 
the hazard ratios (log rank) are compared to the Trp53-/- genotype. 
 
Genotype 
Median survival 
cisplatin (days) 
Hazard ratio 
(log-rank) 
p= 
Trp53-/- 81 - - 
Trp53-/-;Brca1-/- 97 0.227 <0.0001 
Trp53-/-;Brca2-/- 113 0.218 <0.0001 
Trp53-/-;Brca2-/-
;Pten-/- 
99 0.231 <0.0001 
Trp53-/-;Pten-/- 69 3.315 0.0002 
Trp53-/-;Nf1-/- 71 2.693 0.002 
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4.2.2 Palb2 and BRCT2 binding domains 
The cisplatin in vivo experiment used both the Trp53-/-;Brca1-/- (BRCT2) and 
Trp53-/-;Brca1-/- (Palb2) clones. Results for Trp53-/-;Brca1-/- clones were 
separated and the Kaplan-Meier curve illustrated below in Figure 4.4. The 1.36 
Trp53-/-;Brca1-/- clone had a median survival of 97 days compared to 89 days 
in the 6.20 Trp53-/-;Brca1-/- clone. When compared to the Trp53-/- genotype 
(median survival 80.5 days) the 1.36 Trp53-/-;Brca1-/- clone had a hazard ratio 
of 0.2623 (p=0.0002) and the 6.20 Trp53-/-;Brca1-/- clone of 0.2788 (p=0.0004) 
(Figure 4.4 and Table 4.2). The difference between the two BRCA1 clones was 
not significant (p=0.07). 
 
 
Figure 4.4: Kaplan-Meier survival curve comparing the binding domains. 
The 1.36 Trp53-/-;Brca1-/- (Palb2) clone had a non-significant superior survival 
compared to the 6.20 Trp53-/-;Brca1-/- (BRCT2) clone. 
 
Table 4.2: In vivo survival in the cisplatin treated Palb2 and BRCT2 clones. 
The median survival of the cisplatin treated groups are outlined in the table below and 
the hazard ratios (log-rank) are compared to the Trp53-/- genotype. 
 
Genotype 
Median survival 
cisplatin (days) 
Hazard ratio 
(log-rank) 
p= 
Trp53-/- 80.5 - - 
Trp53-/-;Brca1-/- 
(Palb2) 
97 0.2623 0.0002 
Trp53-/-;Brca1-/- 
(BRCT2) 
89 0.2788 0.0004 
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4.3 Cell culture of ascites 
The tumour cells in the ascites from the in vivo cisplatin experiment were 
cultured using ID8 medium (see Methods - section 2.8). The first aim was to 
determine if it was possible to culture tumour cells from frozen ascites whilst 
the second aim was to investigate potential differences in cisplatin sensitivity 
between the PBS and cisplatin treated groups.  
 
Ascites cells from both PBS or cisplatin treated mice were cultured from the 
following clones - F3 Trp53-/-, 2.14 Trp53-/-;Brca2-/- and 3.15 Trp53-/-;Brca2-
/-.   
 
WT1 expression is used clinically as a diagnostic marker for HGSOC. Previous 
work has shown the ID8 cell line to be strongly positive for Wt1 and it was 
therefore used to determine whether tumour cells were specifically being 
cultured (Walton et al., 2016).  
 
The Wt1 antibody concentration was initially optimised by culturing ascites 
cells from a mouse bearing F3 Trp53-/- tumour. The murine fibroblast cell line 
3T3 was used as a negative control and the F3 Trp53-/- cell line as a positive 
control. A high-content imaging system (Operatta, Perkin Elmer) was used to 
visualise the cells following staining with Wt1 and DAPI.  
 
The cells were positively stained with Wt1 confirming that tumour cells were 
being cultured from the ascites. The optimal Wt1 antibody concentration was 
determined to be 1 in 100 (Figure 4.5). 
 
4.3.1 Cisplatin sensitivity 
The ascites samples all had positive Wt1 staining. The Trp53-/-;Brca2-/- clones 
(2.14 and 3.15) cultured from the ascites remained significantly more sensitive 
to cisplatin compared to the F3 Trp53-/- cell lines. However, there was no 
significant difference in cisplatin sensitivity between the PBS treated and 
cisplatin treated ascites (Figure 4.6).   
 
139 
 
 
Figure 4.5: Wt1 primary antibody optimisation of cultured ascites.  
A, Wt1 (1/100) and DAPI staining of 3T3 cell line (negative control), F3 (positive control) 
and F3 (sample 1) (cisplatin treated ascites sample) with positive staining in the ascites 
sample confirming the presence of tumour cells. B, The green corresponds to the mean 
Wt1 nuclear intensity per well (Alexa 488) showing 1 in 100 as the optimal Wt1 
concentration. There was no Wt1 staining present in the negative control (3T3) or 
isotype controls.  
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Figure 4.6: Wt1 and DAPI staining of ascites and cisplatin sensitivity. 
A, Wt1 and DAPI staining of ascites confirming the presence of tumour cells. No Wt1 
staining was present in the negative (3T3) or isotype controls. The sample numbers 
correspond to different ascites samples. B, Cisplatin sensitivity comparing the PBS and 
cisplatin treated groups of each genotype. Each dot represents an IC50 value. The 
Trp53-/-;Brca2-/- clones were significantly more sensitive to cisplatin but no 
difference was shown between the treated and untreated groups.  
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4.4 Generation of fluorescent ID8 cell lines 
To try to investigate tumour heterogeneity further and how dominant clones 
develop in HGSOC, we generated a GFP-expressing F3 Trp53-/- cell line and an 
mCherry-expressing 3.15 Trp53-/-;Brca2-/- cell line (see Methods – section 2.4). 
These cell lines were characterised to ensure they were as close as possible in 
terms of growth and drug sensitivity to non-expressing cells prior to undertaking 
in vivo experiments. 
 
4.4.1 In vitro growth and drug sensitivity 
There was no significant difference in in vitro growth using linear regression 
analysis between the F3 and GFP-expressing F3 cell line (p=0.52) and between 
the 3.15 and mCherry-expressing 3.15 cell line (p=0.76). There was also no 
difference found in in vitro cisplatin sensitivity between the F3GFP and F3 cell 
line and in cisplatin and rucaparib sensitivity between the 3.15mCherry and 
3.15 cell lines (Figure 4.7).  
 
4.4.2 In vitro confocal and flow cytometry analysis 
The fluorescent ID8 cell lines were visualised using confocal microscopy to 
confirm the expression of GFP in the F3 Trp53-/- cell line and mCherry in the 
3.15 Trp53-/-;Brca2-/- line. This was also confirmed by flow cytometry (Figure 
4.7). In preparation for in vivo experiments, flow cytometry analysis was 
performed on fixed (2% PFA) and non-fixed GFP-expressing F3 and mCherry-
expressing 3.15 cell lines. There was no difference in GFP or mCherry 
fluorescence shown between the fixed and non-fixed samples. The two cell 
lines were also mixed 50:50, and two different fluorescent populations were 
able to be identified (Figure 4.8).  
 
These experiments showed that there was no difference in vitro in growth and 
drug sensitivity with the expression of GFP and mCherry. The in vitro flow 
cytometry also showed we would be able to identify and analyse the different 
populations which would be required for in vivo experiments.   
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Figure 4.7: In vitro characterisation of ID8 fluorescent cell lines. 
A, Cell proliferation assay comparing the GFP-expressing F3 and mCherry-expressing 
3.15 with non-expressing cells. Using linear regression analysis, no difference in growth 
was shown (F3GFP p=0.52, 3.15mCherry p=0.76). B, Cisplatin sensitivity comparing the 
F3GFP and F3 cell line and showing no difference. Cisplatin and rucaparib sensitivity 
comparing the 3.15mCherry and 3.15 cell line again showing no difference. Each dot 
represents an IC50 value. C, D, Confocal microscopy and flow cytometry analysis 
showing the expression of both GFP and mCherry in the F3 and 3.15 cell line 
respectively.  
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Figure 4.8: In vitro flow cytometry analysis of the ID8 fluorescent cell lines. 
A, Flow cytometry comparing fixed (2% PFA) and unfixed samples of the F3GFP and 
3.15mCherry cell lines, showing no difference in fluorescence intensity between the 
samples. B, Flow cytometry showing identification of both F3GFP and 3.15mCherry 
from a mixed population. F3 (negative), F3GFP (positive) and 3.15mCherry (positive) 
were used as controls.  
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4.4.3 In vivo data 
The F3GFP, 3.15mCherry and equal mix of F3GFP/3.15mCherry cell lines were 
injected intraperitoneally as described previously (see Methods – section 2.7). 
There were 4 mice per cell line. The mice were monitored daily and killed when 
they reached UK Home Office limits. 
 
The F3GFP cell line had a median survival of 57 days, 3.15mCherry of 48 days 
and the F3GFP/3.15mCherry mix of 56.5 days (Figure 4.9). This compared to 
the previous in vivo experiment where the non-expressing F3 Trp53-/- cell line 
had a median survival of 45 days and the 3.15 Trp53-/-;Brca2-/- cell line of 53 
days (Figure 4.2).  
 
Flow cytometry analysis was performed on the ascites. Only 1 of the 4 mixed 
samples (F3GFP/3.15mCherry) had ascites at endpoint and there were <1% 
positive mCherry cells present compared to 30.4% GFP positive cells. The four 
3.15mCherry ascites samples had 0.81, 0.85, 8.74 and 9.61% positive mCherry 
cells. Only 3 of the 4 F3GFP samples had ascites at endpoint with 4.17, 51.4 
and 47.1% GFP positive cells following analysis (Figure 4.9). 
 
The murine tumour samples were visualised using the confocal microscope with 
obvious areas of tumour expressing GFP and more subtle areas expressing 
mCherry in the mixed samples (Figure 4.10). A concern was that the mCherry 
expressing cells had a low intensity of fluorescence and was therefore difficult 
to identify with flow cytometry and confocal analysis. 
 
Staining the tumour samples for mCherry and GFP by immunohistochemistry 
would identify any weakly positive cells. The F3GFP tumour samples were 
almost 100% positive for GFP and the 3.15mCherry samples were also nearly 
100% for mCherry suggesting that the confocal had underestimated the number 
of mCherry positive cells. We therefore stained the F3GFP/mCherry mixed 
tumour sample for GFP and any unstained tumour was assumed to be mCherry 
positive. The four mixed samples had an average % mCherry positivity of 24% 
(inferred) and an average % GFP positivity of 76% (Figure 4.10).  
 
145 
 
 
Figure 4.9: In vivo experiments using the ID8 fluorescent cell lines. 
A, Kaplan-Meier survival curves comparing the F3GFP, 3.15mCherry and mixed 
F3GFP/3.15mCherry cell lines. B, Example of flow cytometry analysis on an F3GFP 
ascites sample, showing 51.4% GFP positivity.  
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Figure 4.10: Ex vivo analysis of fluorescent tumour samples. 
A, Confocal microscopy of murine tumour samples showing obvious areas of GFP 
positivity and small areas of mCherry positivity. B, GFP immunohistochemistry staining 
of an F3GFP tumour showing 100% GFP staining. C, GFP immunohistochemistry staining 
of a mixed F3GFP/3.15mCherry sample showing non-stained areas assumed to be 
mCherry positive. D, Bar chart illustrating the average % of mCherry (inferred) and GFP 
positivity within the four mixed samples. mCherry staining was not performed on the 
mixed samples but areas not stained by GFP were inferred to be mCherry positive.  
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4.5 Discussion 
Bolton et al have found that patients with a germline BRCA1 or BRCA2 mutation 
have an improved overall survival compared to non-carriers, with loss of BRCA2 
offering the best prognosis (Bolton et al., 2012). This contrasts with the TCGA 
that found that BRCA2 carriers had a positive prognosis, but they found no 
difference in prognosis between BRCA1 carriers and non-carriers. However, this 
is now thought to be due to a lack of power in the TCGA data to detect survival 
differences (Bolton et al., 2012). A follow up study by Candido-dos-Reis et al 
confirmed a short-term survival benefit in patients with a BRCA1 or BRCA2 
mutation. However, this survival benefit was found to reduce over time with 
an eventual reversal in BRCA1 carriers after approximately 10 years (Candido-
dos-Reis et al., 2015). 
 
Our cisplatin in vivo data correlate closely with what has been found in patients. 
Clinically most patients with HGSOC receive platinum-based chemotherapy and 
therefore the in vivo survival following cisplatin treatment is relevant to patient 
survival data. The Trp53-/- genotype had a median survival of 80.5 days 
following cisplatin treatment. Like clinical data, the Trp53-/-;Brca1-/- and 
Trp53-/-;Brca2-/- genotypes had the greatest extension in survival after 
cisplatin treatment compared to the Trp53-/- genotype. The Trp53-/-;Brca1-/- 
genotype had a median survival of 97 days (HR 0.227; p=<0.0001). The Trp53-
/-;Brca2-/- genotype had a median survival of 113 days (HR 0.218; p=<0.0001) 
(Figure 4.2 and Figure 4.3). 
 
As discussed previously the site of BRCA1 mutation may influence cisplatin 
sensitivity and survival. By separating the two Trp53-/-;Brca1-/- clones we 
found that the 1.36 Trp53-/-;Brca1-/- clone (Palb2) had a median survival of 97 
days (HR 0.2623; p=0.0002) and the 6.20 Trp53-/-;Brca1-/- clone (BRCT2) had 
a median survival of 89 days (HR 0.2788; p=0.0004) (Figure 4.4). From our 
previous in vitro data, we showed that BRCA1 mutations in the PALB2-binding 
domain were more sensitive to cisplatin compared to clones with mutations in 
the BRCT2 domain (Chapter 3 – Figure 3.9). These in vivo findings are consistent 
with what was found in vitro and suggest that cisplatin sensitivity and therefore 
overall survival can be influenced by the site of Brca1 mutation. We have not 
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looked at exact mechanisms behind the differing cisplatin sensitivities between 
the two clones, but a possible explanation may be the greater functional role 
of the PALB2 domain compared to the BRCT2 domain in the homologous 
recombination pathway. A mutation within the PALB2 domain could result in a 
lower overall Brca1 expression.   
 
TCGA was the first to identify PTEN homozygous deletion in 6.7% of cases and 
a small fraction of the homozygous deletions were intragenic i.e. only part of 
the gene affected (Cancer Genome Atlas Research, 2011). The TCGA data were 
reanalysed by Martins et al, who found PTEN loss to be a common event with 
heterozygous loss found in 36% of tumours. They found during IHC analysis that 
the downregulation or loss of PTEN was strongly associated with a poor overall 
survival and even a weak PTEN expression had a negative impact on survival 
(Martins et al., 2014).  Thus, loss of PTEN is a relatively common event in HGSOC 
and is associated with a negative prognosis.   
 
Our cisplatin in vivo data correlate with previous clinical data that have found 
PTEN to be a poor prognostic factor. The Trp53-/-;Pten-/- genotype had the 
shortest extension in survival compared to the Trp53-/- genotype with a median 
survival of 69 days (HR 3.315; p=0.0002) following cisplatin treatment (Figure 
4.2 and Figure 4.3). 
 
TCGA analysis found co-existing mutations of either single and/or double copy 
deletions of BRCA1 and PTEN in 31% of cases and BRCA2 and PTEN in 25% of 
cases. They also found homozygous PTEN loss in 7% of TP53; BRCA2 cases 
(Cancer Genome Atlas Research, 2011). This highlights the importance of the 
ID8 triple knockouts as a relevant model of HGSOC. From our in vivo data the 
Trp53-/-;Brca2-/-;Pten-/- genotype had a median survival of 99 days (HR 0.231; 
p=<0.0001) after cisplatin treatment which is a significant reduction in survival 
compared to the Trp53-/-;Brca2-/- genotype (median survival 113 days) (Figure 
4.2 and Figure 4.3). This shows that the loss of Pten not only has a negative 
impact on survival in the Trp53-/-;Pten-/- genotype but also on the background 
of Brca2-/- loss following cisplatin treatment. This also means that BRCA1 and 
BRCA2 mutated tumours are not a homogenous group and may partially explain 
the wide variation in survival seen in patients with these mutations.  
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The TCGA identified loss of NF1 in 12% of cases (deletion 8%, mutation 4%) 
(Cancer Genome Atlas Research, 2011). Patch et al looked at inactivating 
mutations caused by gene breakage that would result in copy number neutral 
loss of transcription in the absence of single nucleotide variation. They found 
that inclusion of gene breakage increased the frequency of NF1 loss to 20% 
(Patch et al., 2015). Alterations in NF1 are thought to result in resistance to 
chemotherapy with recent studies showing MAPK activation to be associated 
with a poor prognosis in ovarian cancer (Hew et al., 2016).  
 
Our cisplatin in vivo data are consistent with what has been found in other non-
ovarian tumours with NF1 loss. The Trp53-/-;Nf1-/- genotype had a shorter 
extension in survival compared to the Trp53-/- genotype with a median survival 
of 71 days (HR 2.693; p=0.002) (Figure 4.2 and Figure 4.3). Although no 
difference in cisplatin sensitivity was found in vitro in the Trp53-/-;Nf1-/- 
genotype, we found that the loss of Nf1 was associated with poor outcome 
following platinum chemotherapy in vivo. 
 
Culturing of the tumour cells from ascites offered an opportunity to investigate 
whether the cells had acquired resistance to cisplatin and if so by what 
mechanism e.g. BRCA1/2 reversion. The cells were stained for Wt1 to confirm 
tumour cells were being cultured prior to undertaking assessment of in vitro 
cisplatin sensitivity. All the ascites samples cultured had positive Wt1 staining 
however no difference was found in cisplatin sensitivity between the cisplatin 
and PBS treated samples (Figure 4.5 and Figure 4.6). A possible explanation for 
this is that the mice only received 3 dosages of cisplatin over 3 weeks (day 28, 
35 and 42) and were taken at the Home office endpoint to determine survival. 
Multiple continuous cisplatin dosages may be required for the tumours to begin 
to acquire resistance. 
 
The generation of different ID8 genotypes expressing fluorescent proteins 
would allow us to start looking at the tumour heterogeneity of tumours in more 
detail. It is known that there is a diverse population of different genotypes 
within a primary tumour but also within and between metastatic deposits 
(Bashashati et al., 2013). Patch el al found BRCA1/2 reversion events within 
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different individual tumour deposits following selection pressure from 
chemotherapy (Patch et al., 2015). The aim was to try and determine using the 
ID8 fluorescent cell lines whether dominant clones form within a tumour in 
response to cisplatin treatment. 
 
The F3GFP Trp53-/- and 3.15mCherry Trp53-/-;Brca2-/- cell lines were 
characterised in vitro prior to undertaking in vivo experiments. There was no 
difference found in the growth and cisplatin sensitivity between the expressing 
and non-expressing cell lines (Figure 4.7). However, the expression of GFP and 
mCherry seemed to affect the in vivo survival. The F3 GFP had a median survival 
of 57 days and this compared to 45 days in the non-expressing F3 cell line 
(p=0.005, **). The 3.15mCherry had a median survival of 48 days, compared to 
53 days in the non-expressing 3.15 cell line (p=0.17, ns) (Figure 4.9). There was 
also concerns that the fluorescence intensity of mCherry was low, making it 
difficult to identify mCherry positive cells. We therefore used GFP and mCherry 
IHC staining that identified weakly positive mCherry tumour. The IHC 
determined that about a quarter (24% - inferred) of the mixed tumour was 
mCherry positive (Trp53-/-;Brca2-/-) and the remaining tumour (76%) was GFP 
positive (Trp53-/-) (Figure 4.10). It is unclear whether this cell fraction is 
correct from IHC alone, next generation sequencing to look at the BRCA2 
mutant allele fraction would be required to determine whether this cell mix is 
genuine.  
 
It was decided not to continue with further in vivo experiments using the 
fluorescent cell lines because it was not possible to identify the mCherry 
positive cells reliably using flow cytometry and due to concerns that the 
fluorescent protein expression was having an effect upon survival.  
 
In summary, we have identified good and poor prognostic groups and shown 
that the cisplatin in vivo sensitivity for different ID8 genotypes closely correlate 
with clinical data. The Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- genotypes have 
the longest survival whereas the loss of Pten or Nf1 has a negative impact on 
survival. This transplantable in vivo model offers a unique opportunity to 
further understand the biology of HGSOC and why these key genetic mutations 
influence survival. The next step was to investigate the tumour 
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microenvironment between the genotypes and following cisplatin treatment to 
attempt to explain the difference in prognosis between genotypes. 
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5 Tumour microenvironment and influence of 
platinum chemotherapy
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5.1 Introduction 
The dissemination of tumour throughout the peritoneal cavity with the 
development of widespread ascites and the predisposition of the tumour for the 
omentum are unique features of high grade serous ovarian cancer (Thibault et 
al., 2014). The tumour microenvironment has a complex interaction between 
the malignant and non-malignant cells. These non-malignant cells have a 
dynamic and often tumour-promoting function (Hanahan and Coussens, 2012). 
 
HGSOC is an immunogenic tumour with evidence of activated T cells in both the 
tumour microenvironment and ascites (Ioannides et al., 1991, Zhang et al., 
2003). Increased levels of tumour-infiltrating leukocytes (TIL) have been 
associated with an improved overall survival in patients (Zhang et al., 2003). 
Non-malignant cells can make up over half the tumour microenvironment but 
with unanswered questions regarding their tumour promoting or inhibitory 
functions. As described previously, tumour-associated macrophages (TAMs) can 
have either pro-tumour or anti-tumour properties depending on the surrounding 
cytokines present (Balkwill et al., 2005). Myeloid-derived suppressor cells 
(MDSCs) are thought to contribute to an immunosuppressive environment and 
have been found to accumulate in ascites in patients with ovarian cancer 
(Obermajer et al., 2011). 
 
It is now believed that chemotherapy can be immune stimulatory in some 
circumstances with evidence of immunogenic cell death following treatment by 
both taxane and platinum chemotherapy (Galluzzi et al., 2015). Böhm et al and 
Lo et al have both shown that platinum chemotherapy can influence the tumour 
microenvironment and alter the different immune populations. Both studies 
showed increased levels of CD3+ and CD8+ but this was counteracted by an 
increase in expression of the immune checkpoint molecule PD-1 (Bohm et al., 
2016, Lo et al., 2017). 
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This chapter uses the tumour and ascites samples from the cisplatin in vivo 
experiments described in the previous chapter to investigate the tumour 
microenvironment. I used flow cytometry, immunohistochemistry, RT-qPCR and 
RNA sequencing to look at how the environment is altered between the 
genotypes and following cisplatin treatment. The aim was to establish an 
explanation for the poor prognosis in the Trp53-/-;Pten-/- and Trp53-/-;Nf1-/- 
genotypes.   
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5.2 Flow cytometry  
Flow cytometry analysis was performed on frozen ascites from the in vivo 
cisplatin experiment using a 12 colour fluorochrome panel (see Methods – Table 
2.4). The gating strategy was consistent across the experiments (see Methods – 
Figure 2.4). We focussed on three genotypes – Trp53-/-, Trp53-/-;Brca2-/- and 
Trp53-/-;Pten-/-, which had marked differences in in vivo survival. 
 
5.2.1 Overall cisplatin effect 
We started with an unselected analysis where the PBS-treated, and cisplatin-
treated groups from all genotypes were combined which is similar to analysis 
of an unselected patient population. This allowed us to investigate whether 
there were any subtle differences in immune cell populations following the 
treatment with cisplatin. We then went on to analyse the individual genotypes 
separately.  
 
The CD45+ (*) and CD11b+ (**) populations were significantly increased with 
cisplatin treatment. In addition, the monocytic (Ly6C+G-) levels were 
significantly decreased (****) and the granulocytic (Ly6C-G+) levels significantly 
increased (*) following treatment. However, there was no difference in 
Ly6C+Ly6G+ (Gr-1+) expression between the PBS and cisplatin treated groups 
(Figure 5.1).  
 
CD3+ and CD8a+ populations were significantly increased in cisplatin treated 
samples (CD3+***, CD8a+*). The F4/80+ population was significantly increased 
in the cisplatin group (**) but there was no difference in MHCII+ expression and 
CD19+ levels between the two groups. (Figure 5.1 and Figure 5.2). 
 
There was a non-significant decrease in PDL-1 expression on CD3 cells after 
cisplatin treatment (p=0.05) but no significant difference in CD8 PDL-1 
expression and a significant decrease on CD19 cells (****). CD86+ expression was 
significantly decreased on both CD3+ and CD19+ populations (****) (Figure 5.2). 
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Figure 5.1: Flow cytometry analysis of ascites comparing the untreated PBS and 
treated cisplatin groups. 
The figure shows the overall cisplatin effect with the different genotypes combined. 
A, Flow analysis showing a significant increase in CD45+ (*), CD11b+ (**) and 
granulocytic MDSC (*) in the cisplatin treated group, with a significant decrease in the 
monocytic MDSC (****) population in the cisplatin group. There was no significant 
change in Ly6C+Ly6G+ (Gr-1) between the groups. B, Flow analysis showing a 
significant increase in CD3+ (***) and CD8a+ (*) in the cisplatin treated group compared 
to the PBS treated group.    
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Figure 5.2: Flow cytometry analysis of ascites comparing the untreated PBS and 
treated cisplatin groups. 
This figure again shows the overall cisplatin effect with the different genotypes 
combined. 
A, Flow analysis showing a significant increase in F4/80+ (**) in the cisplatin treated 
compared to PBS treated groups and no difference in MHCII+/F480 levels between the 
groups. B, Flow analysis showing a significant decrease in PDL1+ expression on CD19 
cells (****) in the cisplatin group. C, Flow analysis showing a significant decrease in 
CD86+ expression on CD3 and CD19 cells (****) in the cisplatin groups.  
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5.2.2 Differences between genotypes  
There were similar levels of CD45+ and CD11b+ cells between the genotypes. 
The proportion of CD45+ cells within the live cell population was >90% in most 
samples, of which >50% were CD11b+. There was an increase in the monocytic 
MDSC (Ly6C+G-; CD11b+) population but no obvious increase in granulocytic 
(Ly6C-G+) cells in the Trp53-/-;Pten-/- genotype compared to the Trp53-/- 
genotype. However, the Ly6C+Ly6G+ (Gr-1+) (combined monocytic and 
granulocytic) population was significantly increased in the Trp53-/-;Pten-/- 
genotype (*). The proportion of Ly6C+Ly6G+ cells was also significantly lower in 
the Trp53-/-;Brca2-/- genotype compared to the Trp53-/-;Pten-/- genotype (**). 
 
There were no significant differences between the genotypes in proportions of 
CD3+, CD8a+ and F4/80+ cells. However, there was a non-significant reduction 
in number of CD19+ cells in the Trp53-/-;Brca2-/- compared to the Trp53-/- 
genotype (Figure 5.3 and Figure 5.4). 
 
5.2.3 Influence of cisplatin between genotypes 
Treatment with cisplatin did not significantly change the proportion of CD45+ 
and CD11b+ cells between the different genotypes. There was also no change 
in monocytic and granulocytic MDSC populations after treatment (Figure 5.3). 
However, the number of CD3+ cells were significantly increased between the 
Trp53-/-;Pten-/- (PBS treated) and Trp53-/-;Pten-/- (cisplatin treated) groups 
(*) and a non-significant increase was seen in the other cisplatin treated 
genotypes. There was no difference in CD8a+ populations after treatment but 
the cisplatin-treated Trp53-/-;Pten-/- genotype had a significantly higher 
number of CD8a+ cells compared to the treated Trp53-/- (*) and Trp53-
/-;Brca2-/- (*) groups (Figure 5.3). 
The number of F4/80+ cells was non-significantly increased in the Trp53-
/-;Pten-/- cisplatin treated group compared to the PBS treated group. There 
was no difference in MHCII/F480 expression between the genotypes and 
following cisplatin treatment (Figure 5.4). 
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CD19+ cells were significantly increased in the Trp53-/-;Brca2-/- (PBS treated) 
and Trp53-/-;Brca2-/- (cisplatin treated) groups (*) (Figure 5.4).  
 
 
Figure 5.3 Flow cytometry analysis of ascites and following cisplatin treatment. 
A, Flow analysis showing no difference in CD45+ and CD11b+ populations between the 
groups. There was a significant increase in Ly6C+Ly6G+ (Gr-1) between the Trp53-/- 
and Trp53-/-;Pten-/- genotypes (*) and between Trp53-/-;Brca2-/- and Trp53-/-;Pten-
/- (**). B, Flow analysis showing a significant increase in CD3+ between the Trp53-
/-;Pten-/- (PBS treated) and Trp53-/-;Pten-/- (cisplatin treated) groups (*). There was 
a significant increase in CD8a+ between the Trp53-/- (cisplatin), Trp53-/-;Brca2-/- 
(cisplatin) and the Trp53-/-;Pten-/- (cisplatin) group (*) (*). 
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Figure 5.4 Flow cytometry analysis of ascites comparing the Trp53-/-, Trp53-
/-;Pten-/-, Trp53-/-;Brca2-/- genotypes and following cisplatin treatment. 
Flow analysis showing a non-significant increase in F4/80+ between the Trp53-/-;Pten-
/- (PBS) and Trp53-/-;Pten-/- (cisplatin) groups. There was no significant difference in 
MHCII+/F480 levels between the genotypes and treatment groups. There was a 
significant increase in CD19+ between the Trp53-/-;Brca2-/- (PBS) and Trp53-/-;Brca2-
/- (cisplatin) groups (*). 
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5.3 Tissue Microarrays  
Three tissue microarrays (TMAs) were generated from the cisplatin in vivo 
experiment. Each TMA contained cores from at least four different genotypes 
and contained PBS and cisplatin treated cores (Methods – section 2.5) (Figure 
5.5). The TMAs were stained for CD3, CD8a, F4/80, p-Akt, CD206 and iNOS 
(Figure 5.6) and scored using HALO software. 
  
 
Figure 5.5: An example of one TMA from the cisplatin in vivo experiment. 
The TMA was generated from 1mm cores from paraffin-embedded blocks. Four blocks 
were used per genotype and cisplatin group and three tumour cores were taken from 
each block. The cores were spread across three different TMAs.  
 
5.3.1 CD3  
CD3 staining of the murine tumour showed a significant increase in CD3 levels 
in the Trp53-/-;Pten-/- compared to the Trp53-/- genotype (*) and a non-
significant increase in the Trp53-/-;Brca2-/-;Pten-/- genotype. There were no 
other significant differences between the genotypes. There were also no 
differences shown in CD3 levels in cisplatin treated samples (Figure 5.7).  
 
When the PBS treated and cisplatin treated samples were combined there was 
a significant decrease in CD3 staining in the cisplatin group (*). The histoscores 
for CD3 were low with the majority scoring <5 (Figure 5.7).  
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Figure 5.6: Examples of TMA staining. 
Staining for p-Akt (Ser473), CD3, CD8a, F4/80, CD206 and iNOS (20x magnification). 
 
5.3.2 CD8a 
CD8a staining showed a non-significant increase in the Trp53-/-;Pten-/- 
compared to Trp53-/- genotype and a significant increase in the Trp53-
/-;Brca2-/-;Pten-/- genotype (*).  There were no other significant differences 
between the genotypes. There were also no differences shown in CD8a levels 
in cisplatin treated samples (Figure 5.8).  
 
When the PBS treated and cisplatin treated samples were combined, there was 
no difference in CD8a staining between the groups. The histoscores for CD8a 
were low, with the majority scoring <2 (Figure 5.8). 
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Figure 5.7: CD3 immunohistochemistry staining of tumour. 
A, CD3 histoscores from PBS and cisplatin treated genotypes showing a significant 
increase in CD3 between the Trp53-/- and Trp53-/-;Pten-/- genotypes (*). B, CD3 
histoscores showing the differences between the genotypes. There was a significant 
decrease in CD3 in the cisplatin treated group when the different genotypes were 
combined to show the overall cisplatin effect (*). 
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Figure 5.8: CD8a immunohistochemistry staining of tumour. 
A, CD8 histoscores from PBS and cisplatin treated genotypes showing a non-significant 
increase in CD8 between the Trp53-/- and Trp53-/-;Pten-/- genotypes and a significant 
increase between the Trp53-/- and Trp53-/-;Brca2-/-;Pten-/- genotypes (*). B, CD8 
histoscores showing the differences between the genotypes. There was no significant 
difference in CD8 staining between the two treatment groups when the different 
genotypes were combined to show the overall cisplatin effect. 
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Figure 5.9: F4/80 immunohistochemistry staining of tumour. 
A, F4/80 histoscores from PBS and cisplatin treated genotypes showing a significant 
increase in F4/80 between Trp53-/- and the Trp53-/-;Pten-/- (****) and Trp53-
/-;Brca2-/-;Pten-/- (****) genotypes. There was also a significant increase in F4/80 
between the Trp53-/-;Brca2-/- and Trp53-/-;Brca2-/-;Pten-/- genotype (****). B, 
F4/80 histoscores showing a non-significant decrease in F4/80 in the Trp53-/-;Pten-/- 
cisplatin group and significant decrease in the Trp53-/-;Brca2-/-;Pten-/- cisplatin 
group (**). There was a non-significant increase in F4/80 in the Trp53-/-;Nf1-/- 
cisplatin group. 
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5.3.3 F4/80 (macrophage marker) 
F4/80 staining showed a significant increase in F4/80 levels in both the Trp53-
/-;Pten-/- and Trp53-/-;Brca2-/-;Pten-/- (****) genotypes compared to Trp53-
/- genotype (****). There was also a significant increase in F4/80 staining in the 
Trp53-/-;Brca2-/-;Pten-/- compared to the Trp53-/-;Brca2-/- genotype (****). 
F4/80 staining was significantly increased in the Trp53-/-;Nf1-/- compared to 
the Trp53-/- genotype (*) (Figure 5.9). 
 
F4/80 levels were significantly increased in cisplatin-treated Trp53-/-;Pten-/- 
(**) and Trp53-/-;Brca2-/-;Pten-/- (**) tumours compared to the Trp53-/- 
cisplatin group. There was also a significant increase in F4/80 in the Trp53-
/-;Brca2-/-;Pten-/- cisplatin-treated compared to the Trp53-/-;Brca2-/- 
cisplatin-treated genotype (*). F4/80 staining was significantly increased in the 
Trp53-/-;Nf1-/- cisplatin treated compared to the Trp53-/- cisplatin treated 
genotype (****) (Figure 5.9). 
 
There was a non-significant decrease in F4/80 in the Trp53-/-;Pten-/- cisplatin 
group compared to the PBS treated Trp53-/-;Pten-/- group (p=0.05) and a 
significant decrease when comparing the PBS and cisplatin treated Trp53-
/-;Brca2-/-;Pten-/- genotype (**). There was also a non-significant increase in 
F4/80 staining in the cisplatin treated Trp53-/-;Nf1-/- group compared to the 
PBS treated (Figure 5.9).  
 
When the PBS treated and cisplatin treated samples were combined there was 
no difference in F4/80 staining between the groups (Figure 5.9).  
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5.4 RNA sequencing 
RNA sequencing was performed on tumour samples from the cisplatin in vivo 
experiment. Tumour cellularity was checked prior to RNA extraction and RIN 
determined prior to sequencing (see Methods – section 2.6). RNA sequencing 
was performed on PBS-treated and cisplatin-treated tumour samples from the 
following genotypes: Trp53+/+, Trp53-/-, Trp53-/-;Pten-/-, Trp53-/-;Brca1-/-, 
Trp53-/-;Brca2-/- and Trp53-/-;Nf1-/-.  
 
The percentage of reads mapped to the mouse genome ranged from 71.1-93% 
with the GC content ranging from 49-56% and duplicates from 6.9-20.7%. The 
mean Phred quality score for all samples and per sequence were >30 (base call 
accuracy 99.9%) (Appendix 1, Appendix 3 and Appendix 5).    
 
Trp53 expression was reduced in the Trp53-/-, Trp53-/-;Pten-/-, Trp53-
/-;Brca1-/-, Trp53-/-;Brca2-/- and Trp53-/-;Nf1-/- samples compared to the 
Trp53+/+ genotype. Pten expression was reduced in the Trp53-/-;Pten-/- 
genotype compared to the Trp53-/-. Brca1 expression was reduced in the 
Trp53-/-;Brca1-/- samples compared to the Trp53-/- genotype. By contrast, the 
expression of Brca2 was increased in the Trp53-/-;Brca2-/- samples compared 
to the Trp53-/- genotype and Nf1 expression was increased in the Trp53-/-;Nf1-
/- samples compared to Trp53-/- (Appendix 2, Appendix 4 and Appendix 6). 
 
The top 50 significantly up regulated and down regulated genes in the different 
genotypes and following cisplatin treatment (R package – edgeR) are outlined 
in Appendix 7. 
 
5.4.1 Trp53+/+, Trp53-/- 
There were a significant number of genes up- and downregulated with the loss 
of Trp53 when comparing the Trp53+/+ and Trp53-/- genotypes. The 
enrichment analysis showed the chemokine activity, genes involved in 
chromosomal stability and dsDNA binding to be amongst the pathways 
upregulated in the Trp53-/- genotype. 
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Only a small number of genes were downregulated in the Trp53-/- cisplatin 
treated group compared to the PBS treated group and therefore enrichment 
analysis was unable to be performed (Figure 5.10).  
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Figure 5.10: RNA sequencing of murine tumours from Trp53+/+, Trp53-/- (PBS 
treated) and Trp53-/- (cisplatin treated) genotypes. 
A, Gene expression heat map comparing the Trp53+/+ and Trp53-/- groups and 
enrichment analysis showing an upregulation of pathways involved in chemokine 
activity, chromosome stability and dsDNA binding. B, Gene expression heat map 
comparing Trp53-/- (PBS treated) and Trp53-/- (cisplatin treated) samples and showing 
a limited number of downregulated genes in the Trp53-/- (cisplatin treated) group.  
170 
 
5.4.2 Trp53-/-;Pten-/-  
There were a significant number of genes up- and downregulated with the loss 
of Pten when comparing the Trp53-/- and Trp53-/-;Pten-/- genotypes (see 
section 5.5, Figure 5.18). 
 
Comparing the PBS-treated, and cisplatin-treated Trp53-/-;Pten-/- groups, an 
even greater number of genes were up- and downregulated following treatment. 
The enrichment analysis showed a downregulation in the chemokine activity 
and immune response and an upregulation in the canonical Wnt signalling 
pathway in the cisplatin treated samples (Figure 5.11). 
 
5.4.3 Trp53-/-;Brca1-/- and Brca2-/- 
The loss of Brca1 and Brca2 did not result in many significantly up- or 
downregulated genes when comparing both the Trp53-/-;Brca1-/- and Trp53-
/-;Brca2-/- to the Trp53-/- genotype. A similar lack of altered gene expression 
was found when comparing the PBS treated and cisplatin treated samples from 
the two genotypes (Figure 5.12 and Figure 5.13).  
 
Enrichment analysis of these genotypes was unable to be performed due to the 
lack of differences in gene expression.  
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Figure 5.11: RNA sequencing of murine tumours from Trp53-/-;Pten-/- (PBS treated) 
and Trp53-/-;Pten-/- (cisplatin treated) genotypes. 
A, Gene expression heat map comparing the Trp53-/- and Trp53-/-;Pten-/- genotypes, 
(see Figure 5.18 for enrichment analysis). B, Gene expression heat map comparing 
Trp53-/-;Pten-/- (PBS treated) and Trp53-/-;Pten-/- (cisplatin treated) samples and 
enrichment analysis showing a downregulation of pathways involved in chemokine 
activity and immune response, and upregulation in the canonical Wnt signalling 
pathway. 
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Figure 5.12: RNA sequencing of murine tumours from Trp53-/-;Brca1-/- (PBS 
treated) and Trp53-/-;Brca1-/- (cisplatin treated). 
A, Gene expression heat map comparing the Trp53-/- and Trp53-/-;Brca1-/- genotypes. 
B, Gene expression heat map comparing the Trp53-/-;Brca1-/- (PBS treated) and 
Trp53-/-;Brca1-/- (cisplatin treated). 
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Figure 5.13: RNA sequencing of murine tumours from Trp53-/-;Brca2-/- (PBS 
treated) and Trp53-/-;Brca2-/- (cisplatin treated). 
A, Gene expression heat map comparing the Trp53-/- and Trp53-/-;Brca2-/- genotypes. 
B, Gene expression heat map comparing the Trp53-/-;Brca1-/- (PBS treated) and 
Trp53-/-;Brca2-/- (cisplatin treated). 
 
 
  
174 
 
5.4.4 Trp53-/-;Nf1-/- 
There were a significant number of genes up- and downregulated with the loss 
of Nf1. The enrichment analysis showed the chemokine activity and immune 
response to be amongst the pathways significantly downregulated and genes 
involved in neurotransmitter transport were significantly upregulated in the 
Trp53-/-;Nf1-/- genotype compared to Trp53-/- (Figure 5.14).   
 
Comparing the PBS treated, and cisplatin treated Trp53-/-;Nf1-/- groups an 
even greater number of genes were up- and downregulated following treatment. 
The enrichment analysis showed a downregulation in genes responsible for the 
inflammatory response and chemotaxis and an upregulation in genes involved 
in the function of the cell junction in the cisplatin treated samples (Figure 5.15).  
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Figure 5.14: RNA sequencing of murine tumours from Trp53-/-;Nf1-/- genotype. 
Gene expression heat map comparing the Trp53-/- and Trp53-/-;Nf1-/- groups. 
Enrichment analysis showing a downregulation of pathways involved in chemokine 
activity and immune response, and an upregulation in genes involved in 
neurotransmitter transport in the Trp53-/-;Nf1-/- genotype.  
 
 
 
 
 
 
176 
 
 
Figure 5.15: RNA sequencing of murine tumours from cisplatin treated Trp53-
/-;Nf1-/- genotype. 
Gene expression heat map comparing Trp53-/-;Nf1-/- (PBS treated) and Trp53-/-;Nf1-
/- (cisplatin treated) samples. Enrichment analysis showing a downregulation of 
pathways involved in inflammatory response and chemotaxis, and an upregulation in 
genes involved in the function of the cell junction in the Trp53-/-;Nf1-/- (cisplatin 
treated) samples. 
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5.5 Pten loss 
We focussed on the effect of loss of Pten and summarised the findings from 
flow cytometry, cytokine array, RNA seq, RT-qPCR and immunohistochemistry 
experiments.  
 
Staining of the three TMAs for pAkt (Ser473) showed a significant increase in 
staining in the Trp53-/-;Pten-/- genotype compared to Trp53-/- (**). There was 
also a significant increase in pAkt staining in the Trp53-/-;Brca2-/-;Pten-/- 
genotype compared to Trp53-/-;Brca2-/- (****) (Figure 5.16). 
 
An in vitro chemokine/cytokine array comparing the Trp53-/- and Trp53-
/-;Pten-/- cell lines following serum starvation showed a significant increase in 
Ccl2 and Ccl7 expression and a significant reduction in IL16 and Thpo expression 
in the Trp53-/-;Pten-/- group (Figure 5.17). These findings were confirmed by 
performing RT-qPCR on murine tumour samples looking at changes in Ccl2, Ccl7 
and Pten expression. In the Trp53-/-;Pten-/- genotype there was a decrease in 
Pten expression relative to the Trp53-/- samples (****) and an increase in Ccl7 
and Ccl2 expression relative to the Trp53-/- samples (****) (Figure 5.17). 
 
RNA sequencing was done on murine tumours from both Trp53-/- and Trp53-
/-;Pten-/- genotypes. The enrichment analysis showed the chemokine activity, 
immune response, inflammatory response and T cell receptor signalling 
pathway to be upregulated in the Trp53-/-;Pten-/- genotype compared to 
Trp53-/- (Figure 5.18). Upregulated genes in the Trp53-/-;Pten-/- genotypes 
that are involved in the recruitment and function of tumour-associated 
macrophages include Ccl2, 5, 8, 9, 17, 22 and Cxcl9 and 10 and IL-4 and αTNF. 
Upregulated genes in recruitment and function of myeloid-derived suppressor 
cells include Ccl2, 5, 7 and IL-4 and αTNF (Figure 5.18).  
 
Following on from the chemokine/cytokine array and RT-qPCR data, the 
chemokines Ccl2 and Ccl7 from RNA seq analysis were also found to be 
overexpressed in the Trp53-/-;Pten-/- compared to Trp53-/- genotype (p=0.46). 
(Figure 5.18). 
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Figure 5.16: Data showing the effect of Pten loss.  
p-Akt (Ser473) immunohistochemistry showing a significant increase in staining 
between the Trp53-/- and Trp53-/-;Pten-/- genotypes (**) and Trp53-/-;Brca2-/- and 
Trp53-/-;Brca2-/-;Pten-/- genotypes (****).  
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Figure 5.17: Chemokine/cytokine array on cell lines and RT-qPCR on tumour 
samples. 
A, In vitro chemokine/cytokine array (performed by Josephine Walton) comparing the 
Trp53-/- vs Trp53-/-;Pten-/- cell lines following serum starvation, showing a 
significant increase in Ccl2 and Ccl7 and a significant decrease in IL16 in the Trp53-
/-;Pten-/- genotype. B, RT-qPCR murine samples comparing the Trp53-/- and Trp53-
/-;Pten-/- genotypes. Values were normalised to Rpl34. There was a significant 
decrease in Pten expression relative to the Trp53-/- genotype (****) and a significant 
increase in Ccl7 (****) and Ccl2 (****) expression relative to the Trp53-/- genotype.  
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Figure 5.18: RNA sequencing of murine tumours from Trp53-/-;Pten-/- genotype 
A, Gene expression heat map comparing Trp53-/- and Trp53-/-;Pten-/- samples and 
enrichment analysis showing an upregulation of genes involved in chemokine activity, 
immune response, inflammatory response and the T cell receptor signalling pathway. 
B, Upregulated chemokines/cytokines in the Trp53-/-;Pten-/- genotype responsible for 
recruitment and function of tumour-associated macrophages and myeloid-derived 
suppressor cells. C, Ccl2 and Ccl7 expression from RNA seq data showing a non-
significant increase in the Trp53-/-;Pten-/- genotype. 
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Flow cytometry analysis of ascites from in vivo experiments showed a 
significant increase in Ly6C+Ly6G+ (Gr-1+) levels in the Trp53-/-;Pten-/- 
genotype compared to Trp53-/- (*). In the ascites samples, there was no 
significant difference in F4/80 levels between the samples (Figure 5.19).  
 
Flow cytometry analysis of tumour samples from fresh in vivo experiments 
showed a significant increase in Gr-1+ levels in the Trp53-/-;Pten-/- genotype 
compared to Trp53-/- (**). There was also a significant increase in F4/80 levels 
in the Trp53-/-;Pten-/- samples (**) (Figure 5.19).  
 
Consistent with flow cytometry data of tumour samples, staining of the three 
TMAs for F4/80 showed a significant increase in F4/80 levels in the Trp53-
/-;Pten-/- genotype compared to Trp53-/- (****). There was also a significant 
increase in iNOS (M1 marker) (***) and CD206 (M2 marker) (**) staining in the 
Trp53-/-;Pten-/- genotype (Figure 5.20). 
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Figure 5.19: Flow cytometry analysis showing the effect of Pten loss. 
A, Flow cytometry analysis of ascites, showing a significant increase in Ly6C+Ly6G+ 
(Gr-1+) levels in ascites in the Trp53-/-;Pten-/- genotype (*) but no significant 
difference in F4/80 levels. B, Flow cytometry analysis of murine tumour, showing a 
significant increase in Gr-1+ levels (**) in the Trp53-/-; Pten-/- genotype and a 
significant increase in F4/80 (**). Analysis of tumour samples was performed by 
Josephine Walton. 
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Figure 5.20 Immunohistochemistry of macrophage markers 
Immunohistochemistry of TMAs from murine tumours showing a significant increase in 
F4/80, iNOS (M1-marker) and CD206 (M2 marker) with the loss of Pten. 
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5.6 Discussion 
The tumour microenvironment is known to be important in tumour progression 
with non-malignant cells not only regulating tumour growth but facilitating its 
metastatic dissemination. In advanced ovarian cancer the widespread 
dissemination of disease within the peritoneal cavity results in an inflammatory 
response and the accumulation of ascites (Thibault et al., 2014). Ascites from 
ovarian cancer patients has been found to contain molecules that promote 
tumour activity by influencing the proliferation, angiogenesis and metastatic 
spread (Xu et al., 1995).  
 
Similarly, the microenvironment within the tumour is known to influence 
disease progression with the presence of intratumoral T cells on 
immunohistochemistry found to be associated with an improved prognosis in 
advanced ovarian cancer (PFS HR 0.14, 95% CI 0.08-0.36, p=<0.001) (Zhang et 
al., 2003). 
 
There is increasing evidence that the tumour microenvironment can be altered 
following treatment with platinum chemotherapy. Bohm et al showed that neo-
adjuvant platinum-based chemotherapy might enhance the host immune 
response and therefore help to prolong survival (Bohm et al., 2016).   
 
Flow cytometry was performed on ascites from the cisplatin experiment to 
investigate differences in the tumour microenvironment between genotypes 
and the influence of cisplatin chemotherapy. Samples were analysed from the 
Trp53-/-, Trp53-/-;Pten-/- (negative in vivo prognosis) and Trp53-/-;Brca2-/- 
(positive in vivo prognosis) genotypes. 
 
From the ascites samples the MDSC monocytic (Ly6C+G-) but not MDSC 
granulocytic (Ly6C-G+) population was increased in the Trp53-/-;Pten-/- 
genotype and when these two populations were combined (Ly6C+Ly6G+) it was 
significantly increased compared to the Trp53-/- genotype (*). The loss of Brca2 
resulted in significantly lower Ly6C+Ly6G+ levels (**) and a non-significant 
reduction in CD19+ levels compared to the Trp53-/- genotype (Figure 5.3, 
Figure 5.4 and Figure 5.19). 
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This shows that the overall MDSC population is increased in the ascites following 
the loss of Pten which is associated with the worst prognosis whereas the MDSC 
levels were decreased following Brca2 loss which is the group with the best 
prognosis. This suggests that the immunosuppressive environment created by 
increased MDSC levels are having an influence on in vivo survival.   
 
Studies have found using transgenic mouse models for melanoma that elevated 
levels of MDSCs in addition to immunosuppression also stimulate tumourigenesis 
and tumour growth (Sevko and Umansky, 2013). There is currently no evidence 
that activation of the PI3K/AKT pathway influences MDSC infiltrates in ovarian 
cancer. A study by Garcia et al however found that Pten deletion in a prostate 
mouse model resulted in an increased inflammatory response and accumulation 
of MDSCs (Garcia et al., 2014).  
 
The role of increased B cells (CD19+) in the Trp53-/;Brca2-/-  genotype was 
unclear. Flow cytometry was performed on frozen ascites samples and this may 
have influenced the granulocytic+ population as subsequent experiments on 
fresh samples have shown an increase in the Trp53-/-;Pten-/- genotype. 
 
The CD3+ levels were significantly increased following cisplatin treatment in 
the Trp53-/-;Pten-/- genotype (*) and there was also a non-significant increase 
in all other genotypes. The CD8+ levels did not change significantly with 
cisplatin treatment however the Trp53-/-;Pten-/- cisplatin treated group had 
a significantly higher CD8+ level compared to the Trp53-/- cisplatin (*) and 
Trp53-/-;Brca2-/- cisplatin (*) groups (Figure 5.3). 
 
The increase in CD3+ levels after cisplatin treatment is consistent with studies 
previously  mentioned where both Böhm et al and Lo et al found neoadjuvant 
chemotherapy to be immune stimulatory in tumour samples (Bohm et al., 2016, 
Lo et al., 2017). A possible explanation for the high CD3+ and CD8+ levels after 
cisplatin with the loss of Pten may be as a counter response to the 
immunosuppressive environment discussed earlier.   
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Due to the small number of samples per genotype and variability within each 
genotype, the PBS treated, and cisplatin treated groups were combined to 
investigate whether there were any subtle differences in immune infiltrates 
following cisplatin treatment. 
 
The CD45+, CD11b+, F4/80+, CD3+ and CD8+ populations were significantly 
increased with cisplatin treatment. The monocytic+ (Ly6C+G-) levels were 
significantly decreased (****) and granulocytic+ (Ly6C-G+) significantly 
increased (*) but when combined there was no significant difference in 
Ly6C+Ly6G+ levels after cisplatin treatment. PDL-1+ expression on CD3 cells 
was decreased after cisplatin treatment (p=0.05) and significantly decreased 
on CD19 cells (****) (Figure 5.1 and Figure 5.2). 
 
The overall cisplatin effect found in the ascites samples supports the finding of 
an enhanced immune response discussed previously and found no difference in 
the overall MDSC population following treatment. The same studies from Böhm 
et al and Lo et also found an increase in PDL-1+ expression on T cells as a 
response to chemotherapy (Bohm et al., 2016, Lo et al., 2017). However, our 
data showed that PDL-1 was decreased but there were very low levels of 
CD3+/PDL1 expression in all samples.  
 
The tissue microarrays (TMAs) allowed us to look at the tumour infiltrates within 
tumour samples. CD3 staining was significantly increased in the Trp53-/-;Pten-
/- genotype (*) with a non-significant increase in the Trp53-/-;Brca2-/-;Pten-/- 
group. No difference was found in CD3 levels after cisplatin treatment between 
the genotypes. However, when the PBS and cisplatin groups were combined 
there was a significant decrease in CD3 staining in the cisplatin group (*) (Figure 
5.7).  
 
The CD8a levels were non-significantly increased in the Trp53-/-;Pten-/- 
genotype and significantly increased in the Trp53-/-;Brca2-/-;Pten-/- group (*). 
There were no differences in CD8a levels after cisplatin treatment or when the 
PBS and cisplatin groups were combined (Figure 5.8). 
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These results differ from our flow cytometry data of ascites, where no 
difference was found in CD3 and CD8 levels between genotypes but there was 
an increase in CD3+ levels across all genotypes and significantly Trp53-/-;Pten-
/- after cisplatin treatment. The higher levels of CD3 and CD8 in the tumour 
with the loss of Pten may also be a counter response to the immunosuppressive 
environment. The reduced levels of CD3 in the tumour after cisplatin treatment 
is not consistent with studies that have suggested that platinum chemotherapy 
stimulates an immune response.  
 
F4/80 (macrophage marker) staining was significantly increased in Trp53-
/-;Pten-/- (****), Trp53-/-;Brca2-/-;Pten-/- (****) and Trp53-/-;Nf1-/- (*) 
genotypes compared to the Trp53-/- group. After cisplatin treatment the F4/80 
staining was significantly increased in the Trp53-/-;Pten-/- (**), Trp53-
/-;Brca2-/-;Pten-/- (**) and Trp53-/-;Nf1-/- (****) genotypes compared to the 
cisplatin treated Trp53-/- group (Figure 5.9). 
 
When comparing the PBS and cisplatin treated groups, both Trp53-/-;Pten-/- 
(p=0.05) and Trp53-/-;Brca2-/-;Pten-/- (**) had a decrease in F4/80 staining 
after cisplatin treatment. However, the Trp53-/-;Nf1-/- genotype had a non-
significant increase in F4/80 following cisplatin treatment (Figure 5.9).  
 
This shows that, in addition to changes in the level of MDSCs, there is also a 
significant increase in tumour-associated macrophages (F4/80) with the loss of 
Pten and the loss of Nf1. These two genotypes had the worst in vivo survival, 
and this suggests that the macrophages may contribute to tumour progression 
(see Chapter 4 – Figure 4.3). 
 
Tumour-associated macrophages have been shown to adopt pro-tumour 
properties in vivo and promote angiogenesis, tumour invasion and motility 
(Biswas and Mantovani, 2010). Coussens et al also found that TAMs can suppress 
the T cell response and can therefore lead to an immunosuppressive 
environment (Coussens et al., 2013). As discussed previously two states of 
polarised macrophages (M1 and M2) have been recognised both with distinct 
chemokine/cytokine profiles. M1-type macrophages are thought to inhibit cell 
proliferation and tissue repair whereas M2-type macrophages are thought to 
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promote cell proliferation, tissue remodelling and therefore tumour progression 
(Noy and Pollard, 2014). This is a useful but oversimplified model for 
classification as macrophages have been shown to adapt to a range of activation 
states depending on the signals present within the microenvironment 
(Heusinkveld and van der Burg, 2011). 
 
F4/80 is a pan-macrophage marker and therefore does not differentiate 
between M1-like and M2-like states.  
 
RNA sequencing of murine tumour samples allowed us to look at the differences 
between the genotypes and following cisplatin treatment at the transcript level. 
The Trp53-/- expression was reduced in all samples compared to the Trp53+/+ 
genotype, which is expected as all samples had a background knockout of Trp53. 
Similarly, Pten expression was reduced in the Trp53-/-;Pten-/- and Brca1 
expression reduced in the Trp53-/-;Brca1-/- genotypes. However, the 
expression of Brca2 was increased in the Trp53-/-;Brca2-/- and Nf1-/- increased 
in the Trp53-/-;Nf1-/- genotypes. A possible reason for this increase in 
expression is that there is reduced nonsense-mediated decay (NMD) taking 
place in the cells with Brca2 and Nf1 mutations. NMD is an mRNA surveillance 
pathway that degrades transcripts and the efficiency can vary between cells 
and between transcripts with some more prone to NMD than others.  This can 
result in a deleterious gain-of-function with a compensatory increase in 
expression (Lindeboom et al., 2016) (Appendix 2, Appendix 4 and Appendix 6). 
 
The enrichment analysis found that genes involved in cytokine activity, 
chromosomal stability and DNA binding were upregulated with the loss of Trp53. 
The treatment with cisplatin in the Trp53-/- group did not result in a significant 
up- or down-regulation of genes and therefore it is difficult to make any 
comment (Figure 5.10). 
 
There was a significant number of genes up- and down- regulated in the Trp53-
/-;Pten-/- genotype. Enrichment analysis found that in Trp53-/-;Pten-/- 
samples treated with cisplatin there was a downregulation in the immune 
response and an upregulation in the canonical Wnt signalling pathway. This is 
consistent with our immunohistochemistry data, which indicated a significant 
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decrease in CD3+ levels (*) following cisplatin treatment when the PBS and 
cisplatin groups were combined from all genotypes (Figure 5.7). The activation 
of the Wnt/β-catenin pathway has been found to correlate with poor outcomes 
in HGSOC with a recent study showing that activation of the pathway is a critical 
driver in chemotherapy resistance (Nagaraj et al., 2015). This offers a possible 
explanation for the decreased in vivo platinum sensitivity with the loss of Pten 
(Figure 5.11). 
 
RNA sequencing data from the Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- 
genotypes was relatively ‘bland’ with very few up- or downregulated genes 
compared to Trp53-/- and also following treatment with cisplatin. We had 
expected to find a down-regulation in genes responsible for double-stand DNA 
repair however it was not possible to perform enrichment analysis on these 
genotypes due to the limited number of altered genes (Figure 5.12 and Figure 
5.13). This could be because both Brca1 and Brca2 have a much narrower 
activity and are therefore less likely to cause huge changes in overall gene 
expression. The RNA sequencing analysis included tumour and non-tumour cells 
so changes in DNA repair genes in tumour may be hard to quantify overall or it 
could be that the changes in these genes occur at a post-transcriptional level 
so would only be detected by protein-based assays. 
 
The Trp53-/-;Nf1-/- genotype like the Trp53-/-;Pten-/- group had a significant 
number of genes up- and downregulated compared to Trp53-/- and also 
following cisplatin treatment. This is not surprising given that both Pten 
(PI3K/AKT pathway) and Nf1 (RAS/MAPK pathway) regulate complicated 
pathways. Enrichment analysis of Trp53-/-;Nf1-/- found the chemokine activity 
and immune response to be downregulated and pathways involved in 
neurotransmitter transport to be upregulated. This upregulation may be 
partially explained by the higher level of Nf1 rRNA in the Nf1-/- knockouts 
(Appendix 6). The RNA sequencing findings are the opposite to those found in 
the Trp53-/-;Pten-/- genotype (i.e. increased immune/inflammatory response) 
and although we previously found an increase in F4/80 with the loss of Nf1-/- 
the immunosuppressive environment may be achieved by a different mechanism 
to the Pten knockouts (Figure 5.14).  
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Trp53-/-;Nf1-/- samples treated with cisplatin showed a downregulation in the 
inflammatory response/chemotaxis and upregulation in genes responsible for 
the function of the cell junction (Figure 5.15). These enrichment findings are 
similar to the cisplatin treated Trp53-/-;Pten-/- samples where we also found 
from IH data a significant decrease in CD3+ levels after cisplatin treatment.   
 
We focussed on the effect of Pten loss and summarised some of the findings 
that might explain its poor in vivo prognosis. Following on from previously 
published data that confirmed biallelic deletion of Pten and an increase in Akt 
phosphorylation on western blot in the Trp53-/-;Pten-/- genotype (Walton et 
al., 2017) we also showed a significant increase in p-Akt (Ser473) on 
immunohistochemistry in the Trp53-/-;Pten-/- and Trp53-/-;Brca2-/-;Pten-/- 
genotypes confirming the activation of the PI3K/AKT pathway (Figure 5.16).  
 
An in vitro chemokine/cytokine array comparing the Trp53-/- and Trp53-
/-;Pten-/- groups showed a significant increase in Ccl2 and Ccl7 in the Trp53-
/-;Pten-/- genotype. This was also confirmed by RT-qPCR and RNA sequencing 
on murine tumour samples that showed an increase in expression of these 
cytokines with the loss of Pten (****) (Figure 5.17 and Figure 5.18).  
 
Ccl2 has been shown to attract monocytic and granulocytic MDSCs in breast, 
colorectal and lung cancer and to maintain immunosuppressive activity (Sevko 
and Umansky, 2013). The recruitment of inflammatory monocytes and tumour-
associated macrophages by tumour and stroma have been found to depend on 
Ccl2 (Qian et al., 2011, Noy and Pollard, 2014). Studies have shown that 
inhibiting the CCL2-CCR2 signalling axis decreases the infiltration of TAMs and 
MDSCs and prolongs the survival in tumour-bearing mice (Qian et al., 2011, Zollo 
et al., 2012). 
 
Ccl7 has been reported to be involved in monocytic recruitment with studies 
showing an important role for the chemokine in enrichment of MDSC in an in 
vivo colon cancer model (Sevko and Umansky, 2013, Ichikawa et al., 2011). The 
same study also showed that a reduction in Ccl7, Ccl5 and Cxcl1 and MDSC 
infiltration was associated with a significant reduction in tumour growth and 
metastasis (Ichikawa et al., 2011).    
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RNA sequencing was performed on the Trp53-/-;Pten-/- tumours. Enrichment 
analysis showed an upregulation in chemokine activity, inflammatory response 
and the T cell receptor signalling pathway compared to Trp53-/-. Upregulated 
genes in the Trp53-/-;Pten-/- tumours that are involved in the activity of 
tumour-associated macrophages and myeloid-derived suppressor cells were 
identified and summarised in Figure 5.18. These included Ccl2, 5, 8, 9, 17, 22 
and Cxcl9 and 10 and IL-4 and TNFα involved in tumour-associated macrophage 
function and Ccl2, 5, 7 and IL-4 and TNFα involved in myeloid-derived 
suppressor cell function. 
 
As mentioned previously, Ccl2 and Ccl7 have been shown to influence MDSC 
infiltration but Ccl5 has been found to be important in both MDSC recruitment 
and macrophage differentiation (Ugel et al., 2015). IL-4 contributes to an 
immuno-suppressive phenotype by supporting the survival of both TAMs and 
MDSC (Ugel et al., 2015). IL-4 activation of macrophages with the help of TH2 
cells induces the polarisation to M2-like macrophages (Coussens et al., 2013, 
Gocheva et al., 2010), whereas TNFα has been shown to mediate the generation 
of highly suppressive MDSCs from PBMCs and induce the polarisation to M1-like 
macrophages (Lechner et al., 2010, Mills, 2012).  
 
In addition to Ccl2, Ccl5 and Ccl9 are known to recruit immature myeloid cells 
and been found to be expressed on tumour-associated macrophages (Kitamura 
et al., 2010, Liou et al., 2013). The polarisation of macrophages is guided by 
the surrounding cytokines. M1 and M2 macrophages promote TH1 and TH2 
response respectively (Mills, 2012). Polarising chemokines that have been found 
in multiple studies to favour polarisation to M1-like macrophages include Cxcl9, 
10 and Ccl8 and those favouring polarisation to M2-like macrophages include 
Ccl17, Ccl22, Ccl24 (Martinez et al., 2006, Biswas and Mantovani, 2010). 
 
Flow cytometry analysis from both ascites and tumour showed a significant 
increase in MDSCs (Ly6C+Ly6G+) in ascites and tumour with the loss of Pten. 
There was also a significant increase in tumour F4/80 levels in the Trp53-
/-;Pten-/- genotype from flow cytometry and immunohistochemistry analysis 
(Figure 5.19). Immunohistochemistry analysis showed a significant increase in 
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iNOS (M1-like marker) and CD206 (M2-like marker) staining in the same 
genotype but with no evidence of favouring an M2-like state (Figure 5.20). 
However, to confidently determine macrophage polarisation, analysis by flow 
cytometry or IHC staining for multiple markers is required.  
 
These findings support the hypothesis that the loss of Pten and activation of 
the PI3K/AKT pathway leads to an immunosuppressive microenvironment that 
helps to drive tumour progression and impact survival. The environment is 
altered by specific chemokine/cytokine responses that result in increased levels 
of MDSC and tumour-associated macrophages. The macrophages are likely to be 
skewed towards an M2-like phenotype that encourages tumour growth and 
invasion.  
 
In summary, data in this chapter show that the tumour microenvironment is 
different between genotypes and can be altered with the addition of platinum 
chemotherapy. The cisplatin effect was not necessarily the same in the ascites 
and tumour samples as evidenced by different levels of CD3/CD8. The subtle 
changes within the microenvironment offer potential explanations for 
differences in in vivo survival between the genotypes.  
 
We decided to focus on Pten loss as this offered an exciting therapeutic target 
that could potentially have an impact clinically. The next step was to attempt 
to reverse the effect of Pten by targeting the chemokine/cytokine receptors 
and PI3K/AKT pathway. 
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6 Reversing the effect of Pten loss
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6.1 Introduction 
PTEN is a phosphatase that acts as a tumour suppressor. A deletion or loss of 
function mutation of PTEN results in the activation of the PI3K/AKT pathway 
that can lead to increased proliferation and cell growth. TCGA and ICGC data 
suggest the loss of PTEN to be a common event in HGSOC with up to 36% of 
tumours demonstrating at least heterozygous PTEN loss (Martins et al., 2014, 
Patch et al., 2015).  
 
Loss of PTEN is a negative prognostic factor with a recent study showing the 
loss or downregulation of PTEN to be strongly associated with a worse overall 
survival (Martins et al., 2014). The activation of the PI3K/AKT pathway in 
ovarian cancer has also been associated with chemotherapy resistance in 
several studies (Kolasa et al., 2009, Yang et al., 2008). 
 
As described in the previous chapters, we found that the knockout of Pten was 
associated with a poor prognosis in an in vivo model. We also showed that there 
were significant changes in the tumour microenvironment with increased levels 
of MDSCs and TAMs (see Chapter 4 and 5).    
 
There are a broad range of drugs and potential targets that we could have used 
to attempt to reverse the effect of Pten. Isoform-specific PI3K inhibitors (e.g. 
p110α and p110β) have been shown in clinical trials to have fewer toxicities 
and result in a more complete inhibition of the PI3K/AKT pathway compared to 
pan-class I PI3K inhibitors (Furman et al., 2014). There is also evidence in PTEN-
mutant tumours that p110α activity is suppressed and the PI3K pathway is 
driven by p110β (Schwartz et al., 2015).  
 
We decided to target both the cytokine/chemokine response directly by using 
a transgenic mouse model and the PI3K/AKT pathway by using a PI3K inhibitor 
p110β. This chapter describes these two in vivo experiments to reverse the 
effect of Pten.  
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6.2 GGTACKO in vivo pilot experiment 
A pilot experiment using only 17 mice was performed to establish whether this 
transgenic mouse model influenced the tumour microenvironment in the Trp53-
/-;Pten-/- genotype and, if so, whether this altered the survival. The GGTACKO 
mice, which are on a C57Bl/6n background, have constitutive knockout of CCR1, 
2, 3 and 5. These encode the chemokine receptors CCR1, 2, 3 and 5, which in 
turn are the receptors for a wide variety of chemokines, including Ccl2 and Ccl7 
that were shown in the last chapter to be upregulated in Trp53-/-;Pten-/- ID8 
cells and tumours.  
 
 
Figure 6.1: Outline of the GGTACKO in-vivo experiment.  
GGTACKO mice were used to investigate the effect of knocking out CCR1, 2, 3 and 5 
receptors on the tumour microenvironment. The C57BL/6n WT or KO (female) mice 
were injected i.p with 5x106 cells of either the Trp53-/- or Trp53-/-;Pten-/- genotype.  
The mice were then taken at the Home office endpoint. 
 
6.2.1 Survival 
The 17 mice were injected intraperitoneally as described above (Figure 6.1). 7 
wild-type mice were used, 3 injected with the Trp53-/- (F3) genotype and 4 
injected with the Trp53-/-;Pten-/- (1.14) genotype. 10 knockout mice were 
used, 5 injected with Trp53-/- (F3) and 5 with Trp53-/-;Pten-/- (1.14) genotype. 
The mice were monitored daily and killed when they reached UK Home Office 
limits.  
 
Both the wild-type and knockout mice injected with F3 (Trp53-/-) had a median 
survival of 53 days. The wild-type mice injected with 1.14 (Trp53-/-;Pten-/-) 
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had a median survival of 32 days compared to a median survival of 36 days in 
the knock-out mice injected with the 1.14 cell line (Figure 6.2 and Table 6.1); 
however, this difference was not significant.  
 
 
Figure 6.2: In vivo GGTACKO experiment showing the survival and ascites volumes 
A, Kaplan-Meier survival curves comparing the WT and KO mice with either Trp53-/- 
or Trp53-/-;Pten-/- cell lines injected with the median survival (days) B, Ascites 
volumes from the different genotypes and WT/KO mice. 
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Table 6.1: GGTACKO Median Survival 
Genotype Median survival (days) 
WT_Trp53-/-;Pten-/- 32 
KO_Trp53-/-;Pten-/- 36 
WT_Trp53-/- 53 
KO_Trp53-/- 53 
 
Ascites volumes between the different groups were similar however, there 
were significantly lower volumes in the WT_Trp53-/- group compared to the 
KO_Trp53-/- group (*) (Figure 6.2). 
 
6.2.2 Flow cytometry 
Flow cytometry analysis was performed on the fresh ascites and tumour samples 
using the same 12 antibody panel used previously (see Methods – Table 2.5). 
 
There was no obvious difference in CD11b+ and F4/80 levels in the ascites 
samples between the different genotypes and between the wild-type and 
knock-out mice. The Ly6C+Ly6G+ (Gr-1+) levels appeared to be higher in the 
WT and KO mice injected with the Trp53-/-;Pten-/- cell line compared to the 
Trp53-/- genotype (Figure 6.3).  
 
In the tumour samples, the F4/80, CD11b+ and Ly6C+Ly6G+ levels were higher 
in the WT mice injected with Trp53-/-;Pten-/- (1.14) with lower levels in the 
mice injected with Trp53-/- (F3). Although there was only one mouse tumour 
sample, there appeared to be a reduction in F4/80, CD11b+ and Ly6C+Ly6G+ 
levels in the Trp53-/-;Pten-/- tumours in the knockout mouse compared to the 
WT mice (Figure 6.3).  
 
Due to the limited number of mice used for the experiment, statistical analysis 
was not performed to compare any differences.  
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Figure 6.3: Flow cytometry analysis of ascites and murine tumour from the 
GGTACKO pilot experiment. 
A, Ascites samples showing a higher level of Ly6C+Ly6G+ (Gr-1+) in the Trp53-/-;Pten-
/- genotypes in both WT and KO mice. B, Tumour samples showing a higher level of 
CD11b+, F4/80 and Gr-1+ in the Trp53-/-;Pten-/- genotype in the WT mice compared 
to the KO mouse. 
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6.2.3 Full blood count 
A full blood count was taken from each mouse once they had reached the Home 
Office endpoint. The HGB (haemoglobin), PLT (platelets) and NEUT:LYMPH ratio 
data are summarised in Figure 6.4. The WT and KO mice injected with the 
Trp53-/-;Pten-/- genotype had lower levels of HGB compared to the mice 
injected with the Trp53-/- cell line. There did not appear to be any difference 
in HGB levels between the wild-type and knockout mice (Figure 6.4).  
 
There was no obvious difference in platelet levels between the WT and KO mice 
and the different genotypes. 
 
The NEUT:LYMPH ratio showed a trend towards a higher level in the WT and KO 
mice injected with Trp53-/-;Pten-/- compared to those injected with the 
Trp53-/- genotype. There was also no obvious difference between the wild-
type and knockout mice (Figure 6.4). 
 
Statistical analysis was not performed to compare any differences again due to 
the limited number of mice used.  
 
6.2.4 Immunohistochemistry 
The GGTACKO murine tumours were stained for pAkt (Ser473), F4/80, iNOS and 
CD206. There was a significant increase in pAkt staining between the 
WT_Trp53-/- and WT_Trp53-/-;Pten-/- genotypes (*) and between the 
KO_Trp53-/- and KO_Trp53-/-;Pten-/- genotypes (**). There was no significant 
difference in F4/80, iNOS and CD206 levels between the wild-type and knockout 
mice and between different genotypes (Figure 6.5). 
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Figure 6.4: Full blood counts (FBC) from the GGTACKO mice.  
The HGB (haemoglobin) is reduced in the 1.14 Trp53-/-;Pten-/- compared to the F3 
Trp53-/- genotype. No obvious difference in platelets is observed and an increase is 
shown in the NEUT:LYMPH ratio in the 1.14 Trp53-/-;Pten-/- genotype.  
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Figure 6.5: Immunohistochemistry from the GGTACKO pilot experiment 
Immunohistochemistry from murine tumours showing a significant increase in pAkt in 
the Trp53-/-;Pten-/- in both the wild-type and knockout mice but no obvious 
difference in F4/80, iNOS (M1-marker) and CD206 (M2 marker) levels.  
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6.3 AZD8186 in vivo experiment 
AZD8186 is a small molecule that selectively inhibits PI3Kβ signalling. It has 
been shown to reduce p-AKT (Ser473) levels and inhibit tumour growth in breast 
and prostate in vivo PTEN-null models (Hancox et al., 2015). 
 
The aim of this initial experiment was to block the activated PI3K/AKT pathway 
in our Pten knockout cell lines and therefore reverse the changes we have 
previously described in the tumour microenvironment.  
 
The injection and treatment protocol are described in the Methods section 
(Chapter 2, 2.7.3 and Figure 6.6). 
 
 
Figure 6.6: Outline of the AZD8186 in vivo experiment. 
A p110β PI3K inhibitor (AZD8186) was used to block the PI3K/AKT pathway and attempt 
to reverse the Pten effect. C57BL/6 (female) mice were injected i.p with 5x106 cells 
of either the F3 (Trp53-/-) or 1.14 (Trp53-/-;Pten-/-) cell lines. The F3 mice were 
treated by twice daily oral gavage with either the control (0.5% hydroxyl-propyl-
methycellulose + 0.1% tween-80) or AZD8186 from days 37 to 42 and then culled on 
day 42. The 1.14 mice were treated on days 25 to 30 and then culled on day 30.  
 
The next step was to perform in vitro experiments to optimise the AZD8186 
drug prior to under taking the in vivo experiment. 
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6.3.1 Optimisation of drug 
The in vitro optimisation experiments were performed by Josephine Walton 
(post-doc). The 1.14 Trp53-/-;Pten-/- cell line was treated with the AZD8186 
drug to determine the optimal concentration required to inhibit the PI3K/AKT 
pathway. The cells were serum starved overnight and treated for 2 hours in 
serum-free medium with a range of drug concentrations (10, 100, 250, 500, 
1000nM). A western blot showed the minimum concentration required to 
prevent Akt (Ser473) phosphorylation was 100nM (Figure 6.7). 
 
A time course showed that cells treated with 250nM of AZD8186 had a reduced 
expression of p-Akt for 2 hours but by 4 hours the expression was back to pre-
treatment levels. This corresponded with RT-qPCR data that showed a 
reduction in Ccl2 and Ccl7 levels until 2 hours after treatment, after which 
there was a steady increase until back to pre-treatment levels after 24 hours 
(Figure 6.7). 
 
A dose of 50mg/kg of AZD8186 had been previously published in vivo and 
showed pathway inactivation with no adverse toxicity (Hancox et al., 2015). I 
therefore used this dose for the in vivo experiment. 
 
 
Figure 6.7: In vitro optimisation of the AZD8186 drug. 
This experiment was performed by Josephine Walton (post-doc). 
A, Western blot showing absent p-Akt (Ser473) expression after overnight serum-
starvation and 2hrs treatment with AZD8186 (100nM) in the 1.14 cell line. B, A time 
course showing reduced p-Akt expression up until 4 hours on western blot after 2hrs 
treatment of the 1.14 cell line with AZD8186 (250nM). C, RT-qPCR showing the time 
course of expression of Ccl2 and Ccl7 following treatment with AZD8186 (250nM) 
relative to time 0.  
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6.3.2 Flow cytometry 
Flow cytometry analysis was performed on the fresh ascites and tumour samples 
using the same 12 antibody panel used previously in the GGTACKO pilot 
experiment. 
 
In the ascites samples, there was no obvious difference in the F4/80 levels in 
between the different genotypes and treatment groups. There was a non-
significant increase in the Ly6C+Ly6G+ level in the 1.14 (Trp53-/-;Pten-/-) 
(control) compared to the F3 (Trp53-/-) (control) group. There was a non-
significant decrease in Ly6C+Ly6G+ levels between the control and AZD8186 
mice injected with F3 however there was a significant decrease in levels 
between the control and AZD8186 treated mice injected with 1.14 (***) (Figure 
6.8). 
 
In the tumour samples, there was again no obvious difference in the F4/80 
levels between the different genotypes and treatment groups. There was a 
significant increase in the Ly6C+Ly6G+ level in the 1.14 (Trp53-/-;Pten-/-) 
(control) compared to the F3 (Trp53-/-) (control) group (***). Following 
treatment with AZD8186 there was a non-significant decrease in Gr-1+ levels in 
the 1.14 cell line (Figure 6.8). 
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Figure 6.8: Flow cytometry analysis of ascites and murine tumour from the 
AZD8186 experiment. 
A, Ascites samples showing a significant decrease in Ly6C+Ly6G+ (Gr-1+) levels 
following AZD8186 treatment in the Trp53-/-;Pten-/- (1.14) genotype but no 
difference in the F4/80 levels B, Tumour samples showing a non-significant decrease 
in Ly6C+Ly6G+ levels following AZD8186 treatment in the Trp53-/-;Pten-/- (1.14) 
genotype but again no difference in the F4/80 levels. 
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6.3.3 Full blood count 
A full blood count was taken from each mouse once they had reached the Home 
Office endpoint. There was no difference in HGB between the control and 
AZD8186 treated mice injected with F3 (Trp53-/-).  The HGB was significantly 
increased in the AZD8186 treated group compared to the control group in mice 
injected with 1.14 (Trp53-/-;Pten) (****). There was also a significant reduction 
in HGB levels between the F3 and 1.14 (control) groups (Figure 6.9).  
 
The platelet levels were not significantly different between the genotypes or 
between different treatment groups. 
 
There was no significant difference in the NEUT:LYMPH ratio between the 1.14 
(control) compared to the F3 (control) group. There was a significant reduction 
in the AZD8186 treatment groups (F3 and 1.14) compared to both the controls 
(**) (Figure 6.9).  
 
6.3.4 RT-qPCR 
The RT-qPCR from the tumours showed a decrease in Pten expression and an 
increase in Ccl2 and Ccl7 when comparing the F3 (control) and 1.14 (control), 
which is comparable to our previous in vivo data (****) (Figure 6.10). 
 
AZD8186 treatment did not alter Pten expression in the Trp53-/-;Pten-/- 
tumours, but did decrease Ccl2 and Ccl7 expression (****). Interestingly, Ccl2 
and Ccl7 also reduced in the Trp53-/- tumours following AZD8186 (****). When 
comparing both genotypes treated with AZD8186 the levels of Ccl2 (***) and 
Ccl7 (****) were still higher in the Trp53-/-;Pten-/- tumours (Figure 6.10).  
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Figure 6.9: Full blood counts (FBC) from the AZD8186 experiment. 
Each dot represents the FBC from one mouse. The HGB (haemoglobin) levels are 
reduced in the 1.14 Trp53-/-;Pten-/- compared to the F3 Trp53-/- genotype as shown 
in previous in vivo data. There is a significant increase in the HGB level in the 1.14 cell 
line following treatment with AZD8186 (****). No obvious difference in platelets is 
observed. A significant reduction in the NEUT:LYMPH ratio is shown in both the F3 and 
1.14 cell line following AZD8186 treatment (**).  
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Figure 6.10 RT-qPCR on murine tumour samples from the AZD8186 experiment. 
A, F3 (control) vs 1.14 (control) showing reduced expression of Pten and increased Ccl2 
and Ccl7 expression. B, F3 (control) vs F3 (AZD8186) showing no change in Pten 
expression and reduced expression of Ccl2 and Ccl7. C, 1.14 (control) vs 1.14 (AZD8186) 
showing no change in Pten and reduced expression of Ccl2 and Ccl7 following AZD8186 
treatment. D, F3 (AZD8186) vs 1.14 (AZD8186) showing reduced expression of Pten and 
increased Ccl2 and Ccl7 expression.  
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6.3.5 Immunohistochemistry 
The AZD8186 treated and untreated murine samples were stained for BrDU, 
pAkt (Ser473), F4/80, iNOS and CD206. There was no significant difference in 
BrDU levels between the genotypes treated with vehicle or following treatment 
with AZD8186. As previously shown there was a significant increase in p-Akt 
(Ser473) in the Trp53-/-;Pten-/- compared to the Trp53-/- genotype. Phospho-
Akt staining was reduced in the Trp53-/-;Pten-/- tumours after AZD8186 
treatment, although not significantly.  
 
There was a non-significant increase in F4/80 levels in the Trp53-/-;Pten-/- 
control group compared to the Trp53-/- control group. However, treatment 
with AZD8186 did not alter these levels significantly.  
 
The Trp53-/-;Pten-/- genotype had a significantly lower level of iNOS staining 
(M1-marker) compared to the Trp53-/- genotype with a non-significant 
decrease in levels in the same genotype after treatment with AZD8186. There 
was no significant difference in CD206 levels between the genotypes or after 
treatment (Figure 6.11).  
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Figure 6.11: Immunohistochemistry from the AZD8186 experiment 
Immunohistochemistry from murine tumours showing no significant difference in BrDU, 
F4/80, iNOS and CD206 levels following treatment with AZD8186 in both genotypes and 
a non-significant decrease in p-Akt (Ser473) levels in the Trp53-/-;Pten-/- genotype 
after AZD8186 treatment. The iNOS level (M1-type) was significantly reduced in the 
Trp53-/-;Pten-/- (1.14) compared to the Trp53-/- (F3) genotype. 
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6.4 Discussion 
A complex chemokine network within the tumour microenvironment has been 
shown to influence the phenotype of the immune infiltrates and impact on 
tumour growth and migration as reviewed by Balkwill et al (Balkwill, 2004). The 
GGTACKO mice have constitutive deletions in CCR1, 2, 3 and 5 and these mice 
allowed us to target the chemokine/cytokine response directly.  
 
Inhibition of CCR1 has been shown to block the accumulation of immature 
myeloid cells resulting in reduced tumour dissemination and significantly 
prolonging survival in a colon cancer mouse model (Kitamura et al., 2010). 
CCL2/CCR2 chemokine axis is critical in the recruitment and mobilisation of 
inflammatory monocytes in tumour. In pancreatic cancer in mice, CCR2 
blockade has been found to reduce the levels of both inflammatory monocytes 
and macrophages resulting in decreased tumour growth (Sanford et al., 2013).  
 
CCR3 expression has been found on cells that are important for M2-like 
polarisation these include Treg, TH2 cells, eosinophils and basophils (Mantovani 
et al., 2004b). The CCL5/CCR5 axis has been shown to be a significant regulator 
of immunosuppressive myeloid cells. Studies have found the absence of CCL5 
or CCR5 to delay tumour progression with a reduction in both monocytic and 
granulocytic myeloid-derived suppressor cells and tumour-associated 
macrophages (Schlecker et al., 2012, Ban et al., 2017).  
 
Our previous findings have found an increase in MDSCs and TAMs with the loss 
of Pten. By using this GGTACKO transgenic in vivo model that targeted 
specifically the CCR1, 2, 3, and 5 receptors we hoped to reduce the level of 
these immune infiltrates and therefore prolong survival in the Pten-/- genotype.  
 
The wild-type mice injected with the F3 cell line (Trp53-/-) had a median 
survival of 53 days compared to the knock-out mice with a median survival of 
53 days. The wild-type mice injected with the 1.14 cell line (Trp53-/-;Pten-/-) 
had a median survival of 32 days and this was compared to 36 days in the knock-
out mice (Figure 6.2).  
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The difference in survival between the Trp53-/- and Trp53-/-;Pten-/- 
genotypes in the wild-type mice is comparable with previous in vivo data (see 
Chapter 4, Figure 4.2). There was no obvious difference in survival with the 
Trp53-/- genotype between the WT and KO mice. The Trp53-/-;Pten-/- 
genotype in the KO mice extended survival by 4 days compared to the wild-type 
mice with the same genotype, however this was not significant. A larger 
experiment would be required to demonstrate whether there was a real 
difference in survival.  
 
Flow cytometry from ascites showed a trend towards a higher level of 
Ly6C+Ly6G+ expression in both the WT and KO mice injected with the Trp53-
/-;Pten-/- compared to Trp53-/- cell line (Figure 6.3). This was similar to 
previous flow cytometry analysis of ascites (see Chapter 5, Figure 5.19). 
However, no difference was seen in Ly6C+Ly6G+ expression when comparing 
the WT and KO mice.  
 
Flow cytometry performed on fresh tumour samples showed a trend towards a 
higher level of CD11b+, Ly6C+Ly6G+ and F4/80+ expression in the WT mice 
injected with Trp53-/-;Pten-/- compared to the WT and KO mice injected with 
Trp53-/-. No obvious difference in expression levels in the tumour between the 
KO and WT mice injected with F3 (Trp53-/) were found. However, there 
appeared to be a reduction in the level of CD11b+, Ly6C+Ly6G+ and F4/80 
expression in the tumour in the KO mouse injected with 1.14 (Trp53-/-;Pten-/-) 
(Figure 6.3). Unfortunately, only one tumour sample from the KO mice injected 
with the 1.14 cell line was analysed and it is therefore difficult to make any 
valid conclusions.   
 
A full blood count (FBC) was taken from each mouse when they were culled at 
the Home Office endpoint. The WT and KO mice with Trp53-/-;Pten-/- were 
more anaemic with lower levels of haemoglobin compared to the mice injected 
with the Trp53-/- cell line (Figure 6.4). There was no difference in ascites 
volumes or bloody appearance of the ascites between the mice that might have 
explained the anaemia (Figure 6.2). Previous in vivo experiments using the 
Trp53-/-;Pten-/- genotype had shown the mice to be anaemic but there was no 
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obvious reversal in this experiment using these knockout mice, implying that 
signalling via CCR1, 2, 3 or 5 was not responsible for the anaemia.  
 
Thrombocytosis has been found to be associated with advanced disease and a 
worse overall survival in ovarian cancer (Stone et al., 2012). We found no 
difference in platelet levels between the mice. A high neutrophil to lymphocyte 
ratio has also been shown to be associated with an adverse overall survival in 
many solid tumours including ovarian cancer (Templeton et al., 2014, Cho et 
al., 2009). There was a trend towards a higher NEUT:LYMPH ratio in the Trp53-
/-;Pten-/- compared to the Trp53-/- genotype but there was no obvious 
difference between the WT and KO mice (Figure 6.4). 
 
Immunohistochemistry staining of the GGTACKO tumours showed no obvious 
differences in the F4/80, iNOS and CD206 staining between the wild-type and 
knockout mice. We also were unable to show increased levels of these 
macrophage markers in the Trp53-/-;Pten-/- although the numbers analysed 
were small (Figure 6.5). 
 
The GGTACKO in vivo experiment was a pilot experiment to determine whether 
the knockout of these CCR receptors influenced not only the immune infiltrates 
within the tumour but also survival. The early results were encouraging but a 
repeat experiment is required before valid conclusions can be made. It is 
possible that knocking out specific CCR receptors may have a limited impact on 
macrophage and MDSC levels and that the function and recruitment of these 
infiltrates is more complicated.  
 
In the AZD8186 in vivo experiment we used an alternative approach to reverse 
the effect of Pten by targeting the PI3K/AKT pathway. The in vitro optimisation 
determined the optimal concentration of drug to inhibit p-Akt (Ser473) and 
change the cytokine profile. The p-Akt (Ser473) expression was inhibited but 
returned to pre-treatment levels after 4 hours and Ccl2 and 7 were at their 
lowest level at 2 hours post-treatment. These findings confirmed that the mice 
needed to be culled no later than 2 hours after the final treatment dose so as 
we could identify any changes within the tumour. 
 
214 
 
From recent AZD8186 in vivo studies on PTEN null tumour xenograft models 
(786-0 renal and U87-MG glioma), 5 days of twice daily treatment (50mg/kg) 
was found to reduce tumour growth by 87% compared to 93% with constant 
dosing (Hancox et al., 2015). From this information and our recent in vitro data, 
we decided on a treatment regime of twice daily gavage (50mg/kg) for 5 days 
and culling of the mice 2 hours after their final dose. The timing of the 
treatment was determined by previous in vivo survival data (see Chapter 4, 
Figure 4.2). 
 
Flow cytometry showed similar data to previous in vivo experiments with a 
significantly higher level of Ly6C+Ly6G+ in both the ascites and tumour in the 
1.14 mice (Trp53-/-;Pten-/-) compared to mice injected with F3 (Trp53-/-). 
However we were unable to replicate the high levels of F4/80 we had previously 
seen in the Trp53-/-;Pten-/- genotype. We showed no obvious difference in 
Ly6C+Ly6G+ and F4/80 levels between the control and AZD8186 treated mice 
injected with F3 (Trp53-/-). However, there was a significant reduction in 
Ly6C+Ly6G+ levels in the ascites in the AZD8186 treated group injected with 
1.14 (Trp53-/;Pten-/-) compared to the control group and a non-significant 
decrease in levels in the tumour samples. As mentioned there was no obvious 
difference in F4/80 levels between the samples (Figure 6.8). 
 
These data show that the AZD8186 drug has started to reverse some of the 
immunosuppressive changes we had previously described in the tumour 
microenvironment with the loss of Pten. The reason for the low F4/80 levels 
between all samples is unknown. 
 
A full blood count from these mice showed no difference between the control 
and AZD8186 treated mice injected with F3. However, there was a reduction in 
the level of anaemia in the AZD8186 treated group injected with the 1.14 clone 
with an increase in haemoglobin (HGB) levels compared to the control. These 
changes suggest that the AZD8186 drug has reversed the anaemic state 
previously seen in the Trp53-/-;Pten-/- genotype, the exact mechanism of this 
is unclear (Figure 6.9).  
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As discussed previously the NEUT:LYMPH ratio is associated with a worse 
prognosis. Both AZD8186 treatment groups (F3 and 1.14) had a significant 
reduction in the ratio compared to the control. However we did not show a 
higher baseline level in the 1.14 control group which previous in vivo data had 
shown. This reduction in the ratio with AZD8186 treatment is difficult to explain 
for both genotypes as the drug inhibits the PI3K/AKT pathway which has been 
shown not to be activated in the F3 (Trp53-/-) genotype. The drug may be 
having some off-target effects that influence the circulating leukocyte 
population (Figure 6.9). 
 
The RT-qPCR from the murine tumours showed a decrease in Pten expression 
and an increase in Ccl2 and Ccl7 expression when comparing the F3 (control) 
and 1.14 (control), which is comparable to our previous in vivo data (****). 
However, when comparing the 1.14 (AZD8186) and 1.14 (control) samples there 
was no change in Pten expression but a decrease in Ccl2 and Ccl7 expression 
(****). This shows that in addition to AZD8186 reversing the level of MDSCs the 
expression of specific cytokines associated with macrophage and MDSC activity 
are reduced. Similar cytokine changes were seen when comparing the F3 
(control) and F3 (AZD8186) samples that suggests that the AZD8186 drug is 
having an overall effect on cytokine levels. We also compared the two AZD8186 
treatment groups (F3 and 1.14) and showed that the Ccl2 (***) and Ccl7 (****) 
levels remained higher in the 1.14 (Trp53-/-;Pten-/-) genotype (Figure 6.10).   
 
As shown previously immunohistochemistry analysis from the murine tumours 
showed a higher level of p-Akt (Ser473) in the Trp53-/-;Pten-/- (1.14) genotype 
and a non-significant decrease in levels following AZD8186 treatment. This non-
significant reduction may show that the PI3K/AKT pathway has been partially 
inhibited by the drug and could be due to inadequate treatment length or 
alternative mechanisms leading to on-going activation of the pathway. Staining 
with BrDU did not show any differences between the genotypes, suggesting that 
the more aggressive tumour behaviour seen in the Trp53-/-;Pten-/- genotype is 
not because of increased cell proliferation (Figure 6.11).  
 
The Trp53-/-;Pten-/- genotype showed higher levels of F4/80 as shown 
previously but a significantly lower level of iNOS staining (M1-marker) with no 
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difference in CD206 levels (M2-marker). The differences in iNOS staining were 
not seen on the TMAs but this result does provide some evidence of polarisation 
of the Trp53-/-;Pten-/- genotype to a pro-tumour M2-like state. Consistent with 
the flow cytometry data, there was no significant difference in F4/80 levels 
following treatment with AZD8186 and this could be as result of incomplete 
inactivation of the PI3K/AKT pathway (Figure 6.11). 
 
In summary, we have shown by these two in vivo experiments that it is possible 
to reverse the effect of Pten loss, at least partially. We targeted the PI3K/AKT 
pathway and showed that the immunosuppressive microenvironment can be 
reversed. The GGTACKO experiment targeted the chemokine/cytokine 
response directly and although only a pilot showed encouraging data that 
supports this as a potential target. A repeat of the GGTACKO experiment is on-
going and an in vivo AZD8186 survival experiment is the next step to establish 
whether by altering the tumour microenvironment we can improve survival in 
the Trp53-/-;Pten-/- genotype.  
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7 Final Discussion
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The treatment of high grade serous ovarian cancer has improved over the last 
30 years with the introduction of platinum and taxane-based chemotherapy. 
Platinum chemotherapy often leads to an initial clinical response, however 
most patients will ultimately relapse and there remains a sub-group of patients 
who are intrinsically resistant to platinum (Galluzzi et al., 2012). Improving our 
understanding of these resistant mechanisms will help us to develop alternative 
therapeutic strategies.    
 
Until recently there was a ‘one size fits all’ approach to ovarian cancer 
management with no acknowledgement of the histological subtypes and how 
these differed in terms of chemotherapy response, survival, genetics and tissue 
of origin. Most cases of high grade serous ovarian cancer are now thought to 
originate from the fallopian tube. This has important implications for future 
management in terms of prevention, early detection and surgical intervention 
(Labidi-Galy et al., 2017b). 
 
An improved understanding of the molecular diversity and tumour 
microenvironment has allowed us to make progress in drug development. PARP 
inhibitors and VEGF inhibitors (bevacizumab) are the first new drugs for use in 
ovarian cancer for over 20 years.   
 
The Cancer Genome Atlas (TCGA) has helped to map out the genetic landscape 
of HGSOC. Homologous recombination is known to be an important pathway in 
the repair of double-strand DNA and in addition to BRCA1 and BRCA2 mutations, 
defective homologous recombination is thought to be present in up to 50% of 
cases. This has important therapeutic implications as PARP inhibitors currently 
have FDA approval in patients with known BRCA1/2 mutations and last year 
have been approved for use in non-BRCA patients with recurrent epithelial 
ovarian cancer who had a complete or partial response to platinum-based 
chemotherapy.  
 
A greater understanding of the genetic landscape has helped to identify the 
most common but also least frequently mutated genes in HGSOC. BRCA1/2 
mutations in ovarian cancer are well known and tend to respond well to both 
platinum chemotherapy and PARP inhibitors. However, knowledge regarding 
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prognosis and chemotherapy response in tumours with less frequently mutated 
genes such as RB1, NF1 and PTEN is limited.  
 
These ID8 CRISPR-generated models represent a novel and simple tool to 
investigate the biology of HGSOC. In this thesis I have shown that a defective 
homologous recombination pathway is associated in most cases with a greater 
sensitivity to platinum chemotherapy and PARP inhibitors. However, when I 
combine data from other ovarian cancer cell lines with known HR status the 
relationship between cisplatin sensitivity and defective homologous 
recombination is more complicated. 
 
We know from clinical data that around 15% of women with a BRCA1/2 mutation 
are refractory or resistant to platinum chemotherapy (Alsop et al., 2012). Our 
data has shown that although the Brca1-/- and Brca2-/- ID8 derivatives are 
more sensitive to cisplatin, there is a greater sensitivity in clones with 
mutations in the PALB2 domain compared to the BRCT2 domain. In addition, 
the loss of Pten in the Trp53-/-;Brca2-/- genotype was shown to reduce 
sensitivity to cisplatin. These findings show that the location of the mutation 
and presence of confounding mutations in Brca1-/- and Brca2-/- can influence 
the sensitivity to platinum chemotherapy and might explain why a sub-group of 
these patients respond poorly to conventional treatment.   
 
The in vivo data showed that the Brca1-/- and Brca2-/- genotypes responded 
the best to platinum chemotherapy and the Pten-/- and Nf1-/- genotypes had 
the worst prognosis. This correlates well with what we know about clinical 
responses to platinum chemotherapy. As this was a transplantable in vivo model 
it allowed us to look closely at the tumour microenvironment and how this 
differed between the genotypes and following treatment with cisplatin. At 
present we know that certain mutations in women are associated with a worse 
prognosis but in most cases, we don’t know the exact mechanism for this 
treatment resistance. This ID8 model offered a unique opportunity to 
investigate this further.  
 
The tumour microenvironment is known to play an important role in the tumour 
progression and metastatic spread of disease. The interaction between the non-
220 
 
malignant and malignant cells within this environment is thought to offer a 
potential therapeutic target. In ovarian cancer particularly, the tumour has a 
predisposition for the omentum and its dissemination is aided by the circulating 
ascites within the peritoneal cavity (Thibault et al., 2014).  
 
I have shown that treatment with cisplatin alters the tumour microenvironment 
and as well as an overall cisplatin effect there are also differences between 
genotypes. When all genotypes were combined there was a significant increase 
in CD45+, CD11b+, CD3+, CD8+ and F4/80+ levels in the ascites after cisplatin 
treatment. The monocytic+ level was decreased, granulocytic+ level increased 
but overall the MDSC level (Ly6C+Ly6G+) was not changed following cisplatin 
treatment. In the Pten-/- genotype there was an increase in CD3+ levels and 
although not increased the CD8+ level was higher compared to the other 
genotypes. The MDSCs also remained high despite cisplatin treatment in the 
Pten-/- genotype. 
 
However, RNA sequencing of the tumours showed that cisplatin suppressed the 
immune response in all genotypes, and this was further supported by a decrease 
in tumour CD3+ levels by immunohistochemistry. These findings show that 
cisplatin can induce an immuno-stimulatory response in the ascites and an 
immuno-inhibitory response within the tumour and these two opposing 
responses may contribute to chemotherapy resistance. The cisplatin treatment 
does not appear to influence the MDSC level in the Pten-/- genotype and this 
may explain its poor prognosis. The influence of cisplatin chemotherapy is 
summarised in Figure 7.1. 
 
I showed that changes in both the ascites and tumour supported an 
immunosuppressive microenvironment in the Pten-/- and Nf1-/- genotypes 
which were associated with the worst in vivo survival. We decided to focus on 
the loss of Pten. The hypothesis was that Pten loss created an 
immunosuppressive microenvironment that helps to drive tumour progression 
and result in a poor prognosis. Our data from flow cytometry, RNA sequencing, 
RT-qPCR and immunohistochemistry supported this hypothesis. We found a 
significant increase in the MDSCs population in both ascites and tumour samples 
from flow cytometry and an increase in TAMs in tumour samples from  
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Figure 7.1: Summary of the influence of platinum chemotherapy 
Cisplatin showing an immune-stimulatory response in ascites and an immune-
stimulatory response in tumour. The MDSC and TAM populations are unchanged 
following cisplatin treatment in the BRCA1 and BRCA2 genotypes (positive prognosis) 
but clones with mutations within the PALB2 domain show greater sensitivity. The TAMs 
are increased in the Nf1-/- genotype (poor prognosis) and both MDSCs and TAMs 
although not increased, remain high in the Pten-/- genotype (poor prognosis) after 
treatment. 
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flow cytometry and immunohistochemistry data. From cytokine array and RT-
qPCR, we showed specific chemokines (Ccl2 and Ccl7) involved in MDSC and 
TAM recruitment to be upregulated in the Pten-/- genotype. This was further 
supported by RNA sequencing of murine tumours that showed a range of 
upregulated cytokine/chemokines important in MDSC activity, TAM recruitment 
and polarisation. 
 
We also showed evidence of TAM polarisation to a pro-tumour M2-like state with 
the loss of Pten. RNA sequencing of tumours highlighted several 
chemokine/cytokines present in both M1 and M2-like macrophages. Specifically, 
Ccl2 which was identified in the chemokine array and confirmed on RT-qPCR 
and RNA seq to be significantly upregulated. This chemokine is important in 
polarisation of macrophages to an M2-like state. However 
immunohistochemistry data from the TMAs showed a significant increase in both 
iNOS (M1-marker) and CD206 (M2-marker) with the loss of Pten but no obvious 
polarisation to an M2-like state.   
 
Pten offers an attractive therapeutic target. We have shown that this 
immunosuppressive microenvironment is a possible explanation for the more 
aggressive tumour progression and poor prognosis in the Pten-/- genotype. The 
next step was to attempt to reverse the effect of Pten with the eventual goal 
of improving survival. The AZD8186 in vivo experiment targeted the PI3K/AKT 
pathway directly by selectively inhibiting PI3Kβ whereas the GGTACKO in vivo 
experiment directly targeted CCR receptors involved in both MDSC and TAM 
activity.  
 
We showed from the initial GGTACKO pilot experiment that by inhibiting the 
receptors CCR1, 2, 3, and 5 the MDSC and TAM populations were reduced in the 
Pten-/- genotype and survival was extended. This experiment is currently being 
repeated to confirm these findings. The AZD8186 experiment showed that by 
inhibiting PI3Kβ, that the MDSCs that had previously been increased were 
reduced in the Pten-/- genotype. In addition, Ccl2 and Ccl7 were reduced and 
iNOS levels (M1-like) were reduced showing some evidence to support an M2-
like macrophage state. The effect of Pten loss is summarised in Figure 7.2. 
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Figure 7.2: Summary of Pten loss 
Pten loss showing the activation of the PI3K/AKT pathway resulting in an inflammatory 
response and an increase in MDSCs and TAMs. A counter-response is shown with an 
increase in CD3 and CD8. The loss of Pten also results in polarisation of TAMS to an M2-
like state (pro-tumour). The CCR receptors (blue) knocked out in the GGTACKO mice 
that are involved in MDSC and TAM activity are shown.  
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In this thesis, I have looked to improve the understanding of platinum sensitivity 
and the influence of the tumour microenvironment in high grade serous ovarian 
cancer. I established that cisplatin sensitivity is more complicated than simply 
a defective homologous recombination pathway and is likely to involve a 
multitude of factors, particularly the tumour microenvironment. I have used a 
transplantable in vivo model for HGSOC to investigate potential mechanisms of 
platinum sensitivity and identified poor prognostic genotypes. Finally, I have 
found Pten loss to be associated with an immunosuppressive microenvironment 
and by targeting the activated PI3K/AKT pathway and CCR receptors we can 
begin to reverse the effect of Pten. The next in vivo experiment will be to 
determine whether reversing the immunosuppressive microenvironment in the 
Pten-/- genotype with AZD8186 results in a prolonged survival.  
 
The research undertaken in this thesis has helped to further our knowledge of 
HGSOC and will hopefully contribute to the ovarian cancer research community. 
Ovarian cancer is one of the most lethal malignancies and results in a poor 
prognostic outlook for many patients. However the management is going to 
change significantly in the next 20 years. TCGA has increased our knowledge of 
the mutational landscape of ovarian cancer and is likely to lead to a 
transformation in personalised strategies. We have identified poor prognostic 
groups (Pten, Nf1) and potential therapeutic targets in an in vivo model. The 
next step will be to confirm these findings on other in vivo models and primary 
tissue. By identifying patients with specific mutations, we can tailor treatment 
to the individual and hopefully begin to improve survival dramatically.  
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Appendix 1: Quality scores and GC content from the RNAseq data of ID8 Trp53+/+, 
Trp53-/- and Trp53-/-;Pten-/- tumours. 
 
 
 
A, Mean Quality Scores B, Per Sequence Quality Scores C, Per Sequence GC Content 
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Appendix 2: Trp53 and Pten expression from the RNAseq of ID8 Trp53+/+ tumours 
and in the Trp53-/- and Trp53-/-;Pten-/- tumours treated with cisplatin or PBS. 
 
 
 
A, Trp53 expression B, Pten expression  
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Appendix 3: Quality scores and GC content from the RNAseq data of ID8 Trp53-
/;Brca1-/- and Trp53-/-;Brca2-/-tumours. 
 
 
A, Mean Quality Scores B, Per Sequence Quality Scores C, Per Sequence GC Content 
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Appendix 4: Trp53, Brca1 and Brca2 expression from the RNAseq of ID8 Trp53+/+ 
and Trp53-/- tumours and in the Trp53-/-;Brca1-/- and Trp53-/-;Brca2-/- tumours 
treated with cisplatin or PBS. 
 
 
 
A, Trp53 expression B, Brca1 expression C, Brca2 expression  
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Appendix 5: Quality scores and GC content from the RNAseq data of ID8 Trp53-
/;Nf1-/- tumours. 
 
 
 
A, Mean Quality Scores B, Per Sequence Quality Scores C, Per Sequence GC Content 
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Appendix 6: Trp53 and Nf1 expression from the RNAseq of ID8 Trp53+/+ and 
Trp53-/- tumours and in the Trp53-/-;Nf1-/- tumours treated with cisplatin or PBS. 
 
 
 
A, Trp53 expression B, Nf1 expression 
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Appendix 7: Tables outlining differential gene expression from RNA sequencing 
analysis.   
 
The tables below outlines the significantly up-regulated and down-regulated genes in the 
different genotypes and following cisplatin treatment (R package – edgeR). Only the top 
50 most significant genes are shown in the tables below. 
Wild-type versus Trp53-/- 
 
 
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Rn7sk 4.09E-18 434.007 Lrrc4 3.51E-26 51.644
Mup16 8.18E-18 11.985 Tnni3 2.28E-23 96.870
Znrf4 6.98E-17 103.561 Cacna1h 7.87E-20 167.554
H2-K1 7.63E-16 15422.589 Prrg3 1.92E-17 170.836
Mup17 9.27E-16 67.447 Unc13b 2.14E-17 205.296
Cd82 1.10E-14 2565.646 Sez6l 4.43E-17 184.755
Cryaa 4.16E-14 53.711 Bnc1 5.82E-17 79.158
Mup18 5.17E-14 37.603 Tmem132a 6.28E-17 296.963
Alppl2 8.95E-14 54.592 Wnt5a 1.04E-16 236.776
Fam118a 2.88E-13 558.879 Gata5 1.27E-16 46.387
2610528A11Rik 6.49E-12 162.618 Ccnjl 8.57E-16 23.344
Cdhr1 6.47E-12 144.108 Krt10 1.21E-15 5279.469
Olfr1372-ps1 6.97E-12 140.887 Slc12a2 7.79E-15 361.260
Ndp 6.09E-11 72.072 Mboat2 1.06E-14 92.736
Gm14002 2.46E-10 29.694 Wnt9a 2.00E-14 198.809
H2-D1 4.91E-10 12701.864 Pla2g5 1.34E-13 59.919
Lctl 5.83E-10 433.105 Kcnd2 9.09E-13 48.328
Piwil4 6.46E-10 59.802 Fa2h 9.72E-13 86.169
B2m 8.55E-10 15222.523 Kif1a 1.12E-12 96.067
1700008I05Rik 9.73E-10 33.858 Slmap 1.81E-12 1251.860
Plxnb3 9.95E-10 363.467 Dnajc14 3.38E-12 749.179
Rprl2 1.19E-09 42.726 Ccdc64 4.14E-12 354.466
A430093F15Rik 8.12E-09 31.079 Mecom 7.95E-12 95.464
Cotl1 9.75E-09 3308.428 Nxph3 1.55E-11 20.846
Topaz1 1.25E-08 24.307 Myh11 1.96E-11 2222.835
Dut 1.62E-08 803.345 Cacnb2 3.35E-11 28.716
5033428I22Rik 2.05E-08 36.130 Fut2 3.77E-11 90.820
Xaf1 2.74E-08 445.615 Col23a1 6.24E-11 115.533
3110035E14Rik 3.60E-08 136.472 Emx2os 1.90E-10 13.876
Zbp1 3.66E-08 502.549 Rcan2 1.99E-10 393.842
Oas1g 4.47E-08 81.932 Arnt2 2.13E-10 49.833
Irf7 4.69E-08 1160.636 B3gnt7 2.96E-10 68.267
Aire 5.78E-08 23.867 Scn5a 2.97E-10 44.835
AY036118 7.11E-08 19.674 9330159F19Rik 3.23E-10 45.142
AA467197 8.80E-08 752.896 Gas6 3.44E-10 3542.796
Sin3b 1.21E-07 1709.481 Spock2 3.42E-10 148.687
Amz1 1.97E-07 107.759 Cst6 5.86E-10 161.398
Slc12a1 2.79E-07 21.647 Epcam 9.91E-10 155.559
Bst2 3.39E-07 1883.359 Gpr116 9.27E-10 805.607
Rsph1 3.47E-07 63.303 Jazf1 9.39E-10 20.020
Rad51 3.52E-07 211.430 Krt1 9.93E-10 4281.354
Rai14 3.77E-07 2466.851 Tns1 1.18E-09 3591.463
AU018091 4.09E-07 18.097 Sobp 1.25E-09 46.559
Gm14088 4.38E-07 37.944 Lurap1 1.31E-09 64.704
AI848285 4.56E-07 861.049 Sgpp2 1.37E-09 101.683
Slc27a6 5.23E-07 235.274 Map4k3 1.42E-09 704.668
Slfn4 5.37E-07 79.010 Tmtc1 1.64E-09 296.648
AI427809 7.69E-07 36.285 Cttnbp2 1.72E-09 21.758
Ceacam15 8.49E-07 34.922 Efs 2.00E-09 72.397
Edn2 8.70E-07 191.592 Bmp6 2.11E-09 77.898
Down-regulated Up-regulated
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Trp53-/- (PBS) versus Trp53-/- (cisplatin) 
Up-regulated 
Gene 
Adjusted P 
value 
Log2 fold 
change 
Rn7sk 1.06E-16 434.007 
Rprl2 7.66E-10 42.726 
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Trp53-/- versus Trp53-/-;Pten-/- 
 
  
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Ighv9-4 1.24E-12 146.619 Gprasp2 1.52E-13 52.042
Mmel1 4.49E-08 39.674 Rn7sk 3.49E-12 434.007
Ighv1-81 1.90E-07 164.629 Tmem255a 1.69E-11 914.593
Igkv1-110 2.15E-07 148.708 Rprl2 2.79E-10 42.726
Igkv3-7 1.56E-06 56.303 Sema5a 2.30E-09 1186.711
Haus7 6.02E-06 264.559 Slc4a11 1.50E-07 484.154
Ucp1 2.47E-05 330.522 Cntln 5.06E-07 184.020
Igkv8-24 2.85E-05 38.618 Mylk3 4.74E-07 178.748
Prr5 4.12E-05 134.867 Adam33 8.67E-07 603.247
Scand1 4.11E-05 546.245 Pcdhb19 8.12E-07 38.584
Utp3 4.00E-05 528.331 0610007N19Rik 1.01E-06 429.547
Ighv1-12 5.63E-05 11.927 Wnt9a 2.19E-06 198.809
Ighv1-19 6.27E-05 116.894 Kif5c 2.94E-06 79.869
Igkv1-135 0.000100894 79.656 Espn 3.41E-06 392.377
Unc119 0.000111335 478.892 Ermp1 8.31E-06 1693.199
Stx1b 1.30E-05 76.738
2610028E06Rik 2.72E-05 8.989
Crip3 3.58E-05 80.822
Olfm4 3.67E-05 21.366
Pkhd1l1 6.33E-05 1009.668
5033428I22Rik 9.93E-05 36.130
Bcam 0.000107477 2589.363
Zfp644 0.000111501 414.867
Up-regulatedDown-regulated
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Trp53-/-;Pten-/- (PBS) versus Trp53-/-;Pten-/- (cisplatin) 
 
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Wnt9a 2.25E-12 198.809 Mup18 1.72E-22 37.603
Dync1i1 6.28E-11 326.445 Gm13775 2.29E-20 31.618
Upk3b 1.27E-10 2409.312 Igkv4-55 1.85E-12 172.989
Tmem255a 8.23E-09 914.593 Ighv9-4 7.04E-10 146.619
Gm7361 1.05E-08 25.926 Timd4 9.93E-10 66.700
Espnl 8.78E-08 9.858 Pla2g4d 3.13E-09 23.753
Slc48a1 1.01E-07 1998.491 Adam11 3.00E-08 78.438
Dlg2 1.98E-07 100.079 Agr2 4.48E-08 44.873
Pkhd1l1 5.06E-07 1009.668 Siglech 1.23E-07 35.621
Wwtr1 5.53E-07 1706.562 Plac8 1.49E-07 513.427
Tmx4 1.13E-06 391.649 Defb4 2.38E-07 23.215
Tmtc4 1.45E-06 297.300 Ighv1-81 2.37E-07 164.629
Gdf6 1.69E-06 217.186 Cd209b 3.38E-07 134.677
Lgals1 2.66E-06 24111.167 Cd209f 3.80E-07 50.011
Hmcn1 2.72E-06 181.143 Sorcs1 4.43E-07 68.119
Arhgap29 2.82E-06 2263.335 Bst2 4.81E-07 1883.359
Ermp1 3.09E-06 1693.199 Ighm 6.56E-07 9010.879
B3galnt2 3.47E-06 558.775 Igkv3-7 7.02E-07 56.303
Txnrd1 3.51E-06 1826.192 Fcer2a 9.67E-07 110.152
Ttll1 5.91E-06 208.509 Plbd1 1.24E-06 729.267
Garnl3 7.96E-06 362.842 Igkv9-124 1.39E-06 90.814
Scn5a 7.83E-06 44.835 Bace2 1.48E-06 205.233
Rab6a 1.08E-05 1350.036 Susd1 1.55E-06 74.004
Bcam 1.24E-05 2589.363 Irf9 1.87E-06 697.860
Srxn1 1.25E-05 882.293 Faim3 2.01E-06 121.881
Hs6st2 1.78E-05 261.346 Rasgrp2 2.01E-06 265.191
Mrgprf 1.81E-05 137.662 Gm11131 3.02E-06 25.370
Pcdh9 1.80E-05 21.563 Aff3 3.29E-06 57.007
Sema5a 1.89E-05 1186.711 Aven 3.54E-06 201.596
Carhsp1 1.99E-05 2121.817 AW011738 3.30E-06 40.000
Dcbld2 1.98E-05 1449.347 Ighv5-16 3.39E-06 47.420
Wnt4 2.04E-05 2225.340 Wdr86 3.78E-06 19.533
Il10 2.22E-05 23.252 Il4i1 3.89E-06 123.828
Zfp647 2.25E-05 51.704 Itpr2 4.33E-06 367.308
Galc 2.37E-05 378.377 Zap70 4.48E-06 106.657
Sgtb 2.50E-05 51.397 Trafd1 4.67E-06 1228.205
Apbb1 2.59E-05 186.966 Lyz1 5.11E-06 80.785
Mmel1 2.60E-05 39.674 Acp5 5.57E-06 753.817
Ttll5 2.75E-05 302.777 Ltb 5.40E-06 185.251
2610203C20Rik 3.06E-05 818.638 Ly6d 5.57E-06 443.159
Axin2 3.13E-05 462.676 Adrbk2 6.74E-06 155.383
Dnah7b 3.33E-05 27.466 Cxcr5 6.89E-06 66.186
Cercam 5.11E-05 554.322 Bcl7a 7.24E-06 110.001
Pcdhb20 4.88E-05 61.716 Bank1 8.02E-06 93.303
Ppp2r5b 5.09E-05 1031.640 Cd19 7.68E-06 229.494
Wnt11 4.92E-05 869.925 Cd209g 8.21E-06 18.688
Sv2a 5.38E-05 181.766 Zfp629 8.27E-06 188.246
Gm996 6.06E-05 76.243 Flywch2 8.65E-06 12.817
Nebl 6.14E-05 643.940 H2-Q7 8.62E-06 538.454
Pcdhb19 6.42E-05 38.584 Batf3 9.34E-06 32.383
Up-regulatedDown-regulated
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Trp53-/- versus Trp53-/-;Brca1-/- 
 
 
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Cotl1 4.33E-24 6408.518 Rn7sk 2.44E-24 550.386
Cd82 7.39E-23 4614.267 AY036118 9.85E-11 22.681
H2-D1 9.00E-23 19093.937 Rprl2 8.30E-11 54.093
Cryaa 1.34E-21 308.248 Gm5210 1.39E-08 6.834
H2-K1 2.14E-21 22837.618 Klhl5 3.53E-06 718.336
Alppl2 1.15E-20 109.063 n-R5-8s1 4.49E-06 83.774
Samhd1 1.81E-19 3817.135 Rmrp 3.94E-06 22.828
Znrf4 2.93E-19 157.767 Acbd4 1.07E-05 555.954
Hat1 8.03E-19 1333.544 Pex13 1.18E-05 626.057
Tapbp 2.30E-18 10010.628 Rps3a3 1.22E-05 22.241
Cdhr1 1.25E-17 386.363 Gpr135 3.12E-05 13.571
Atp1a3 5.38E-17 1120.143 Nxt2 3.37E-05 253.855
Gm14002 8.10E-17 54.216 Gm14420 6.14E-05 72.569
Stk32b 1.13E-16 316.030 Gm20721 5.89E-05 58.048
Arrb2 7.85E-16 1096.714 Ndfip1 5.47E-05 3153.819
Rai14 1.64E-15 4048.789
Tap2 4.49E-15 2115.504
Flt4 1.63E-14 2731.462
Cdt1 2.06E-14 592.664
Dut 2.03E-14 1380.501
B2m 2.70E-14 22869.500
Piwil4 3.54E-14 170.075
AI427809 1.22E-13 80.262
Ndp 2.76E-13 127.377
Gpsm3 4.81E-13 553.824
Tap1 5.84E-13 1928.616
Dpy19l3 6.88E-13 1688.500
H2-T22 7.91E-13 1424.198
Mcm8 9.47E-13 252.573
Ogfr 1.27E-12 1594.347
Piwil2 1.67E-12 1134.610
Fam118a 2.02E-12 1018.080
Foxs1 2.79E-12 601.151
Ece2 5.52E-12 460.551
Gpr176 6.56E-12 797.340
Cxcl10 6.65E-12 526.369
Olfr1372-ps1 7.34E-12 259.597
Cdca7 7.73E-12 674.462
Usp18 1.25E-11 431.760
E2f1 1.30E-11 514.711
Lig1 1.66E-11 1316.464
Palm3 1.67E-11 353.388
Zbp1 1.89E-11 652.588
Oas1a 2.04E-11 306.588
Lpar2 2.29E-11 1062.748
Exosc8 3.70E-11 521.103
Dsn1 3.74E-11 326.966
Rcc2 4.26E-11 3453.340
Unc5c 4.81E-11 118.524
Bub1b 4.99E-11 1267.941
Down-regulated Up-regulated
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Trp53-/-;Brca1-/- (PBS) versus Trp53-/-;Brca1-/- (cisplatin) 
 
 
  
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Igkv6-13 2.98E-06 50.813 Gm1110 1.33E-15 24.189
Lypd8 4.82E-06 52.806 Tceal7 9.63E-14 37.803
Gkn3 1.44E-05 90.152 Kprp 2.46E-12 397.555
Muc5ac 4.87E-05 71.568 Lce1f 2.32E-11 154.745
Clca3 7.93E-05 27.535 Casp14 7.00E-11 193.716
Muc6 7.81E-05 45.467 Hrnr 6.74E-10 229.869
Lce1d 8.25E-10 227.115
Lce3a 4.95E-09 76.030
Serpinb3a 8.70E-09 146.206
Lce1a2 3.03E-08 201.170
Tmprss11f 8.20E-08 28.920
Flg 2.65E-07 197.834
Lce1b 4.82E-07 144.190
Usp18 5.05E-07 431.760
Lce1c 5.88E-07 182.904
Lce1a1 7.36E-07 232.437
Oas1a 8.16E-07 306.588
Klk5 2.61E-06 93.799
Isg15 6.42E-06 703.111
Lce1e 1.01E-05 104.485
Lce3b 1.04E-05 51.419
Lce3c 9.87E-06 77.348
Lce1i 1.38E-05 74.684
Hamp 2.01E-05 595.306
Gm6548 2.36E-05 356.728
Lce1g 2.38E-05 98.590
Lce1l 3.00E-05 89.023
2310050C09Rik 4.20E-05 122.882
Bst2 7.09E-05 2378.200
2810007J24Rik 8.09E-05 511.086
Irf7 7.88E-05 1632.101
Myh8 8.36E-05 1696.772
Down-regulated Up-regulated
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Trp53-/- versus Trp53-/-; Brca2-/- 
 
 
 
  
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Cryaa 1.13E-24 308.248 Rn7sk 7.07E-20 550.386
Cd82 9.25E-23 4614.267 AY036118 2.29E-11 22.681
Cotl1 2.84E-22 6408.518 Lce1f 1.83E-10 154.745
Stk32b 7.32E-22 316.030 Lce1d 5.16E-09 227.115
Cdhr1 3.91E-21 386.363 Espn 2.03E-08 463.067
H2-D1 4.63E-20 19093.937 Gm5210 6.99E-08 6.834
Alppl2 2.11E-19 109.063 Rprl2 9.62E-08 54.093
Atp1a3 2.17E-19 1120.143 Lce1a2 1.11E-07 201.170
Hat1 1.04E-18 1333.544 Sis 2.51E-07 20.199
H2-K1 1.38E-17 22837.618 Lce1a1 1.97E-06 232.437
Znrf4 2.65E-17 157.767 Lce1b 2.77E-06 144.190
Tapbp 9.91E-17 10010.628 Gpaa1 3.05E-06 916.159
Piwil4 5.46E-16 170.075 Flg 3.99E-06 197.834
Gm14002 8.27E-16 54.216 Rmrp 4.02E-06 22.828
Trmt6 4.02E-15 1117.218 n-R5-8s1 7.85E-06 83.774
Rap2a 5.74E-15 1911.118 Lce1l 1.48E-05 89.023
Samhd1 5.72E-15 3817.135 Lce1m 1.54E-05 254.072
Ccdc109b 1.27E-14 637.137 Pmaip1 1.66E-05 183.431
Dut 2.45E-14 1380.501 Hoxc12 1.86E-05 21.620
Mgarp 3.50E-14 486.669 Fignl2 2.82E-05 124.982
Ece2 3.60E-14 460.551 Igkv3-5 2.77E-05 177.153
Crnkl1 6.04E-14 975.243 Lce1i 3.99E-05 74.684
Gpsm3 1.27E-13 553.824 Rgs16 3.89E-05 519.892
Ager 1.66E-13 144.429 Vegfa 4.65E-05 6962.023
Exosc8 1.93E-13 521.103 Igkv4-72 4.89E-05 87.393
Flt4 3.90E-13 2731.462 Lce1e 7.06E-05 104.485
Dsn1 1.08E-12 326.966 Mdfi 6.83E-05 208.531
Gpr176 1.24E-12 797.340 Lrp2bp 7.52E-05 15.171
5033428I22Rik 1.40E-12 77.663 Trp53 9.69E-05 848.680
Nras 1.95E-12 1785.705 Nrgn 0.000108574 106.482
Rab32 2.39E-12 920.261 Cish 0.000118576 470.397
Arrb2 4.81E-12 1096.714 mt-Nd6 0.000120758 137.465
Dpy19l3 5.19E-12 1688.500 AY761184 0.000156889 5.988
Snx7 5.64E-12 707.379 Gm15408 0.000178273 26.624
Myl12b 6.28E-12 2741.539 Chac2 0.000245043 98.191
Lig1 6.72E-12 1316.464 Socs2 0.000254748 387.902
Ogfr 8.08E-12 1594.347 Fras1 0.000281598 119.964
Slc7a6 1.03E-11 1460.934 Mdm2 0.000280551 820.719
Palm3 1.89E-11 353.388 Tdrkh 0.000290448 57.217
AI427809 2.34E-11 80.262 Nmral1 0.000350786 110.119
Lpar2 2.33E-11 1062.748 Col27a1 0.000374875 224.970
Piwil2 2.33E-11 1134.610 Igkv4-63 0.000445103 29.757
Olfr1372-ps1 2.53E-11 259.597
Trim59 2.57E-11 651.506
Acd 4.60E-11 580.008
Mcm8 5.13E-11 252.573
Tap2 5.09E-11 2115.504
Grin2d 6.50E-11 419.963
B230314M03Rik 6.67E-11 38.594
Rnf181 6.67E-11 3655.727
Up-regulatedDown-regulated
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Trp53-/-;Brca2-/- (PBS) versus Trp53-/-;Brca2-/- (cisplatin) 
 
 
  
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Lce1f 3.12E-11 154.745 Brf2 2.02E-08 172.044
Lce1d 4.88E-10 227.115 Mybphl 2.12E-07 310.013
Lce1a2 2.32E-08 201.170 Sprr2a3 4.69E-07 34.116
Flg 5.06E-07 197.834 Ighv1-7 1.48E-06 122.526
Lce1a1 4.03E-07 232.437 Tm2d2 1.71E-06 1015.913
Lce1b 4.45E-07 144.190 Ing2 7.03E-06 227.023
Lce1m 4.12E-07 254.072 Tmem66 7.02E-06 2871.151
Hmcn1 2.77E-06 349.734 2310045N01Rik 7.51E-06 415.645
P2ry12 8.15E-06 97.603 Tmem35 1.22E-05 179.679
Lce1e 1.20E-05 104.485 Ash2l 1.50E-05 982.941
Lce1i 1.33E-05 74.684 Ddx49 1.82E-05 718.805
Lce1l 1.14E-05 89.023 Uba52 2.16E-05 348.022
Tubb1 1.30E-05 15.701 Prosc 2.32E-05 1119.941
Prokr1 3.47E-05 17.498 Mvb12a 2.48E-05 933.663
Lce1j 5.13E-05 33.192 Sema7a 2.77E-05 1194.781
Nrgn 6.01E-05 106.482 Frg1 3.25E-05 466.821
2310050C09Rik 6.48E-05 122.882 Prap1 3.35E-05 32.328
Igkv3-12 6.34E-05 111.468 Fkbp8 4.10E-05 4924.168
Igfbp5 7.41E-05 7358.120 Shh 6.75E-05 13.794
Bai2 0.000105091 686.892 Ripply1 7.16E-05 50.849
Map3k7 0.00010421 1285.324 1700019B21Rik 7.97E-05 13.514
Ptpn4 0.000115634 183.851 AU015836 8.58E-05 12.300
Tagap 0.000115911 166.907 Pgls 0.000121278 1268.693
Ppbp 0.000120648 31.628 Igkv16-104 0.000127456 368.995
Ighg3 0.000129718 1208.547 Cfdp1 0.000151444 1434.303
Igkv8-16 0.000125743 76.664
Up-regulatedDown-regulated
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Trp53-/- versus Trp53-/-;Nf1-/- 
 
 
  
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Alppl2 1.73E-35 140.139 Rn7sk 4.14E-24 505.652
Atp1a3 7.63E-23 971.421 E330013P04Rik 5.06E-21 72.339
Znrf4 9.47E-23 143.101 Casp14 1.31E-20 181.917
Ager 2.29E-22 151.542 Rspo1 3.65E-15 912.587
Flt4 5.45E-22 2470.028 Il1f5 6.38E-15 293.535
Piwil4 5.23E-22 138.614 Cpq 1.76E-12 1756.715
Dut 1.25E-21 1082.358 Klk7 1.63E-12 133.523
Cd82 3.70E-21 4341.341 Lce1e 9.42E-12 100.132
Cdhr1 8.60E-19 297.321 Lctl 1.78E-11 458.530
Edn2 1.11E-18 198.711 Pgc 1.09E-10 157.537
Slc7a6 1.32E-18 1251.347 Gm10664 3.21E-10 17.775
Galnt10 1.58E-18 2504.629 AY036118 1.60E-09 23.501
Cplx2 3.08E-18 791.801 Kcnt1 2.35E-09 549.226
Lig1 5.02E-18 1307.545 Casp3 3.72E-09 404.724
Cryaa 7.38E-18 160.528 Rmrp 6.50E-09 22.361
Cotl1 1.85E-17 4642.167 Spon2 7.66E-09 482.432
Dpy19l3 1.79E-17 1457.185 Aadacl3 9.50E-09 27.532
Grin2d 5.71E-16 343.614 Upk3b 1.05E-08 2756.311
Olfr1372-ps1 9.59E-16 203.311 Lce1k 1.22E-08 49.925
Sox8 1.34E-15 709.133 Crot 2.15E-08 1846.395
Rai14 1.88E-15 3758.100 Nr2e3 2.29E-08 18.060
Snx7 2.37E-15 571.793 Mdfi 2.47E-08 183.402
Fam118a 8.97E-15 839.886 Rprl2 2.69E-08 48.755
Haus4 9.11E-15 347.859 n-R5-8s1 3.49E-08 76.783
Slc27a6 1.16E-14 391.486 Lcn11 3.84E-08 21.393
Foxs1 2.12E-14 633.250 Hs6st2 4.49E-08 253.494
Syt9 2.88E-14 262.895 Slc13a4 4.77E-08 104.749
Ece2 3.61E-14 396.742 Casp1 5.02E-08 341.339
Plscr1 4.15E-14 874.397 BC023105 5.65E-08 27.202
Carhsp1 6.52E-14 3172.978 Gm12979 8.11E-08 13.984
Lrp8 8.35E-14 162.354 Il17re 9.25E-08 107.163
Plxdc1 1.04E-13 1391.992 Pkhd1l1 9.86E-08 1094.131
Rnf181 1.85E-13 3866.419 Klra2 1.30E-07 87.693
Gpr176 3.82E-13 534.229 Igfbp5 1.54E-07 5436.266
Runx2 4.38E-13 257.287 Cers4 2.25E-07 693.162
Flnb 5.35E-13 7221.178 Fxyd3 2.58E-07 386.865
Camk2n2 5.42E-13 135.054 Gng13 2.84E-07 27.489
Gm14002 8.04E-13 48.387 Lce1g 3.16E-07 98.194
Slc35b4 1.69E-12 1334.078 Pmaip1 3.56E-07 138.986
Nubp2 1.73E-12 759.778 Aire 3.79E-07 18.144
4930486L24Rik 2.95E-12 287.834 Clec7a 3.78E-07 311.615
Limk1 3.59E-12 654.290 Arhgap29 4.18E-07 2533.610
Samhd1 4.65E-12 2872.506 Ptges3 4.54E-07 457.206
Trmt6 5.13E-12 943.312 Gm15536 4.67E-07 25.713
Eya2 5.30E-12 322.264 Pilrb1 5.28E-07 19.121
Scube3 5.85E-12 2040.003 Gm5210 5.86E-07 6.941
Chrd 6.97E-12 615.260 Gbp10 6.20E-07 24.903
Mgarp 7.15E-12 473.038 Ndp 6.35E-07 63.136
Adamts14 8.34E-12 513.091 Gm8430 7.50E-07 22.255
H13 1.14E-11 4129.792 Ccdc64 8.45E-07 403.388
Up-regulatedDown-regulated
273 
 
Trp53-/-;Nf1-/- (PBS) versus Trp53-/-;Nf1 (cisplatin) 
 
 
Gene Adjusted P value Log2 fold change Gene Adjusted P value Log2 fold change
Casp14 9.08E-33 181.917 Ccrl2 3.45E-14 63.643
Rspo1 6.72E-32 912.587 Fas 3.15E-12 165.662
Il1f5 1.33E-28 293.535 Acp2 4.70E-11 916.040
Upk3b 4.54E-26 2756.311 St3gal1 7.13E-11 1600.100
Lce1e 6.63E-22 100.132 Ppbp 2.91E-10 33.260
Klk7 6.26E-21 133.523 C6 3.29E-10 164.606
Podxl 2.61E-18 6104.929 Lrrc32 6.13E-10 525.178
Gpr37 1.16E-17 115.243 Zfp422 8.00E-10 128.324
Aadacl3 4.05E-16 27.532 Dhx58 8.20E-10 240.781
Wwtr1 4.57E-16 2245.709 Tspan11 9.56E-10 207.986
Lce1k 5.93E-16 49.925 Timd4 1.04E-09 61.422
Neo1 8.73E-16 2910.924 Adam23 1.79E-09 159.039
Wt1 9.24E-16 6819.456 Susd4 1.94E-09 34.118
E330013P04Rik 4.98E-15 72.339 Trim25 2.00E-09 1974.371
Dcbld2 9.80E-15 1536.604 Rnf130 3.07E-09 699.686
Wnt11 9.32E-15 1280.586 Fam167b 3.27E-09 89.317
Asic3 1.24E-14 91.026 Clec14a 3.75E-09 217.326
Cdon 1.47E-14 3605.485 Ednrb 4.47E-09 374.221
Add3 1.61E-14 2661.938 Slco1a1 6.63E-09 247.914
Zbtb8a 3.18E-14 219.002 Pcdh17 8.39E-09 112.046
Abca4 5.55E-14 83.324 Col27a1 9.50E-09 219.086
Slc13a4 8.46E-14 104.749 Pros1 9.67E-09 768.242
Unc13c 2.38E-13 64.176 Cd163 1.27E-08 477.921
Faim 2.48E-13 278.874 Serpine1 1.37E-08 4182.702
Kdelc2 3.47E-13 699.360 Bcl6b 1.46E-08 130.107
Necab3 7.22E-13 54.871 Cd97 1.52E-08 1143.120
Ctxn1 7.95E-13 440.477 Colec12 1.72E-08 629.259
Klk5 8.59E-13 85.762 Scarf1 1.89E-08 168.395
Lgals1 8.60E-13 28725.739 Cd209a 1.91E-08 20.999
AI314831 1.26E-12 542.271 S1pr3 2.37E-08 231.377
Lce1g 2.65E-12 98.194 Nrep 2.40E-08 556.933
Cldn26 3.31E-12 55.806 Jam2 2.94E-08 452.216
Ttll5 4.93E-12 424.464 Fgf1 3.22E-08 970.377
Smim1 5.13E-12 1570.112 Itga9 3.21E-08 885.601
Wfikkn2 7.00E-12 253.485 Kdr 3.17E-08 904.306
Gxylt2 1.13E-11 456.425 Scn8a 4.34E-08 11.640
Maged2 1.13E-11 6061.217 Emr4 4.75E-08 42.756
Crb2 1.60E-11 2058.946 Kalrn 4.84E-08 739.429
Lrrn4 1.73E-11 412.909 Kcnj8 5.72E-08 226.150
Pkhd1l1 2.00E-11 1094.131 Efna1 6.12E-08 500.496
Wnt10b 2.41E-11 278.974 Rnf114 6.43E-08 1169.358
Pcnxl2 2.60E-11 393.452 Fam46a 7.14E-08 388.151
Cers4 2.75E-11 693.162 Gm13705 7.54E-08 15.158
Sv2a 2.75E-11 306.539 Angptl4 8.47E-08 1564.356
Kcnab1 3.13E-11 673.662 2210016F16Rik 9.84E-08 259.453
Gng13 3.21E-11 27.489 Lrp3 9.98E-08 191.548
Pappa 4.81E-11 279.079 Itga1 1.19E-07 360.352
Lce1j 5.00E-11 32.551 Tcf24 1.21E-07 20.752
Cercam 5.95E-11 664.033 Ldb2 1.44E-07 100.033
Tyro3 6.79E-11 2796.784 Fancf 1.59E-07 26.130
Down-regulated Up-regulated
